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Abstract
Bm-3a and Bm-3b are members of the POU-domain containing transcription 
factors. Both are found in specific neurons of the CNS and PNS. In mouse and 
human neuroblastoma cell line models, high levels of Bm-3a are found in 
differentiating neurons whereas high levels of Bm-3b are present in actively 
proliferating cells. The reciprocal expression of these two transcription factors in 
neuroblastoma cells is paralleled by their differential regulation on gene promoters. 
While Bm-3a activates several gene promoters whose products are associated 
with neuronal differentiation, Bm-3b has repressive effects on the activity of most 
of these promoters.
Stable cell line systems were developed to test the effects of these factors in 
human neuroblastoma cell line, IMR-32, where the levels of Bm-3a and Bm-3b 
have been manipulated. While results from IMR-32 constitutively over-expressing 
Bm-3a remain to be validated, manipulation of Bm-3b showed profound effects on 
the growth characteristics of these cells. Thus, over-expression of Bm-3b caused 
increased growth rate, saturation density, proliferation, anchorage independent 
colonies, and enhanced migration compared to the mock transfected cells. 
Furthermore, cells with elevated levels of Bm-3b exhibited a stronger ability to form 
tumours in xenograft mouse models compared to controls. IMR-32 cells with 
reduced Bm-3b levels exhibited a significant decrease in growth and proliferation 
parameters. Moreover, Bm-3b over-expressing cells failed to respond to 
differentiation stimulus such as all-trans-retinoic-acid and continued to proliferate in 
its presence, while empty vector control and cells with reduced Bm-3b levels 
ceased to proliferate when grown in the presence of this differentiation stimulus.
The levels of cell cycle regulator protein, cyclin D1 were found to be elevated in 
Bm-3b over-expressing IMR-32 cells, with a concomitant decrease in cells with 
reduced levels of this protein. Using transactivation studies, we have shown for the 
first time that Bm-3b is able to activate the cyclin D1 gene promoter (5’-A TTT CTA 
TGA-3’), and this activation is dependent on a specific octamer sequence located 
between positions -240 and -231 from the transcriptional start site in this promoter. 
Taken together these studies are of fundamental importance in devising targeted 
therapeutic strategies for aggressive stages of human neuroblastomas.
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INTRODUCTION
1.0 Transcriptional regulation in eukaryotes
In eukaryotes formation of a zygote and the subsequent appearance of 
morphologically and functionally distinct cells during development and their 
maintenance in adult life requires a precise and tightly regulated gene expression. 
The importance of aberrant gene expression has been highlighted in a number of 
diseases, including cancers. Most cancers arise from abnormalities in the 
expression of genes that control growth and differentiation (increase in proto- 
oncogenes or decrease of tumour suppressor genes). Various metabolic disorders 
and perturbed hormone function are also the consequence of aberrant gene 
expression.
The control of tightly regulated expression and function of mammalian genes is 
maintained by a number of processes. These include pre-transcriptional control of 
chromatin remodelling; gene transcription, which involves the synthesis of mRNA 
from DNA; post-transcriptional control determining the stability of the mRNA 
transcript; translation which involves the synthesis of proteins; and, finally post- 
translational modifications required for producing a functionally active or inactive 
protein.
1.1 Pre4ranscriptional control of gene expression
Transcriptionally silent genes are condensed and organized into chromatin in the 
eukaryotic nucleus (for review see Latchman, 2002; Felsenfeld and Groudine, 
2003). The term chromatin refers to the organization of DNA in an intricate, 
dynamic nudeoprotein assembly, accomplished by a remarkable feat of biological 
engineering. Chromatin is composed of repeating units called nudeosomes. The 
nudeasome core is composed of an octamer of four highly folded proteins, H2A, 
H2B, H3, and H4 (two of each protein), and of 147 base pairs of DNA wrapped 
around the octamer.
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This chromatin structure imposes barriers for each step in eukaryotic transcription, 
primarily by preventing entry of the transcriptional machinery to the gene regulatory 
sequences. Therefore, the first step in activation of a gene requires remodelling of 
the chromatin to allow entry of transcriptional regulators (Komberg and Lorch, 
1999). Two major classes of multiprotein complexes regulate accessibility of the 
template to DNA binding factors. The first class involves ATP-dependent 
complexes which use ATP hydrolysis to ‘slide’ DNA with respect to the histone 
octamer, and thereby expose or occlude DNA sequences (Meersseman et al, 
1992). The other class is composed of protein complexes that covalently modify 
nudeosomes by adding or removing many chemical moieties in the histone amino 
termini. The best characterized of these complexes are those that cause either 
hyperacetylation (histone acetyltransterase complexes, HAT) or hypoacetylation 
(histone deacetylase complexes, HDAC) of lysines in the amino-terminal tails of 
the core histones (Roth et al, 2001; Vogelauer et al, 2000). It is thought that 
targeting of HAT and HDAC complexes to promoter regions creates specific 
patterns of hyper- and hypoacetylation in a backbone of global acetylation that 
correlate with transcription activation and repression, respectively. Other 
modifications, such as methylation, ubiquitination, and phosphorylation are also 
crudal in regulation of transcription (for review Berger, 2001).
1.1.1 Eukaryotic transcription
Gene expression is primarily controlled at the level of transcription. Eukaryotic 
transcription is the synthesis of RNA from a DNA template by RNA polymerase 
(RNA Pol). There are three dasses of eukaryotic RNA Pols: I, II and III, each 
comprising two large subunits and 12-15 smaller subunits. RNA polymerase II is 
involved in the transcription of all protein genes and most snRNA genes. The 
other two dasses transcribe only RNA genes. RNA Pol I is located in the 
nudeolus, transcribing rRNA genes except 5S rRNA. RNA Pol III is located 
outside the nudeolus, transcribing 5S rRNA, tRNA, U6 snRNA and some small 
RNA genes.
The basal transcription complex indudes the RNA polymerase and additional 
proteins (discussed in section 1.4) that are necessary for correct initiation and
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elongation of RNA synthesis. RNA Pol II is not able to bind the DNA directly. 
Hence, following chromatin remodeling, DNA becomes available to other proteins 
which results in the formation of the pre-initiation complex. RNA Pol II then initiate 
its function by directing 3-hydroxylation of the RNA chain on a ribonudeoside 
triphosphate, leading to extension of the chain in the 5' -> 3' direction (for review 
see Crammer et al, 2001).
1.1.2 DNA sequence elements regulate transcription
The molecular basis for the transcriptional regulation of gene expression is the 
binding of trans-activating proteins (transcription factors) to ds-regulatory DNA 
response elements (Ptashne, 1988; Latchman, 1990). The presence of cis-acting 
DNA sequences establishes the binding sites for transcription fadors at locations 
from which they can interact, either to form the transcription initiation complex (TIC 
- a macromolecular assembly of RNA polymerase II and assodated protein 
cofadors) or to interad with the TIC to modulate transcription.
Several types of ds-adive elements exist, induding promoters, enhancers, 
upstream promoter elements (UPEs) and response elements. Promoter sequence 
is usually located at the 5’ end relative to the coding sequence. Analysis of many 
eukaryotic promoters has revealed some of the sequence motifs that are present 
within the proximal promoter elements of genes that are required for transcription 
at initiation. These indude the A/T rich sequence element (TATA box) and initiator 
(Inr) elements, which are present in many, but not all, RNA polymerase II 
transcribed genes. The TATA box is located 25 to 30 base pairs 5’ to the 
transcriptional start site and is recognized by the TBP (TATA binding protein). In 
general, it is thought that genes containing a TATA box usually initiate transcription 
from a single downstream site, whereas some housekeeping and tissue-spedfic 
genes lacking a TATA box often initiate transcription from initiator elements 
(Y2CAY5 where Y= pyrimidine) that may be found at a distance of -3 to +5 from 
the transcriptional start site (Zawel and Reinberg, 1993). Hence, promoter 
sequences establish the site of transcription initiation and the direction of 
transcription.
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Upstream promoter elements (UPEs) are other regulatory elements that are found 
in a wide variety of genes with different patterns of expression (Goodwin, 1990). 
These sequences are bound by specific transcription factors and play a role in 
stimulating the constitutive basal activity of a promoter. The Sp1 box (a GC rich 
sequence) and the CCAAT box (sequence implied in the name) are both UPEs, 
and promoters may contain one or both in single or multiple copies (Latchman, 
1998b).
Enhancers are DNA sequences that are located 5’ or 3’ to the coding sequence of 
a gene or within an exon or intron of the gene. In contrast to the promoter, 
enhancer function is independent of position and orientation (Thompson and 
McKnight, 1992). Enhancers have a modular structure with each module 
representing a transcription factor binding site. It is the juxtaposition of binding sites 
for multiple factors in close proximity to one another that is the basis for enhancer 
function, as individual modules have little or no enhancing activity. This 
requirement for proximity suggests cooperativity of function, at the level of DNA 
binding and/or transactivation. Enhancer sequences seem to be less protected by 
histories and other chromosomal proteins as they often demonstrate a 
hypersensitivity to digestion by DNase I within nuclei isolated from specific cells. 
This allows greater accessibility to DNase I in vitro and to transcription factors in 
vivo. Enhancers also exhibit the ability to function at distances of 10 kb or more at 
5’ or 3’ from the transcription initiation site. It appears that the formation of a DNA 
loop allows the general transcription factors of the transcription initiation comlex to 
interact with factors bound both 5’ and 3’ to the transcription initiation site.
While transcription factors that bind to these enhancers often activate gene 
expression, there are also some negative regulatory elements (silencers) (for 
review by Renkawitz, 1990), such as the sequence which is recognized by the 
neuron-restrictive silencer factor to inhibit transcriptional activity (Schoenherr and 
Anderson, 1995). Furthermore, sequences which act as positive enhancer in some 
cells may be negative regulators in other cell types depending on the position of its 
binding site in the promoter as well as other transcription factors which may be co­
expressed in the cell.
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Finally, DNA sequences that enhance activation of a promoter in response to 
exposure to different stimuli are termed response elements. These include the 
Heat Shock Element (HSE), Glucocorticoid Response Element (GRE), OEstrogen 
Response Element (ERE) and Metal Response Element (MRE). These elements 
are bound by specific transcription factors induced by a particular stimulus and are 
capable of being induced in response to specific stimulus even when cloned into a 
heterologous promoter. This is exemplified by HSE of the Hsp70 gene doned into 
the promoter of the thymidine kinase gene, which when exposed to an increase in 
temperature caused thymidine kinase production (for review see Latchman, 1997).
1.1.3 The process of transcription: a rendezvous between 
RNA polymerase II and transcription factors
Transcription factors are proteins that bind to ds-DNA elements and play a pivotal 
role in the regulation of gene expression. They indude an array of proteins such as 
activators, co-activators, architectural factors, repressors and co-repressors, 
chromatin remodeling factors and transcription elongation factors. Eukaryotic 
transcription factors can be divided into two main groups, namely general 
transcription factors and, gene specific transcription factors. The mechanism by 
which these proteins act will be discussed briefly.
As RNA polymerase is unable to bind the DNA directly, it is recruited to the 
accessible promoter as a part of a complex with general transcription factors. On 
many promoters this process occurs by the step-wise assembly of general 
transcription factors (TFIID, MB, IIA, HE, IIF and IIH) that form the pre-initiation 
complex (PIC) (Drapkin et al, 1993). On a TATA containing promoter, the initial 
binding of TFIID, consisting of TATA box binding protein (TBP) and the TBP 
assodated factors (TAF), to the TATA elements appears to fadlitate the assembly 
of other transcription factors to the complex. Moreover, binding of TFIID stabilizes 
the nudeosomes in the promoter region and therefore encourages PIC formation 
(White and Jackson, 1992, Buratowski, 1994). Thus, binding of TFIID to the DNA 
is one of the rate-limiting steps of transcription and the TBP component of this 
complex has been shown to be one of the core proteins with which transcriptional
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activators interact to modulate gene expression (Chatterji and Struhl, 1995). 
Another key rate-limiting step for transcription is the recruitment of TFIIB. In fact, it 
is the binding of TFIIB to the TFIID/TFIIA/DNA complex that recruits RNA 
polymerase II to this complex (Lin and Green 1991, Choy and Green, 1993). TFIIB 
most likely acts as a bridge between TFIID/TFIIA/DNA and RNA polymerase II. 
Following binding of RNA polymerase to the PIC, other general transcription 
factors are recruited to this site where they exert their effects to ensure 
transcription of the target gene. These include TFIIE, a DNA-dependent ATPase, 
which provides the energy for transcription, TFIIF which unwinds the DNA, and 
TFIIH which exhibits enzymatic activity required to initiate transcription (Gilbert, 
1994).
While general transcription factors are common to all RNA polymerase II 
transcribed genes, independent of cell type, gene specific transcription factors are 
responsible for the activation or repression of specific genes. These ensure tightly 
controlled temporal and/or tissue-specific expression. Binding of these specific 
transcription factors at short specific sequences, referred to as response elements, 
mostly enhance but may repress the formation of PIC and, thus modulate the 
relative efficiency of transcriptional initiation by activation or repression. The 
specificity of function of this class of transcription is exemplified by the MyoD 
transcription factor which is synthesized exclusively in skeletal muscle cells. Upon 
artificial expression of MyoD in non-muscle cells such as fibroblasts, it is converts 
these cells into muscle cells, indicating that MyoD activates transcription of all the 
genes necessary to produce a differentiated muscle (Olson, 1990). Hence, gene 
specific transcription factors ensure tight control of transcription in a tissue- or time 
specific manner, hence allowing for proper development and maintenance of 
different cell lineages.
Regulation of transcription by specific transcription factors may be controlled at 
different levels. Some transcription factors are activated to bind their DNA 
elements on target promoters after post-translational modifications such as 
phosphorylation, acetylation and/or ubiquitination. For example, tumour suppressor 
protein p53 and its negative regulator Mdm 2 are both subject to phosphorylation, 
and present an excellent case for positive and negative effects of post-translational
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modifications. While p53 is subject to hyperphosphorylation following DNA 
damage and becomes active and stable by this change, Mdm 2 also becomes 
phosphorylated but this change results in its inactivation. It is believed that 
phosphorylation of these two factors causes weaking of the p53-Mdm 2 
association so that p53 is released and free to bind the DNA and controll the target 
gene expression (Hirao et al, 2000; Mayo et al, 1997). Similarly, other inducible 
transcription factors are activated by hormones or growth factors such as the 
steroid and thyroid hormones that combine with intracellular receptors to form 
active transcription factors.
1.1.4 Families of transcription factors
The ability of these factors to modulate transcription is due to their modular 
structure in which distinct regions of the protein mediate its association with the 
DNA and factors involved in the regulation of a gene (Brent and Ptashne, 1985; 
Johnson and McKnight, 1989). Specific domains of eukaryotic transcription factors 
can adopt highly ordered conformations for specific requirements in terms of 
binding to the DNA or other proteins. The presence of domains that allow 
interactions with other proteins that may be expressed at a specific time or in 
response to specific stimulus, provides a mechanism by which the expression of a 
diverse range of genes can be regulated by a relatively limited number of 
transcription factors (Struhl, 1991; Hershlag and Johnson, 1993). Modular 
structure of transcription factors is exemplified by the estrogen and glucocorticoid 
nudear receptors, where different domains are interchangeable so that the DNA- 
binding or ligand-binding can be altered by switching of spedfic domains with 
resultant changes in activation and function (see Hollenberg and Evans, 1988).
On the basis of common evolutionary conserved DNA binding motifs, most 
transcription factors have been grouped into families. These indude the zinc finger 
motif, the basic leudne zipper motif, the helix-loop-helix motif and the related helix- 
tum-helix (HTH) motif (for review see Patikoglou and Burley, 1997; Latchman, 
1990a; 1990b). However, there are several other interesting and important DNA-
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binding proteins that do not fall into any of the classes listed above. An example of 
this is the tumour suppressor p53 protein (Cho et al, 1994).
The zinc finger motif was originally recognized in factor TFIIIA, which is required for 
RNA polymerase III to transcribe 5S rRNA genes. It has since been identified in 
several other transcription factors (and presumed transcription factors). A distinct 
form of the motif is found also in the steroid and thyroid receptors. Retinoic acid 
and vitamin D receptors are also found in this family of transcription factors. A 
single amino add change within one of the zinc fingers of the vitamin D receptor 
has been found to be a cause of hereditary vitamin D-resistant rickets (Mechica et 
al, 1997). Transcription factors with a zinc motif have also been implicated in 
several malignant diseases. Mutations in steroid hormone receptors such as 
oestrogen receptors have been reported in some breast cancers (Webster et al, 
2001; Wang et al, 2004). The oncogene bd-6, which has an important role in 
large-cell lymphoma, is a zinc-finger protein (Ye et al, 1993). Another zinc-finger 
protein, shown to have dinical implications, is Wt-1, a tumour-suppressor protein 
that is inactivated in children with Wilm’s tumours (Schneider et al, 1993).
Leudne zippers consist of a stretch of amino adds with a leucine residue in every 
seventh position. A leudne zipper in one polypeptide interacts with a zipper in 
another polypeptide to form a dimer. Adjacent to each zipper is a stretch of 
positively charged residues that is involved in binding to DNA. The leudne-zipper 
motif underlies the interactions between the proto-oncogene products Jun and 
Fos, which constitute the heterodimeric transcription factor, Ap-1, and are 
implicated in signal-dependent processes that determine cell lineages and growth, 
and hence cardnogenesis (van Dam and Castrillazzi, 2001).
The amphipathic helix-loop-helix (HLH) motif has been identified in some 
developmental regulators and in genes coding for eukaryotic DNA-binding 
proteins. Each amphipathic helix presents a face of hydrophobic residues on one 
side and charged residues on the other side. The length of the connecting loop 
varies from 12-28 amino acids. The motif enables proteins to dimerize, and a basic 
region near this motif contacts DNA. While involved in lymphocyte, muscular, 
neuronal, adipocyte, and epithelial homeostasis (Coppe et al, 2003), aberrant
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transcriptional activity of this group of factors are also implicated in malignant 
disorders such as the aberrant expression of HLH HASH-1 protein in 
neuroblastomas (for review see Axelson, 2004).
The closely related HTH motif of transcription factors was originally identified as 
the DNA-binding domain of phage repressors. One alpha-helix lies in the wide 
groove of DNA; the other lies at an angle across DNA A related form of the motif is 
present in the homeodomain, a sequence first characterized in several proteins 
coded by genes concerned with developmental regulation in Drosophila. It is also 
present in genes for mammalian transcription factors. Some of these regulatory 
proteins are essential for the differentiation of hematopoietic precursor cells, and 
have been implicated in the development of breast cancers where constitutive 
expression of a novel gene product with HTH motif (termed candidate of 
metastasis 1) has been shown to increase metastatic potential (Hansen Ree et al, 
1999).
As this thesis primarily deals with the effect of Bm-3a and Bm-3b which are 
members of the POU-domain of transcription factors, which contain the HTH that 
facilitates DNA binding, the general properties of this family of proteins will be 
discussed in some detail (section 1.2), followed by a detailed account of Bm-3a 
and Bm-3b in section 1.3.
1.2 The POU domain family of transcription factors
In 1988, three mammalian transcription regulators were independently isolated 
and characterized. They included the ubiquitously expressed Oct-1 (Sturm et al, 
1988), the largely B-cell restricted Oct-2 (Muller-lmmergluck et al, 1988; Clerc et al, 
1988; Ko et al, 1988; Scheidereit et al, 1988), and the pituitary-specific Pit-1 
(Bodner et al, 1988; Ingraham et al, 1988). The subsequent comparison of their 
nucleotide and amino acid sequences with the Caenorhabditis elegans 
developmental regulator, Unc-86 (Finney et al, 1988), identified a region of high 
homology encoding a conserved structural component that was common to all 
these factors. Hence, a new family of transcriptional regulators, commonly referred
28
by the acronym POU (derived from the first letter of Pit-1, Oct-112 and Unc-86) 
emerged. Since their initial discovery, several other proteins have been added to 
the family based on the homology shared within the evolutionary conserved POU 
domain. All members have been shown to play important roles in ontogenetic 
development and cellular differentiation in specific cell types of the nervous system 
(for reviews see Anderson and Rosenfeld, 2001; Rosenfeld, 1991; Wegner et al,
1993).
1.2.1 The structurally conserved POU domain
The POU domain is a region of high homology that is unique to all the members of 
the POU-domain protein family. This domain, which varies in length from 147 to 
156 amino adds, comprises two structurally independent sub-domains, the amino- 
terminal POU-specific domain (POUs), of 70 -  80 amino adds, and the carboxyl- 
terminal POU-homeodomain (POUhd), of 60 amino adds (Herr et al, 1988). The 
two sub-domains are linked via a poorly conserved linker region of 14-25 amino 
adds in length (Fig. 1. 2.1).
The sequence homology within the POU domain, including the poorly-conserved 
linker region, has allowed the known mammalian POU domain proteins to be 
further dassified into six groups l-VI (for reviews see Andersen and Rosenfeld, 
2001; Rosenfeld, 1991; Treacy and Rosenfeld, 1992). Outside the POU domain, 
there is significant divergence in the sequence and structure of POU-proteins.
Despite the structural independence of the two sub-domains (Botfield et al, 1992), 
they function as a single functional unit. Mutagenesis studies involving POU 
proteins, Pit-1 and Oct-1, have dearly shown that the two sub-domains are 
required together to allow high-affinity, sequence-spedfic binding to the 
appropriate DNA response elements (Sturm and Herr, 1988; Ingraham et al, 1990; 
Klemm et al, 1994; Kristie and Sharp 1990; Aurora and Herr, 1992; Verrijzer et al, 
1990,1992).
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Fig 1.2.1: Schematic representation of the secondary structural elements of the 
POU domain
The POU domain can be subdivided into the highly conserved, POU specific 
domain (POUs) and the POU homeodomain (POUhd) separated by a linker region 
that varies in length (14-25 amino acids). The POUs domain consists of 75-82 
amino adds, and is composed of four a - helices. The POUhd domain consists of a 
region of 60 amino adds and has three a - helices. Conserved regions of basic 
amino adds are found in both POUs and POUhd (indicated by ® * ) . Highly 
conserved amino-adds among POU domain proteins are written underneath in the
1-letter code. (Adapted from Wegner, 1993)
1.2.1.1 POU-Specific domain (POU,)
The POU spedfic domain (POUs) is unique to the POU-domain proteins and is 
highly conserved among all members of the POU proteins. Nudear magnetic 
resonance spectroscopy (NMR) analysis on the solution structure of POUs of Oct-1 
has been carried out and taken to represent the general structure of POU proteins. 
This has shown that the POUs domain consists of two long and two shorter a- 
helices (Klemm et al, 1994). The second and the third helix form a helix-tum-helix 
(HTH) structure that binds to the major groove of the DNA (Fig. 1.2.1.1). This HTH 
motif is similar to that found in the DNA binding domains of the bacteriophage X 
repressor protein (Dekker et al, 1993; Assa-Munt et al, 1993). The marked 
similarity between the two HTH a-helices in the POUs and bacteriophage DNA-
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binding domains may be suggestive of evolutionary conservation due to the ability 
of this structure to bind DNA efficiently.
1.2.1.2 POU homeodomain (POUhd)
The POU homeodomain (POUhd) shows homology with the homeodomain of 
classic homeobox genes and is also highly conserved in POU proteins. The crystal 
structure of the Oct-1 POU domain bound to a DNA sequence containing an 
octamer site has revealed that the POUhd consists of three a-helices that form a 
compact globular structure, with helix 2 and 3 forming an HTH unit (Klemm et al, 
1994). In this Oct-1/DNA structure it is helix 3 that makes several contacts with the 
the 3’ half of the octamer site (Fig 1.2.1.1).
1.2.1.3 The linker region
The linker element in the POU domain is a poorly conserved spacer region of 14 -  
25 amino acids in length that is found between the POUs domain and the POUhd- 
Analysis of the crystal structure of Oct-1 POU domain has suggested that the 
linker region is a flexible, disordered structure in POU proteins (Klemm et al, 1994). 
The precise function of the linker region remains to be elucidated. However, 
proteolysis studies have ruled out the possibility of the linker being directly bound 
to the DNA since this region is easily accessible to the proteases (Botfield et al, 
1992; Aurora and Herr, 1992). At present, the linker is simply regarded as a flexible 
tether that covalently connects the POUs domain to the POUhd, with a role in 
facilitating the orientation of these two sub-domains on the DNA
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POU Hemcooomum Contact*
POU-Spaahc C ontacts
Fig 1.2.1.1: (A) Schematic representation of the contacts made by the POU- 
specific and POU- homeo domains upon binding to the DNA recognition site. 
Cylinders indicate the positions of the a-helices. The flexible linker which 
connects the two domains are indicated by the solid and dotted lines. (B) Sketch 
summarizing all the DNA contacts made by the POU domain of Oct-1 on its DNA 
recognition sequence. The DNA is represented as a cylindercal projection and 
the Atgc and AAAT subsites recognised by the POU-specific and POU- homeo 
domain, respectively, are highlighted (Taken with permision from Klemm et al, 
1994).
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1.2.2 DNA response elements recognized by the POU domain 
factors
The categorisation of the POU domain proteins into six distinct sub-classes is 
based on similarities in their genetic structure and expression, as well as cis-acting 
DNA response elements that are recognised by members within each class. Each 
POU transcription factor family exhibits preferential binding to a specific DNA 
sequence. For example, the class I Pit-1 protein binds most effectively to the 
consensus sequence 5’-ATGNATAWW-3’ (where N= any base and W=A/T) and 
was first identified as the transcription factor that bound a regulatory region 
common to the growth hormone and prolactin genes (Bodner et al, 1988; 
Ingraham et al, 1988). Class II proteins bind to the octamer motif 5 -ATCGAAAT-3’ 
with the maximum affinity (Aurora and Herr, 1992; Verrijzer et al, 1991; 1992). 
However, the proteins of this class also have the ability to bind other non-canonical 
sequences, but with a commensurate reduction in the binding affinity (Verrijzer et 
al, 1991; 1992; Aurora and Herr, 1992; Baumruker et al, 1988). The class III and 
dass IV POU protein bind with the highest affinity to sites with the consensus 
sequence CAT(N)nWAAT (where N=any base, W=A/T, dass III n=0, 2, or 3, dass 
IV n=3) (Li et al, 1993). Sequences flanking the core recognition site confer a 
moderate but significant influence on the binding affinity of POU-domain proteins 
with the DNA, hence allowing for some degeneracy within the DNA binding motif 
recognised by these proteins (Baumruker et al, 1988). In summary, members of 
the same sub-dass of POU domain factors exhibit similar DNA-binding 
preferences, and all DNA binding sites recognized by POU transcription factors are 
A/T rich sequences and lable sequence similarities.
1.2.3 Bipartite DNA binding by POU domain proteins
POU domain proteins interact with DNA via their unique POU-domains. X-ray 
crystallography and NMR imaging have resolved several structures of POU family 
of transcription factors on their DNA response elements. These analyses have 
revealed in atomic detail the great flexibility allowed by the bipartite DNA binding 
POU domain (Klemm et al, 1994; Jacobson et al, 1997). The two structurally 
independent sub-domains of the POU domain, PoUs and POUhd, both contain HTH
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DNA binding motifs which make sequence specific DNA contacts in a cooperative 
manner (Klemm et al, 1994).
The isolated POU-specific domain binds to the DNA recognition sites with high 
sequence specificity but the binding affinity is low (Strum and Herr, 1988; Ingraham 
et al, 1990; Verrijzer et al, 1992; Aurora and Herr, 1992). In vitro binding assays 
including electromobility shift assay (EMSA) with normal and mutated octamer 
binding sites as well as using ultraviolet cross-linking have shown that the POU- 
specific domain of Oct-1 recognises and binds to the ‘left side’ of the octamer motif 
(Verrijzer et al, 1990,1992; Aurora and Herr, 1992). In agreement crystallography 
studies of the POU domain of Oct-1 bound to an octamer sequence, ATGCAAAT, 
have clearly highlighted that the POUs domain recognises ATGC sequence on the 
5’ half of the POU domain binding site (Klemm et al, 1994). It is, in fact the third a- 
helix of the POUs domain that binds this sub-site in the major groove of the DNA 
(Fig. 1.2.1.1). This high specificity binding of the POUs domain to the DNA- 
recognition site causes bending in the DNA, which may be critical for 
conformational changes to allow transcriptional complex assembly or protein- 
protein interactions, necessary for the POU domain proteins to function (Dekker et 
al,1993). Moreover, POUshas been implicated in DNA replication function by Oct- 
1, and it is thought that the unwinding of the DNA by the torsion at the bend may 
also facilitate DNA replication machinery to bind to the single-stranded, unwound 
DNA (Verrijzer et al, 1990,1991).
The POUhd of Oct-1 has been shown to bind AAAT subunit at the 3’ ends portion 
of the octamer sequence (Klemm et al, 1994). The first nine residues of the POUhd 
form an extended N-terminal arm that fits into the minor groove of the DNA It is 
the third helix that makes base contacts in the major groove of the DNA and is 
referred to as the recognition helix of WFC region. This region contains the 
invariant RVWFCN residues in all known members of the POU domain proteins 
and makes contact with the TAAT sub-site of the recognition sequence. The 
importance of this helix is exemplified by the mutations in the Pit-1 POUhd where 
the conversion of a trytophan residue at position 7 to a cysteine results in the loss 
of binding to the recognition motif (Li et al, 1990). Both the amino- and carboxyl-
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terminals of the POUhd contain a set of basic amino acids, critical for their ability to 
bind DNA (Treacy and Rosenfeld, 1992).
Upon binding the consensus octamer motifs, the two sub-domains are oriented on 
the opposite sides of the DNA, with no contacts between them (Fig 1.2.1.1) 
(Dekker et al, 1993; Klemm et al, 1994). It appears that the POUs domain exerts a 
stronger preference for binding to the cognate DNA sequences and, therefore, 
dictates the overall binding of the POU proteins (Verrijzer et al, 1992a, 1992b). In 
addition, the POUs domain stabilizes the contacts made by the adjacent POUhd 
Hence, the two sub-domains of the POU domain acting in concert confer the high- 
affinity, sequence specific binding to the appropriate recognition sites of the DNA.
1.2.4 Different classes of the POU family members
Following the initial identification of four members of the POU domain proteins, an 
additional twenty two POU domain gene products have been identified in 
mammals, C.elegans, Drosophilia, and Xenopus. These known POU domain 
family members have been subdivided into six distinct classes: l-VI (Table 1.2.4). 
Originally this subdivision into groups was based on the similarities shared within 
the POUs and linker region. However, additional features are conserved within 
these classes. For example, the mammalian dass III POU domain genes are 
intronless and have homologous regions of various homo- and poly-meric residues 
at their amino-terminal (for review see McEvilly and Rosenfeld, 1997). Some 
members of the dass IV POU domain genes contain a conserved region referred 
to as the POU IV box in the amino terminus of the protein that shares homology 
with the mammalian gene MYC-N (discussed in section 3) (Veenstra et al, 1997).
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Class Factor Chromosome
Localization
Expression 
Embryo Adult
Knock-out
Phenotype
I Pit-1 (GHF-1. PUF-1, 
Pou1f1)
Mouse 16 Neural tube Pituitary Dwarfism
II Oct-1(OTF-1, NF-A1, 
NFIII,OBP100,Pou2f1)
Mouse 1 
Human 1
Ubiquitous Ubiquitous Not reported
Oct-2(OTF-2, NF-A2, 
POU2f2)
Mouse 7 
Human 19
Neural tube, 
Brain
Lymphoid cels. 
Nervous system, 
Intestine, Testis, 
Kidney
Aberrant B-cel maturation;
Skn-1 a/l(Oct-11, Otf- 
11. Epoc-1. POU2f3)
Mouse 9 
Human 11
Developing
Epidermis
Epidermis Abnormal terminal differentiation of 
epidermal keratinocytes
III Bm-1(Otf-8, POU3f3) Mouse 1 Developing
nervous
system
CNS. Kidney Not reported
Bm-2(N-Oct3,N-Oct5, 
Otf-7, POU3f2)
Mouse 4 
Human 6
Developing
nervous
system
CNS,
Glioblastoma.
Neuroblastoma
Defects in the differentiation and 
migration of hypothalamic neurons
Bm-4(RHS2, N-Oct4, 
Otf-9, POU3f4)
Mouse X Neural tube CNS (forebrain) Defects in the inner ear 
development 
manifested as deafness
Tst-1(Oct-6,SCIP, Otf- 
6. Pou3f1)
Mouse 4 Blastocyst,
ES/EC cels. 
Brain
Nervous system, 
Testis
Myelinating glia
Defective myeknation; abnormal 
phrenic nucleus
IV Bm-3a(Bm-3.0, RDC- 
1, Pou4f1)
Mouse 14
Human 13
Brainstem
Retina,
Spinal cord
Sensoryganglia
Neuroepithelioma
Nervous system, 
Retina,
Sensory ganglia, 
Ewing's sarcoma
Lack of specific sensory and 
autonomic neurons
Bm-3b(Bm-3.2.
Pou4f2)
Mouse 8 
Human 4
Developing brain, 
Sensory neurons, 
Retina
Nervous system, 
Sensory ganglia, 
Retina, Cervix, 
Ovary
Loss of retinal gang Ion cells 
resulting in blindness
Bm-3c
(Bm-3.1, POU4f3)
Mouse 18 
Human
Sensory neurons, 
neurons, DRG, 
Trigeminal ganglia
Sensory
DRG,
TG
Loss of inner hair cells, resulting in 
deafness
V Oct3/4(Oct-5, Otf-3, 
NF-A3, POU5f1)
Mouse 17 
Human 6
ES/EC cels 
Primordial germ 
cells
Testis, Ovaries
Oocytes All cells in the early embryo become 
trophoblasts
VI Bm-5(Emb, mPOU, 
TCFp, Pou6f1)
Mouse 15 
Human 12
Developing brain Skeletal muscles, 
Brain, Heart,
Lung
Not reported
RPF-1(POU6f2) Mouse 13 
Human 7
Developing brain, 
Lung, Spinal cord
Brain, Heart, 
Adrenal anterior 
pituitary
Not reported
Table 1.2.4: The six classes of POU transcription factors (adapted from 
Andersen and Rosenfeld, 2001; NCBI Entrez Gene)
The alternative names by which these factors may be referred to are also given. 
The chromosomal localization of the genes and their expression pattern during 
development and in adult life are indicated. The phenotypes of the knock-out 
mouse models are also briefly discussed. (ES-embryonic stem cell, EC- embryonic 
carcinoma cell, CNS- central nervous system, TG-trigeminal ganglia, DRG-dorsal 
root ganglia)
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1.2.5 Expression and function of POU domain proteins
Ontogenic studies of the POU-domain gene family have revealed that specific 
POU-domain proteins are expressed temporally in different cells of the developing 
nervous system. In adults, the POU domain transcription factors exhibit a more 
spatially restricted pattern of expression, with the exception of the ubiquitously 
expressed Oct-1 which is thought to be involved in the regulation of expression of 
a number of housekeeping genes such as the histone H2B and snRNA genes 
(Hinkley and Perry, 1992; Mattaj et al, 1985). Subsequent studies using 
developmental mutants or genetic analysis, in which specific POU domain genes 
were mapped to the lod associated with developmental disorders, have further 
highlighted an important role for POU proteins either during early embryogenesis 
or in the terminal differentiation of specific cell types (see review, Rosenfeld, 1991; 
Verrijzer and van der Vilet, 1993; Wegner et al, 1993; Latchman, 1999).
For instance, the class I POU protein, Pit-1, is expressed in the anterior pituitary 
and regulates the expression of the prolactin and growth hormone genes (Nelson 
et al, 1988). Pit-1 is critical for the normal development of the anterior pituitary 
gland and mutations that result in its inactivation have resulted in congenital 
dwarfism in both mice (Li et al, 1990) and in humans (Radovick et al, 1992). Loss 
of Pit-1 is associated with the absence of pituitary hormones prolactin (PRL), 
growth hormone (GH) and thyroid stimulating hormone (TSHp) all of which are 
crucial for normal growth. Besides its role in the regulation of these terminal 
differentiation marker genes (GH, PRL, and TSHp), Pit-1 stimulates cell 
proliferation of pituitary cells, as evidenced in the Pit-1 deficient Snell and Jackson 
dwarf mice, which exhibit a severe failure in the expansion of somatotropes, 
lactotrophes and thyrotropes (Li et al, 1990). Moreover, reduction in the levels of 
Pit-1 using antisense strategy results in decreased cell proliferation of somatotroph 
cells (Castrillo et al, 1991). Pit-1 provides an underlying theme of the involvement 
of POU-domain proteins in the coordination of cell proliferation and orderly 
progression of cellular differentiation.
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Oct-2 is expressed in B lymphocytes as well as in specific neuronal cells in the 
developing and adult nervous system (Hatzopoulos et al, 1990; He et al, 1989). 
Oct-2 exhibits different functions in the two cellular systems such that in B 
lymphocytes, it activates the expression of immunoglobulin genes whose 
promoters contain an octamer motif (Singh et al, 1986; Wirth et al, 1987). In 
contrast in neuronal cells, Oct-2 protein essentially inhibits expression of certain 
genes such as the herpes simplex virus immediate-early genes (Lillycrop et al, 
1991) as well as the cellular tyrosine hydroxylase gene promoter (Dawson et al,
1994). These differences in activity between Oct-2 in neuronal and B-cells result 
from protein variants being produced in the two cell types. Alternative splicing of 
the primary transcript of the Oct-2 gene gives rise to different forms of the mRNA 
encoding different Oct-2 proteins (Oct 2.1 to Oct 2.8), with different transactivation 
function (Wirth et al, 1991; Lillycrop and Latchman, 1992). These different forms of 
Oct-2 are differentially expressed in B-cells and neuronal cells, with the activator 
Oct-2.1 being the predominant form in B-cells whilst repressor isofbrms, Oct 2.4 
and Oct-2.5, are more abundant in neuronal cells (Lillycrop and Latchman, 1992). 
Knock out Oct-2 mice show a failure of the mutants to feed properly and die shortly 
after birth, supporting a critical role for this transcription factor in the normal 
development of the nervous system (Corcoran et al, 1993; Ninkina et al, 1995).
Other POU factors such as Oct-3/4 and SCIP/Oct-6/Tst-1 are expressed in very 
early developmental stages. Oct-3/4 expression is characteristic of a pluripotent 
undifferentiated cell phenotype and is detected in unfertilized oocytes as well as in 
the fertilized ova. The levels of Oct-3/4 expression are downregulated upon 
differentiation of the blastocyst (Scholer et al, 1990; Rosner et al, 1990). The 
SCIP/Oct-6/Tst-1 gene is expressed in pre-implantation embryos and later on in 
the developing brain and specific neuronal cells, but once these cells have 
differentiated and exited the cell cycle, expression of this transcription factor drops 
dramatically (Suzuki et al, 1990; Monuki et al, 1990). Hence, Oct3/4 and SCIP/Oct- 
6/Tst-1 are associated with a proliferative, pluripotent state of the cell.
Similarly, expression of members of the POU IV family of transcription factors are 
also developmentally regulated. For instance, the nematode gene product, Unc- 
86, is developmentally regulated in sensory neurons and is critical for the normal
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development of these cells (Finney et al, 1988; Finney and Ruvkun, 1990; Xue et 
al, 1993). Thus, mutations in Unc-86 gene, which is normally needed for the 
commitment of several sensory neuroblast lineages as well as the specification 
and maintenance of particular neural phenotypes, results in the absence of specific 
sensory neurons (Desai et al, 1988; Finney and Ruvkun, 1990). Members of the 
Bm-3 sub-family of POU IV proteins are also expressed in specific cells of the 
mammalian developing nervous system, with their expression becoming more 
restricted in adults. Inactivation of any of the three closely related POU factors Bm- 
3a, Bm-3b, and Bm-3c results in the absence of specific neuronal cell types 
(discussed in detail in section 3). Similarly, mutations in the gene encoding the Bm- 
4 factor, which result in ffameshift and premature stops in the translation of this 
gene or non-conserved amino acid mutations in the POU domain of the protein, 
have been shown to be associated with the most common form of deafness in 
humans (de Kok et al, 1995).
Studies of the expression pattern of several POU domain genes have highlighted 
some features common to these factors. Firstly, mRNA encoding many POU 
proteins have been widely detected in the developing nervous system and this 
suggests a function for POU domain transcription factors in the development and 
maintenance of the nervous system. Secondly, many POU domain factors appear 
to be critical for the normal development of specific cell types as demonstrated by 
in vitro and in vivo deletion studies. A summary of the expression and function of 
some POU domain proteins during development and in adult tissue is given in 
Table 1.2.4.
1.2.6 Phosphorylation and POU protein function
Phosphorylation, as a mechanism of regulation of proteins at a post-translational 
level, is a recurrent theme in several biochemical pathways. A number of POU 
proteins undergo such modification and this has been shown to directly modulate 
their DNA binding activity and hence their function as transcription factors (for 
review see Jackson, 1992; Caelles et al, 1995). For example, the Oct-1 is 
phosphorylated (possibly on the Ser385 residue in the POU-homeodomain) during
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mitosis and is thereby prevented from binding the H2B response element (Segil et 
al, 1991). This phosphorylation of Oct-1 is reversed as the cells exit mitosis (Segil 
et al, 1991; Roberts et al, 1991). Therefore, while the protein levels of Oct-1 remain 
constant during the cell cycle, its function changes. Similarly, phosphorylation of 
Oct-2 is a prerequisite for the activation of transcription of the (3-globin gene 
promoter (Tanaka and Herr, 1990).
Phosphorylation of Pit-1 protein alters its DNA-binding ability as well as its 
dimerization potential depending on the recognition site. In vitro protein kinase A 
assays have shown that the phosphorylation of a threonine220 residue in the POUhd 
of Pit-1 decreases its binding to the growth hormone response element, while 
increasing its binding affinity on the proximal prolactin promoter and has no effect 
on binding of Pit-1 to its own promoter (Kapiloff et al, 1991). Jun kinase (JNK) / 
stress-activated protein kinase binds the activation domain of Bm-5 and 
phosphorylates its POU domain on sites that are distinct from the aforementioned 
Oct-1/Pit-1 phosphorylation sites. This phosphorylation results in increased binding 
to DNA and enhanced transactivation (Kasibhatla et al, 1999).
1.2.7 Protein-protein interaction by POU domain proteins
In addition to their ability to bind DNA, POU proteins can also mediate interactions 
with other proteins to regulate transcription. Since several members of the POU 
domain family are co-expressed during development the protein-protein 
interactions of different POU proteins may provide an additional control for the 
differential regulation of distinct genes by changes in the levels of different POU 
proteins. This interaction of POU proteins with co-activators in specific cells at 
different developmental stages might explain the highly restricted tissue specificity 
during development by these proteins.
Proteins that interact with POU factors can be classified into four classes: DNA- 
binding proteins transcriptional activators, co-regulators, basal transcription factors, 
and replication factors. Interaction of POU proteins with each class is discussed in
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the following sections and Figure 1.2.7 gives a schematic representation of a few 
POU domain proteins interacting with other proteins on some target promoters.
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Fig 1.2.7: Protein-protein interactions of POU domain factors.
Interactions of POU domain factors with other proteins are effected by the amino 
acid sequence of the POU domain and the sequence of the DNA binding site.
a)Pit-1 interacts with GATA transcription factors. On promoters containing 
binding sites for both Pit-1 and GATA, the interaction seems to be cooperative 
and results in transcriptional activation (left panel). On promoters containing 
GATA-binding sites, but lacking Pit-1 binding sites, Pit-1 can inhibit GATA binding 
to DNA and transactivation (right panel).
b)The cofactors VP16 and OCA-B interact selectively with Oct-1 and Oct-2. VP16 
interacts with Oct-1 on TATGARAT DNA sites, with VP16 contacting the GARAT 
part of the site. This interaction is stabilized by HCF. Oct-1 and VP16 do not 
interact on a classical octamer site and VP16 is incapable of interacting with the 
highly related Oct-2, even on TATGARAT sites, indicating that minor differences 
in the sequence of the POU domain can direct the specificity of protein-protein 
interactions. In contrast, OCA-B can interact both with Oct-1 and Oct-2. However, 
this interaction is restricted to sites related to the classical octamer sequence and
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does not form on TATGARAT sites (Taken with permission from Andersen and 
Rosenfeld, 2001).
1.2.7.1 Interactions with other DNA binding proteins
The complexity of regulatory effects by POU proteins is demonstrated by their 
ability to bind as monomers or dimers (either homo- or heterodimer). For example, 
Pit-1 and Oct-2 have been shown to be largely monomeric in solution (Lebowitz et 
al, 1989; Poellinger and Roeder, 1989; Igraham et al, 1990), but these proteins 
also exhibit cooperative or synergistic interactions with other transcription factors 
on the target gene promoters in order to maximize their transactivation potential. In 
this regard, homodimerisation of Pit-1 is required for the maximal stimulation of the 
prolactin gene. DNA-dependent cooperative binding interactions are encouraged 
by the presence of four Pit-1 recognition sites within the promoter and four more 
sites within the enhancer (Nelson et al, 1988). Most of these sites are able to 
accommodate Pit-1 dimers, allowing a cooperative Pit-1-dependent, cell-specific 
expression of the prolactin promoter (Crenshaw et al, 1989). Similarly, multiple 
binding sites for Pit-1 have also been shown to be present in the promoters of the 
growth hormone gene and the Pit-1 gene itself (Chen et al, 1990; McCormick et al, 
1990).
Similarly, cooperative interactions have been shown between two Oct-2 proteins 
on the immunoglobulin heavy (IgH) chain promoter which contains a heptamer 
element adjacent to the natural response octamer motif for this protein (LeBowitz 
et al, 1989). The heptamer motif enhances activation of the IgH promoter by up to
2-5 fold. Both sites are generally occupied within the IgH promoter so facilitating 
the cooperative interactions between the POU domains of the bound Oct-2 
proteins (Kemler et al, 1989; LeBowitz et al, 1989; Poellinger et al, 1989). 
Mutations in either the canonical octamer site or the adjacent heptamer site results 
in complete loss of transactivation suggesting that interaction of POU domain 
proteins is not restricted to bases within the octamer sequence elements but is 
also influenced by sequences flanking this octamer motif and hence, contributes to 
the specificity and activity of these proteins (Poellinger and Roeder, 1989).
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POU proteins can also form heterodimers with other POU transcription factors. An 
example of this heteromeric complex formation between two different POU 
proteins is provided by interactions between Pit-1 and Oct-1 to mediate synergistic 
induction of the prolactin promoter (Voss et al, 1991). Oct-1 has also been shown 
to heterodimerise with Oct-3, Oct-2 and SCIP/Oct-6/Tst1 (Vigano et al, 1996; 
Verrijzer et al, 1992).
Furthermore, POU proteins can also bind other classes of transcription factors as 
heterodimers to enhance transcription. For example, Pit-1 can interact with the 
oestrogen receptor, and together the two transcription factors are required for the 
maximal stimulation of the prolactin gene expression (Simmons et al, 1990). 
Similarly, Pit-1 can interact and cooperate with the thyroid hormone receptor of the 
growth hormone gene promoter (Schaufele et al, 1992), and the GATA-2 
transcription factor on the thyrotrope-spedfic TSHp promoter (Gordon et al, 1997; 
Dasen et al, 1999). The members of the POU IV sub-family can also interact with 
other transcription factors and modify expression of target genes. For example, 
Bm-3a interacts with p53, which results in differential effects on Bax and 
P2 icipi/wafi expression (Budhram-Mahadeo et al, 2002; Perez-Sanchez et al, 
2002), whereas Bm-3b interacts and cooperates with the oestrogen receptor 
(Budhram-Mahadeo et al, 1998). These interactions of Bm-3 proteins are 
discussed in section 1.3 of this chapter.
Heterodimeristion by POU domain proteins does not only act to enhance 
transactivational effect but depending on the target gene promoters, some act as 
repressors to reduce or prevent transcription. This is exemplified by the 
heterodimerization between two co-expressed Drosophila proteins, l-POU and 
Cfla, an association which prevents Cfla homodimerisation, needed for binding to 
and activation of the DOPA decarboxylase gene (Treacy et al, 1991). It appears 
that the affinity of l-POU for Cfla is much higher than the affinity of the latter for its 
cognate DNA recognition sequence (Treacy et al, 1991). The biological 
significance of this association is provided by the detection of co-expression of 
these two proteins in a sub-set of developing neurons during Drosophila
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development. Therefore, levels of different proteins that are co-expressed will 
influence the effects on transcription of specific genes.
The mammalian POU domain protein, Oct-1, provides another example of 
transcriptional repression achieved by interactions with other proteins. The 
interaction between the nudear hormone receptor, retinoic add receptor (RXR), 
and Oct-1 causes transcriptional repression of the thyroid hormone response 
elements (Kakizawa et al, 1999). Oct-1 represses transcription by sequestering 
RXR and inhibits it from forming active dimers with other members of the nudear 
hormone receptor family.
1.2.7.2 Interaction with co-regulator proteins
POU domain proteins have also been shown to interact with co-regulators proteins 
that fail to bind the DNA directly. One of the most extensively studied examples is 
the interaction between Oct-1 and co-regulator VP16A/mw65/aTIF, a viral protein 
which regulates the expression of HSV immediate-early (IE) genes. VP16 does not 
bind DNA directly, but is recruited to IE promoters by interacting with Oct-1 (Kristie 
et al, 1989; Stem et al, 1989; Stem and Herr, 1991). This complex is stabilized by 
the host cell fador (HCF/C1) (Xiao and Capone, 1990). Oct-1 A/P16/HCF complex 
is recruited to modified octamer sites (5’-TAATGARAT-3’) of immediate early 
genes, ICPO and ICP4. The specific amino adds in the Oct-1 POU domain that 
are important for this interaction have been located on the surface of the second 
helix of the POUhd (Lai et al, 1992; Pomerantz et al, 1992). Another transcriptional 
regulatory region found adjacent to the IE enhancer is that for the cellular 
transcription factor GABP (Triezenberg et al, 1988). Vogel and Kristie (2000) have 
shown Oct-1, GABP and VP16 complex is recruited by HCF/C1 to this enhancer 
site, where HCF/C1 acts as a co-activator of GABP mediated transcription.
Similarly, both Oct-1 and Oct-2 have been shown to transactivate several 
lymphoid-spedfic promoters but only after assodating with the B-cell spedfic co­
activator, OCA-B (also referred to as OBF-1 and Bob-1) (Luo et al, 1992; Strubin et 
al, 1995). By interacting with the POU domains of Oct-1 and Oct-2, OCA-B is
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recruited to a subset of octamer sites where it serves as a coactivator for 
transcription (Babb et al, 1997; Mattias, 1998). In addition to making contacts with 
the POU domains of Oct-1 and Oct-2, it appears that OCA-B also makes direct 
contacts with the DNA backbone at the centre of the octamer site (Chang et al, 
1999; Chasman et al, 1999). A model has been proposed where OCA-B clamps 
the two POU sub-domains together and simultaneously bridges the DNA within the 
octamer motif at several positions. Hence, OCA-B seems to help organize the 
conformation and stabilization of Oct POU domain on DNA (Babb et al, 1997).
1.2.7.3 Interactions with basal transcription factors
Oct-1 and Oct-2 also provides a model of how POU domain proteins are able to 
interact with the basal transcriptional machinery. The POU domains of Oct-1 and 
Oct-2 interact with the TATA box binding protein (TBP) in vitro. This interaction has 
been confirmed in vivo by co-immunopredpitation, and co-transfection 
experiments have shown that introduction of both Oct-2 and TBP gives rise to 
synergistic activation of transcription at an octamer-containing promoter (Zwilling et 
al, 1994). Deletion studies have demonstrated this interaction to be mediated via 
the POU domain of Oct-2 and C-terminal domain of the general transcription 
factor, TFIID (Zwilling et al, 1994). Moreover, Oct-2 seems to be required 
continuously at the promoter for multiple rounds of transcription (Amosti et al, 
1993).
In addition, Oct-1 has also been shown to play a critical role in pre-initiation 
complex recruitement at some promoters that lack the TATA element. For 
example, interaction of Oct-1 with transcription factor II B (TFIIB) stimulates the 
lipoprotein lipase promoter containing an octamer motif (Nakshatri et al, 1995). 
Therefore, in certain cases, Oct-1 appears to functionally substitute for TBP.
1.2.7.4 Interactions with replication factors
The POU domain of Oct-1 interacts with the precursor terminal protein (pTP), a 
viral protein required for adenoviral replication (de Jong and van der Vliet, 1999;
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Botting and Hay, 1999). The Oct-1 interaction affects the conformation of pTP and 
this interaction may activate the DNA polymerase and initiate viral DNA replication 
(Botting and Hay, 1999). However, more extensive studies are required to 
establish the role of POU factors in DNA replication.
1.2.8 Activation and repression domains of POU domain 
proteins
Whilst the POU domain is involved in DNA binding, the major regulatory domain(s) 
of known POU proteins have been mapped outside their DNA binding domain at 
the amino- and carboxyl- terminus of the proteins. These domains are poorly 
conserved between different POU domain factors, reflecting the specificity of 
action of different factors which often bind to the same DNA response elements.
The N- and C- terminal transactivation domains of Oct-2 have been extensively 
characterised (Tanaka and Herr, 1990; Tanaka et al, 1992; 1994; Muller- 
Immergluck et al, 1990). Various isoforms of Oct-2 have different activation 
domains which may be associated with the different transcriptional effects. Thus, 
whereas Oct-2.1 has two activation domains located in the amino and carboxyl 
terminals, Oct-2.5 lacks the carboxyl-terminal activation domain due to post- 
transcriptional processing (Schreiber et al, 1988; Hatzpoulos et al, 1990; Wirth et 
al, 1991). The significance of these differences in the activation domains is seen in 
the ability of Oct-2.1 to activate all octamer containing promoters while Oct-2.5 has 
a generally repressive effect on transcription (Lillycrop et al, 1994; Dent et al, 1991; 
Lillycrop and Latchman, 1992). The identification of other domains such as the 
leucine zipper domains in Oct-2.1 protein may also contribute to protein-protein 
interactions, suggesting that interaction between different factors achieves the 
resultant transcriptional effect of POU proteins (Lillycrop and Latchman, 1992).
SCIP/Oct-6flst-1 has its activation domain located at the amino-terminus of the 
protein. When this domain is coupled to the heterologous Gal4 DNA-binding 
domain, the hybrid protein acts as a strong transactivator of Gal4 target constructs 
in Schwann cells but not in Hela cells. This suggests that SCIP/Oct-6/Tst- 
1 interacts with a cell-specific co-activator that is only present in Schwann cells and
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this transactivation domain may determine the target regulated by SCIP/Oct-6/Tst- 
1. SCIP/Oct-6/Tst-1 acts as a transcriptional activator on some genes, such as 
immunoglobulin promoter (Suzuki et al, 1990) or as a repressor of genes encoding 
myelin specific protein (Monuki et al, 1990). The mechanism by which the 
repression is achieved has not yet been determined.
In general, POU domain proteins contain one or more regulatory domains, and the 
requirement of other cell-type-specific co-factors suggests a complex interaction of 
a number of factors to achieve strong transcriptional effects reported on various 
target gene promoters controlled by these proteins.
1.3 POU IV subclass of POU domain proteins
Following the identification of the four POU-domain containing proteins, He and 
colleagues (1989) subsequently found other novel proteins from different tissues 
within this family. They utilised a technique in which reverse 
transcriptase/polymerase chain reaction strategy was carried out using degenerate 
primers designed from each end of the highly homologous POU domain. These 
primers were used to amplify cDNA made from RNA extracted from human and rat 
brain and testis. One factor isolated from brain cDNA using this approach was 
called Bm-3 (now referred to as Bm-3a, Bm-3.0, or POU4F1). A similar approach 
was utilized by Lillycrop and colleagues (1992) using cDNA prepared from the 
ND7 cells, a cell line derived from the fusion of mouse neuroblastoma cell line and 
sensory neurons derived from dorsal root ganglia (DRG) (see later section 
1.3.6.1.2). Results of these studies identified a protein with high homology to Bm- 
3a in the POU domain, and this is now referred to as Bm-3b (Bm-3.2 or POU4F2) 
(Lillycrop et al, 1992). Similarly, another member of this sub-family, Bm-3c (Bm-3.1 
or POU4F3) has been isolated from a cDNA library prepared from DRG and spinal 
cord (Ninkina et al, 1993).
The mammalian family of Bm-3 proteins together with nematode Unc-86 and 
Drosophila l-POU have been categorised into POU-IV sub-family of POU domain 
proteins. The proteins of this class share a particularly high homology in the POU 
domain. Some members of this family also have a highly conserved region in the
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N-terminal domain referred to as the POU-IV box (Gerrero et al, 1993; Theil et al, 
1993).
As this thesis primarily deals with Bm-3a and Bm-3b, the focus in the next sections 
will be on these two transcription factors in terms of their expression and functional 
roles in different cell types.
1.3.1 Chromosomal localization of Brn-3a and Bm-3b
Bm-3a and Bm-3b proteins are encoded by different genes and localized on 
different chromosomes. While Bm-3a is found on mouse chromosome 14 (14E1- 
3) (Xia et al, 1993; Theil et al, 1994), its human homologue has been mapped to 
chromosome 13 (13q14-q22) (Collum et al, 1992). This is in agreement with the 
evdutionary conserved relationship between human chromosome 13 and mouse 
chromosome 14 (Lyon and Kirby, 1993).
Fluorescent in situ hybridization has mapped Bm-3b gene to human chromosome 
4 (4q31.2) (Xiang et al, 1993) and on chromosome 8 in the mouse (NCBI data 
base).
1.3.2 Isoforms of Brn-3a and Brn-3b
Sequence analysis of Bm-3a and Bm-3b has revealed two distinct isoforms of 
these transcription factors that differ in the amino terminal region (Fig. 1.3.2) (Theil 
et al, 1993; Theil and Moray 1993; Gerrero et al, 1993; Turner et al, 1994). 
Analysis of the genomic sequence for Bm-3a reveals that it is encoded by two 
exons separated by an intron.
Bm-3a locus has two start sites of transcription located about 500 base pairs apart 
in the gene sequence. As a consequence of alternative promoter usage, two 
distinct mRNAs are generated that differ at their 5’ end (Fig. 1.3.2) (Theil et al, 
1993; Theil and Moray, 1994). Hence, two distinct Bm-3a proteins are produced 
that vary in size and have distinct amino terminal domains. The longer Bm-3a
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cDNA [Bm-3a(l)] is generated from the upstream transcription start site and has an 
additional exon at the 5' end, which is not present in the cDNA of the short isoform 
[Bm-3a(s)]. This additional exon gives rise to an mRNA with a coding potential of 
421 amino acid residues, and results in a protein with a molecular weight of 43 
KDa. The shorter intronless Bm-3a(s) cDNA has an open reading frame of 1011 
nucleotides and encodes a protein of 337 amino acids, with a predicted molecular 
weight of approximately, 33.5 KDa. Bm-3a(s) protein lacks approximately 80 
amino terminal residues and so does not have the POU-IV box found in Bm-3a(l).
Bm-3b has a similar genomic organization with the gene being encoded by two 
exons separated by an intron. The two isoforms of Bm-3b are also generated as a 
result of usage of alternative translation start sites. The larger protein [Bm-3b(l)] 
consists of 411 amino add residues, giving rise to a protein of 42 KDa (Turner et 
al, 1994). The shorter isoform [(Bm-3b(s)] consists of 322 residues, with a 
predicted molecular weight of 35 KDa (Theil et al, 1993). Due to the different site of 
exon/intron boundaries in the Bm-3b gene, Bm-3b(s) protein has nine amino- 
terminal residues that are not present in Bm-3b(l) (Fig. 5). However, this shorter 
isoform also lacks the POU IV box found in Bm-3b(l). The effects of these 
differences are still to be determined.
1.3.3 The POU IV box
Outside the highly homologous POU domain that is present at the carboxyl 
terminus of all Bm-3a and Bm-3b proteins, the longer isoforms Bm-3a(l) and Bm- 
3b(l) proteins share another region of significant homology at the amino terminus, 
referred to as the POU-IV box (Fig. 1.3.2; Gerrero et al, 1993; Theil et al, 1993). 
The POU IV box contains forty amino adds which are well conserved in many 
members of the POU-IV proteins. Comparison of the sequence of the POU-IV box 
shows significant homology to the highly conserved region in the N-terminus of the 
o-Myc family members (Collum et al, 1992). In the c-Myc proteins, this region is 
modified by the microtubule assodated protein 2 (MAP-2) kinase for 
transactivation of these proteins (van-Beneden et al, 1986) but its function in POU 
IV proteins remains to be eluddated.
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The functional significance of this additional domain in the longer Bm-3a and Bm- 
3b proteins has yet to be ascertained fully. However, recent studies with Bm-3a 
suggest that this domain but may be required for the increased survival associated 
with Bm-3a (Faulkes et al, 2004). Even though Bm3a(s) and Bm-3b(s) bind DNA, 
they are not capable of this function as they lack the amino-terminal POU-IV box. 
Therefore, the POU IV domain may represent an interface for interacting with other 
co-activators to modify transcription of specific target genes.
Brn-3a short
1 42 109 268 421
l-3b short
POU-Domain
Fig 1.3.2 Schematic representation of the different domains of Bm-3a and Bm-3b 
The long isoform [Bm3a(l), Bm-3b(l)] of both transcription factors is due to an extra 
domain at their N-terminal region. The POU IV box is a highly conserved region 
found only in the longer isoforms of both proteins, Bm-3a(l) and Bm-3b(l), while the 
POU domain is found in both forms of each proteins. Regions of high homology 
are represented by the same pattern. The numbers below each isoform is the 
positions of the amino acids found at the borders of the subdomains. (Adapted 
from Theil etal, 1994)
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1.3.4 Expression and functional role of the Brn-3a and Brn-3b
Analysis of the expression of Bm-3a and Bm-3b during development in the mouse 
has shown overlapping expression of these two factors in the central and 
peripheral nervous systems (Gerrero et al, 1993; Turner et al, 1994; Fedtsova and 
Turner, 1995; Xiang et al, 1993). Bm-3a and Bm-3b have also been identified in 
other non-neuronal tissues including the cervix of uterus (Ndisang et al, 1998), 
breast and ovaries (Budhram-Mahadeo et al, 1998). The expression pattern of 
Bm-3 proteins in specific subset of cells during development and in adult tissues is 
suggestive of their potential roles in regulating expression of genes required for 
distinctive functions in particular tissues.
1.3.5 Expression of Brn-3a and Brn-3b in neuronal tissue
Bm-3a shows high homology to Unc-86, another member of class IV POU protein 
family, which plays a critical role in normal neuronal development in C.elegans. 
This observation, together with the initial isolation of Bm-3 proteins in neuronal 
tissue and cell lines, paved the way for extensive investigations to elucidate the 
role of Bm-3 proteins during the development of the mammalian nervous system. 
Indeed, in v/Vo studies using mouse models in which Bm-3a and Bm-3b 
expression have been knocked out (McEvilly et al, 1996; Xiang et al, 1996; Gan et 
al, 1999; Erkmann et al, 1996), as well as in vitro analyses in neuronal cells 
(Lillycrop et al, 1992; Budhram-Mahadeo et al, 1995a; Smith et al, 1997c) have 
further highlighted the functional roles of these transcription factors in the normal 
development of sensorineuronal and neuroendocrine sysytems and will be 
discussed in detail in the following sections. Table 1.3.5 summarises the 
expression of these two genes in the developing and adult nervous system.
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1.3.5.1 Bm-3a expression
Bm-3a is the most widely expressed of the Bm-3 proteins in the nervous system. 
The expression pattern of Bm-3a in the peripheral nervous system (PNS) is 
distinct from that observed in the central nervous system (CNS). In the PNS, Bm- 
3a expression is first detected in the neuronal precursor cells, immediately before 
the cells exit the cell cycle, as well as in differentiated sensory neurons. In the 
CNS, Bm-3a expression is observed only in post-mitotic neurons (Gerrero et al, 
1993; Turner e al, 1994; Fedtsova and Turner et al, 1995; Xiang et al, 1995).
Analysis of the expression and localization of Bm-3a in the PNS during 
development showed that Bm-3a is first detected at embryonic day 9.5 (E9.5) in 
the migrating neural crest cells, destined for the sensory lineage, just before the 
neurons exit the cell cycle (Fedtsova and Turner, 1995; Greenwood et al, 1999). 
Precursors arising from the neural crest can give rise to both sensory and 
autonomic neurons of the PNS (for review see, LeDouarin et al, 1994). In this 
respect, Bm-3a is expressed in cells destined for sensory neurons but not in those 
of autonomic neuronal lineage. By E9.5, Bm-3a is detected in the dorsal root 
ganglia (DRG) and the spinal cord, when some cells are still dividing (Fedtsova 
and Turner, 1995). It then continues to be expressed in sensory neurons 
throughout development when the cells have become post-mitotic, and remains 
high in trigeminal ganglia (TG) and DRG postnatally (Turner et al, 1994; Fedtsova 
and Turner, 1995; Greenwood et al, 1999). The early expression of Bm-3a in 
precursors cells destined for sensory neurons suggests a role for this factor in 
specification of these cells that is analogous to the role of Unc-86, which is 
activated before the cessation of cell division in the neuronal precursor cells in the 
nematode, and plays a critical role in the commitment of dividing neuronal 
precursors (Finney and Ruvkun, 1990).
In the CNS, Bm-3a is detected at high levels in developing mid-, and hind-brain 
and in the spinal cord, and continues to be expressed in specific regions of adult 
brain. During development of the CNS, Bm-3a is detected at E8.5 in occasional 
cells near the midline of the rostral mesencephlic tectum, prior to the closure of the
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anterior neuropore (Fedtsova and Turner, 1995). Unlike Bm-3a expressing cells in 
the PNS, these cells do not express PCNA and have therefore already exited the 
cell cycle. By E9.5, Bm-3a can be dearly seen in mesencephalic neurons. 
Between E12.5 and E15.5 a strong hybridization signal is observed in the inferior 
olivary complex of the hindbrain, the outer layer of post-mitotic cells in the tectum 
of the midbrain, and in the interpeduncular nudeus of the midbrain. Low level 
expression is also observed in the superior and inferior colliculus, the medial 
habenula and the brainstem. Around this time, Bm-3a expression is also observed 
in the inner retinal neuroblastic layer of the developing eye, when the ganglion cells 
are undergoing their differentiation and axonal outgrowth (Gerrero et al, 1993; 
Turner et al, 1994). By E17.5, Bm-3a RNA is only detected in the medial habenula 
of the diencephalon in the mid-brain (Gerrero et al, 1993; Ninkina et al, 1993; 
Xiang et al, 1993; Turner et al, 1994; Xiang et al, 1995). Hence, during CNS 
development, Bm-3a expression is restricted to post-mitotic neurons in spedfic 
regions of the brain.
In adult tissues, Bm-3a mRNA is detected in similar areas of the brain, but in a 
more restricted manner, compared to the pattern seen during developmental 
stages. Hence, high levels of Bm-3a have been detected in spedfic regions of the 
hind-brain such as the medial habenula, the nudeus ambiguus and the inferior 
olivary complex. Moderate levels are detected in the region of the midbrain such 
as the red nudeus, the mesencephalic nudeus and the superior colliculus. Bm-3a 
is also detected in the adult retina. Moreover, even though present at lower levels, 
Bm-3a is also found in the adult heart (personal communication S. Farooqui) and 
lungs (Budhram-Mahadeo et al, 2001). Bm-3a mRNA is not detected in other 
tissues such as adult liver, kidney, spleen and adrenal glands, suggesting that this 
factor is more characteristic of neuronal cells and hence most studies have 
characterized its expression and function in this cell type (Ninkina et al, 1993; 
Gerrero et al, 1993; Turner et al, 1994; Fedtsova and Turner, 1995).
53
1.3.5.2 Bm-3b expression
Bm-3b expression during development and in adult tissues shows considerable 
overlap with Bm-3a. Table 1.3.5 gives a summary of the expression of these two 
genes in the developing and adult nervous system.
Bm-3b expression is first detected in mouse at E10.5 in the embryonic body, 
followed by expression in the head at E11.5 compared with the earlier onset of 
Bm-3a expression observed at E9.5 in similar structures. There is a decrease in 
the mRNA levels encoding Bm-3b post-partum (Turner et al, 1994).
Detailed analysis for Bm-3b expression in the CNS of the developing mouse 
revealed its localization in the hindbrain and midbrain, with some similarity to Bm- 
3a expression. Bm-3b is first detected in these regions at E13.5. By E15.5 positive 
signals for Bm-3b are also observed in the postmitotic neuronal cell population of 
inferior olivary complex of the hindbrain, paralleling the Bm-3a expression. By 
E17.5, Bm-3b, but not Bm-3a, is uniquely detected in the interpeduncular nucleus 
of the midbrain, where its expression persists in the adult brain (Turner et al, 1994). 
Protein localisation studies at post-natal day 1 (P1) using Bm-3b antibodies have 
confirmed the expression of Bm-3b protein in the cerebullum, inferior colliculus and 
peri-aquaductal gray of the midbrain. In addition, Bm-3b protein levels were also 
detected in the brain stem, the pons and medulla of the hindbrain (Xiang et al,
1993).
In the retina, Bm-3b mRNA is first detected in the innermost layer of ganglion 
precursor cells at E11.5 but is absent from the neuroblast layer of cells (Turner et 
al, 1994). By E17.5, this expression is restricted to the post-mitotic layer. In relation 
to expression in the retina, it is interesting that Bm-3b preceeds Bm-3a so that 
whilst Bm-3b is detected by E11.5, Bm-3a is not detected until two days later. The 
relative expression of both factors peaks at birth but gradually decrease by p30 
(Turner etal, 1994).
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In marked contrast in the PNS, Bm-3b is detected by E13.5 in dorsal root ganglia 
(DRG) and trigeminal ganglia (TG), two days later than the onset of Bm-3a 
expression in these neurons. By E15.5, Bm-3b mRNA is also detected in the 
cochlear and vestibular regions of cranial nerve ganglion VIII, and in the 
glossopharyngeal nerve IX ganglion. In the spinal cord, Bm-3b is widely distributed 
at E12.5 but by E15.5, its expression is restricted to the intermediate gray region 
(Gerrero et al, 1993; Turner et al, 1994).
In the adult mouse and rat neuronal tissues Bm-3b expression is restricted to 
specific regions of the brain and PNS. In particular, it is expressed in the superior 
colliculus, the lateral interpeduncular nucleus of the midbrain and in pontine central 
gray. It is also expressed in the dorsal root and trigeminal ganglia (Turner et al,
1994). However, Bm-3b expression is also observed in adult heart and the 
reproductive tract, but not in the liver, spleen, kidney, lung, pituitary gland and 
thymus (Tumer et al, 1994; Budhram-Mahadeo et al, 2001).
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Bm-3a Bm-3b
Localization
e
15.5
Adult e
15.5
Adult
Brain Structures
Thalamus ++ +++
medial habenula 
lateral habenula
Midbrain ++ +/- +++ +++ superior colliculus 
inferior colliculus 
parabigeminal n. 
periaquaductal 
gray
- Interpeduncular n.
- Mesencephalic n. ++ +++
++ +++
Hindbrain +++ ++/+ +++ - brain stem (motor) 
nucleus ambiguus 
medulla 
pons
inferior olivary n.
Cerebellum (& related) 
- red nucleus ++ ++
Other Neurons
Retina
Sensory neurons
Trigeminal ganglia 
Dorsal root ganglia
++
+++
+++
++
+++
+++
++
++
++
+
+
+
post mitotic 
ganglion cells
Spinal cord ++ ++ ++ + Brn-3a in dorsal gray
Brn-3b in 
intermediate gray.
Table 1.3.5: Expression pattern of Bm-3a and Bm-3b in the developing and adult 
nervous system
(Reproduced from a PhD thesis, titled Regulation and Function of POU domain 
transcription factors, Bm-3a and Bm-3b, UCL, 1995, with permission from the 
author, Dr. Budhram-Mahadeo)
indicates no detectable expression +/- equivocal signal
+ weak signal ++ moderate signal
+++ strong signal n indicates nucleus
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1.3.6 Bm-3a function in neuronal cells
Extensive in vivo and in vitro studies have shown that Bm-3a proteins play a critical 
role in the survival and differentiation of particular neuronal cells. The following 
sections discuss the role of Bm-3a in these specific cell types.
1.3.6.1 Bm-3a knock-out mouse model
Studies in which the Bm-3a allele was deleted by homologous recombination have 
suggested a distinct developmental role for this factor in the maintenance and 
terminal differentiation of specific neuronal cell types. Bm-3a homozygous mutant 
mice (Bm-3aV-) show gross phenotypic abnormalities which result in ineffective 
swallowing, uncoordinated limb and trunk movements. Consequently, these 
mutant mice do not survive beyond 24 hours postpartum.
Histological and hybridization studies of the CNS of Bm-3a-/- have shown a loss of 
neurons at a number of sites that may contribute to some of the observed 
phenotypes. For instance, there is a significant reduction in the number of neurons 
in the caudal region of the inferior olivary nudeus of the hind-brain. Similarly, 
regions in the midbrain show a striking loss of red nudeus neurons, the nudeus 
ambiguus and absence of the motor neurons which innervate oesophagus 
(McEvilly et al, 1996; Xiang et al, 1996).
The red nudeus functions to modulate information from the cerebellum and the 
cerebral cortex to the spinal cord via the rubrospinal tract (for review see Paxinos, 
1995, Academic, San Diego). Therefore, its absence could cause aberrant spinal 
reflexes manifested in the abnormal limb and trunk movement of Bm-3a-/- mice. 
An added factor contributing to the abnormal locomotion and posture in these 
animals could be due to loss of cells in the caudal region of the inferior olivary 
nudeus, which normally integrates sensory information and sends its output to the 
cerebellular Purkinje cells (for review see Paxinos, 1995). The loss of the motor 
neurons which normally innervate oesophagus would result in abnormal peristaltic 
swallowing reflex, accounting for the inability of Bm-3a-/-mutants to suckle.
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From the observations within the CNS of Bm-3a-/- embryos, two possible 
functional roles for Bm-3a have been suggested. Firstly, Bm-3a may be required 
for the response to, or synthesis of cell survival neutrophic factor, at sites such as 
the red nucleus, where extensive cell death occurs between E16.5 and P0.5 in 
Bm-3a-/- embryos. The emergence of the red nudeus neurons and migration to 
appropriate positions even in Bm-3a-/- mice exdudes the role of Bm-3a in these 
earlier events. Secondly, the distortion of specific subunits in the inferior olive and 
nudeus ambiguus due to a failure of cellular migration suggests a role for Bm-3a in 
migration of compact formation neuron. Therefore, Bm-3a may be required to 
control survival and differentiation events in specific neuronal cells in the CNS.
In the PNS of Bm-3a null mutant mice, there is a significant reduction in the 
biochemical markers that characterise sensory neurons (McEvilly et al, 1996; 
Xiang et al, 1996). Eng and colleagues (2001) generated a transgenic mouse in 
which they doned a Lac Z reporter, into the Bm-3a locus. This fadlitated analysis 
of cells that would normally express Bm-3a. Crossing this strain with a Bm-3a 
knock-out therefore allowed the analysis of spedfic neurons where Bm-3a would 
normally be expressed. This study has shown that during early development of the 
PNS the absence of Bm-3a results in abnormal axon bundling in the TG, with 
premature branching of nerves at the opthalmic and maxillary divisions. 
Furthermore, Bm-3a-/- TG neurons do not effectively innervate their peripheral 
targets, particularly obvious in the whisker follides. However, during late 
development, there is a striking loss of neurons by apoptosis in the dorsal division 
of the anteromedial lobe of the TG. Hence, Bm-3a appears to control survival and 
normal differentiation/ path-finding of spedfic neurons.
Analysis of target gene expression showed in Bm-3a-/- embryos, there is a 
decrease in the number of Trk A and Trk B expressing neurons. Moreover, Trk C 
is not detected in TG of Bm-3a -/- mutants, suggesting that Bm-3a is critical for its 
expression (Huang et al, 1999, McEvilly et al, 1996; Xiang et al, 1996). Despite the 
expression of Bm-3a in proliferating precursors of TG, loss of Bm-3a does not 
result in a reduction in the number of these precursor cells, and therefore is not 
needed for the emergence of these cells (Huang et al, 1999).
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The developmental defects observed in TG of Bm-3a-/- embryos have highlighted 
possible functions for this regulator in specific neurons. Evidence so far has 
demonstrated that Bm-3a can have direct and indirect effects on the survival and 
differentiation of specific neurons during development. While it has been shown to 
regulate genes associated with apoptosis (activation of anti-apoptotic Bcl-2 and 
BcI-Xl, and repression of pro-apoptotic Bax and Noxa -  discussed later in section 
1.3.7), it has quite profound effects on neurotrophin receptors. Firstly, the essential 
role of neurotrophins and their receptors in sensory neuronal development is well 
documented. For example, absence of NGF or its receptor Trk-A results in 
approximately 75% loss of sensory neurons. Similarly, absence of BDNF or its 
receptor Trk-B causes loss of 30% of neurons while null mutations in Trk-C 
receptor results in 20% of neuronal loss (for review see Farinas and Reichardt, 
1997; Tessarollo et al, 1997). The timing of the initiation of apoptosis in Bm-3a-/- 
TG provides a vital clue as to the role of Bm-3a in Trk- expressing neurons. A 
major wave of neuronal death in Bm-3a-/- TG occurs at E15.5, after Trk-A and Trk- 
B receptors have decreased below the minimal level required for neuronal survival. 
This suggests that Bm-3a, normally expressed at E9, is not required for the 
initiation, but rather for the maintenance of Trk-A and Trk-B expressing neurons. 
Conversely, the failure of Trk-C expressing neurons to emerge in Bm-3a-/- mice, 
implies that Bm-3a is required for their induction (Huang et al, 1999). However, the 
effects of Bm-3a are complex and its regulation of Trk- receptors is perhaps only 
one mechanism of a complex network that is regulated by Bm-3a to mediate 
survival and differentiation of these cells. Another study has also shown the loss of 
Trk-A expression in Bm-3a-/- in the absence of cell death by utilizing double knock­
out mice of Bm-3a in pro-apoptotic Bax-null background (Ma et al, 2003). The 
requirement for Trk A in these neurons does not affect survival but rather it is 
thought to control appropriate differentiation.
The aberrant axonal guidance observed in TG of Bm-3a-/- mice suggests a role for 
this factor in the development of functional axons. A ligand semaphorin 3A 
(Sema3A) and its receptor Npn-1 have been shown to partly regulate trigeminal 
axon guidance (Koodkin et al, 1997). Interestingly, Npn-1-/- mice show aberrant 
TG branching which strongly resembles the TG axonal abnormality in Bm-3a-/- 
mutants (Kitsukawa et al, 1997; Eng et al, 2001). However, Bm-3a-/- appear to
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express normal levels of Npn-1 in PNS, and in the CNS areas innervated by 
ganglia. Although, this rules out a direct regulation of Bm-3a on Npn-1, it is still 
possible that the absence of a critical co-factor for Npn-1, required for the formation 
of a receptor complex, may account for the abnormal axon pathfinding in Bm-3a-/- 
mice (Eng et al, 2001). To date other regulatory targets through which Bm-3a 
might exert its effect in sensory axonal formation have not been identified.
Bm-3b expression is altered in Bm-3a knock-out mice in the PNS but not in the 
CNS, suggesting that there is no difference in the number or location of normally 
Bm-3b expressing neurons within the superior colliculum, dorsal central gray, or 
interpeduncular nucleus of the midbrain. Therefore, Bm-3b expression is not 
dependent on Bm-3a expression in these regions. However, there is evidence for 
the loss of Bm-3b in the DRG, suggesting that in the PNS cells normally 
expressing Bm-3b need Bm-3a for survival or possibly, that Bm-3a regulates Bm- 
3b expression in these cells.
1.3.6.1.1 in vitro studies to analyse Brn-3a function
To understand how Bm-3a mediates its effects in neuronal cells, cell lines and 
primary cultures have been utilized along with in vivo models as they provide 
systems that can be more readily manipulated. Initial studies were carried out in 
the ND7 cell line which was derived by fusing neurons derived from non-dividing 
rat dorsal root ganglion cells with the C1300 mouse neuroblastoma cell line (Wood 
et al, 1990). One resultant done, called ND7, could proliferate indefinitely in full 
growth medium, behaving like the parental neuroblastoma cells. However, these 
cells can be induced to differentiate upon serum withdrawal and addition of defined 
medium supplemented with growth factors or cydic AMP analogues. Upon 
differentiation, these cells undergo cell cyde arrest and morphological changes 
with extensive neurite outgrowth, accompanied by movement of secretory granule 
component and synaptic veside component to the apex of processes, mimicking 
the events assodated with differentiation of sensory neurons (Suburo et al, 1992). 
As such it has provided a good model for the analysis of changes in gene 
expression as cells transit from a proliferating phenotype to a differentiative state.
60
Bm-3a mRNA and protein levels are found at very low levels in actively 
proliferating ND7 cells. However, upon differentiation of these cells, Bm-3a levels 
are significantly elevated (Lillycrop et al, 1992; Budhram-Mahadeo et al, 1995a). 
Therefore, Bm-3a appears to be associated with neuronal differentiation in this cell 
model. In support of this Smith and colleagues (1997) have shown that artificial 
over-expression of Bm-3a in ND7 cells is sufficient to cause increased (60%) 
greater neurite outgrowth even when cells are grown in foil serum medium that 
would not normally promote process formation (Smith et al, 1997c). Over­
expression of Bm-3a in ND7 cells causes an upregulation of at least four proteins 
that are involved at various stages of the synaptic vesicle cycle, a process of 
multiple steps involved in docking, exocytosis, endocytosis and vesicle 
recruitement (Smith et al, 1997a; for review see Sudhof, 2004). The first of these is 
a presynaptic membrane component the synaptosomal-associated protein 
(SNAP-25), which is involved in vesicle exocytosis and regulates axon outgrowth 
(for review see Bark and Wilson, 1994). The other proteins elevated in Bm-3a 
over-expressing ND7 cells are: synaptophysin (involved in docking with the 
membrane), synaptotagmin I (allowing fusion and exocytosis) and synapsin I (well 
known to be responsible for regulation of trafficking) (for review see Sudhof, 1995).
The correlation of expression of neurofilament protein and Bm-3a in early post­
mitotic neurons in the CNS (Fedtsova et al, 1996) led Smith and colleagues 
(1997b) to investigate a possible link between these factors. The neurofilament 
heavy (NFH), neurofilament medium (NFM) and neurofilament light (NFL) form the 
major intermediate filament component of the neuronal cytoskeleton and are partly 
responsible for maintaining the axon diameter and axonal transport (for review see 
Lee and Cleveland, 1996). All three neurofilaments were elevated at both mRNA 
and protein levels in ND7 cells over-expressing Bm-3a protein (Smith et al, 1997b). 
Moreover, reduction of Bm-3a levels in ND7 cells using anti-sense strategy results 
in failure of extension of neurites even when cells were grown in optimal 
differentiation conditions (Lakin et al, 1995). Taken together, these results support 
a role for Bm-3a in the transition from proliferating ND7 cells to quiescent 
differentiated neurons.
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In addition to its effects on neuronal differentiation, Bm-3a is also implicated in 
survival of neurons. High levels of Bm-3a protect ND7 cells as well as primary 
cultures of trigeminal and dorsal root ganglia from apoptotic stimuli such as the 
withdrawal of nerve growth factor (NGF) from the medium (Smith et al, 1998b, 
Ensor et al, 2001). Similarly, increasing Bm-3a expression protects dorsal root 
ganglia following sciatic nerve lesion (Smith et al, 2001). Conversely, increased 
apoptosis is observed in ND7, TG and DRG neurons in cultures where 
endogenous Bm-3a expression is decreased using an antisense strategy (Ensor et 
al, 2001; Smith et al, 1998b).
Subsequently, anti-apoptotic genes associated with survival in these cells were 
shown to be regulated by Bm-3a. Bm-3a has also been shown to strongly and 
directly activate the Bcl-2 P2 promoter (the predominant promoter that is active for 
this gene in neuronal cells) (Smith et al, 1998a; 1998c). Interestingly, a 
concomitant increase in the expression of the anti-apoptotic protein, Bd-2, has 
been observed in over-expressing Bm-3a cells (Smith et al, 1998a; Ensor et al,
2001). Similarly, decrease in the levels of Bcl-2 expression is evident in Bm-3a 
anti-sense cells. Recent studies have shown Bm-3a can also regulate another 
anti-apoptotic member of the Bd family, Bd-Xi_ which shares high homology to Bcl- 
2 (Boise et al, 1993). Interestingly, phenotypically BcI-Xl knock-out shows some 
similarity to Bm-3a homozygous mutants in terms of its requirement for normal 
neuronal development (Parsadanian et al, 1998). Hence, this supports the 
hypothesis of these factors being in a similar pathway that is required for protection 
in vivo. Moreover, exogenous introduction of Bm-3a into DRG and TG by 
transfection results in a clear elevation in the endogenous mRNA and protein 
levels of BcI-Xl (Smith et al, 2001). Conversely, use of antisense to decrease 
levels of Bm-3a show a concomitant decrease in BcI-Xl levels. Furthermore, Bm- 
3a activates the BcI-Xl promoter in primary sensory neurons and ND7 cells (Smith 
etal, 2001).
Hence, the protective effect of Bm-3a against apoptosis seems to be mediated 
partly via its regulation of Bd-2 gene, which is known to enhance survival in both 
CNS and PNS neurons against a variety of apoptotic stimuli (Allsopp et al, 1992). 
However, the direct control of Bd-X by Bm-3a might be more relevant in protection
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of neurons during development and has been shown to protect sensory neurons 
against apoptosis in NGF-dependent and BDNF-dependent sensory neurons 
against apoptosis (Gonzalez-Garcia et al, 1995). Interestingly, Bm-3a null mutant 
mice and BcI-Xl homozygous mice exhibit similar loss of neurons in terms of time 
of death and the population of neurons affected in the DRG and TG (Motoyama et 
al, 1995; McEvilly et al, 1996; Xiang et al, 1996).
Another possible mechanism by which Bm-3a might enhance the survival of 
neurons during the normal apoptotic period of embryonic development is via its 
regulation of Trk-receptors. In primary cultures of cells prepared from TG, Bm-3a 
seems to exert a more profound effect on the survival of neurons derived from later 
developmental periods (i.e. between E13 and E14, and not at E12 and E11) 
(Ensor et al, 2001). This temporal effect of Bm-3a on survival during development 
is of particular interest as extensive loss of Trk A- and Trk B- expressing neurons in 
Bm-3a null mice occurs at E13.5 (Trk A) and E12.5 (Trk B), while Trk-C expressing 
neurons never appear (Huang et al, 1999). Interpretation of these observations 
suggests that Bm-3a is either involved in regulating the expression of Trk A-, Trk 
B- and Trk-C or in maintaining Trk A- and Trk B- expressing neurons and in the 
generation of Trk C- expressing neurons. Bm-3a has been shown to directly 
regulate Trk A- promoter but Trk-B and Trk-C promoters have not yet been 
analysed (Huang et al, 1999).
1.3.6.2 Bm3b function in neuronal cells
In vivo and in vitro studies aimed at elucidating the role of Bm-3b have revealed a 
complex role for this protein that is highly dependent on cell types and possibly 
other cell specific factors (discussed in detail in the following sections).
1.3.6.2.1 Brn-3b knock out mouse models
Extensive studies using mice models in which Bm-3b gene has been deleted have 
highlighted the role for this protein during development. In 1996, two independent 
groups developed homozygous null Bm-3b mice and showed that these mice
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display normal gross morphology but are blind (Gan et al, 1996; Erkmann et al,
1996). Detailed analysis of the eye of these mutants at a cellular level, revealed 
loss of -70% of their retinal ganglia cells between post-natal days 17 and 20. 
Although Bm-3b is also expressed in other regions of the CNS and PNS (as 
discussed in section 1.3.5.2), there were no apparent defects in these structures, 
suggesting that the absence of Bm-3b is compensated for by other factors such as 
Bm-3a due to redundancy.
The significance of the changes in Bm-3b -/- retinal ganglion cells is demonstrated 
by its high expression in these cells. Bm-3b is expressed earlier than Bm-3a in 
these cells, and is first detected at E11.5 and peaks between E13.5 and E16.5. 
This expression coincides with the emergence of post-mitotic ganglion cell 
precursors en route to the ganglion cell layer (Tumer et al, 1994; Xiang 1998). This 
spatio-temporal correlation between Bm-3b expression and generation of ganglion 
cell suggests that Bm-3b may be involved in the initial and /or terminal 
differentiation of retinal cells.
Another elegant study in which the Lac Z gene was inserted upstream of the Bm- 
3b translational initiation codon at the Bm-3b locus, allowed an in depth analysis of 
the specific subset of cells in the retina that express the Bm-3b gene (Gan et al, 
1999). The progressive loss of Lac Z positive retinal ganglion cells (RGC) after 
birth suggests firstly, that Bm-3b is not involved in the initial cell fate determination 
of retinal ganglion cells and, secondly and more importantly, a possible role for 
Bm-3b in completing the normal differentiation of RGCs.
During normal development, all retinal cell types emerge from a limited population 
of actively dividing neuroblasts that commit to their fate, independently of cell 
lineages, in a temporal manner (Cepko et al, 1996). RGCs are the first cell types to 
commit and migrate from the proliferative zone to the innermost layer of the retina 
(Alexiades and Cepko, 1997). RGCs extend their axons towards the optic disc and 
establish connections in the CNS (Tessier-Lavigne and Goodman, 1996). Bm-3b 
is among one of the earliest markers of RGC formation (Xiang et al, 1993; 1995). 
Interestingly, mutants with no expression of Bm-3b exhibit distinct morphological 
differences in the RGC bodies compared to the wild-type mice. The processes
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projecting from the mutant cells are smaller in diameter, and in fact, form 
numerous dendrites at the expense of mature axon formation. Furthermore, the 
disorganised neurites of RGCs, which fail to fasciculate efficiently in the absence of 
Bm-3b, give rise to thinner optic nerves that fail to make contacts with the optic 
chiasm and subsequently undergo apoptosis (Gan et al, 1999; Wang et al, 2000; 
Erkman et al, 2000). Hence, Bm-3b is critical for regulating genes that allow 
normal ganglion cell differentiation. In fact, in vitro studies have identified Pax-6, a 
master regulator which is involved in the regulation of some of the inductive events 
that occur during the formation of the eye, including axon guidance (Ziman et al,
2001), as a direct downstream target of Bm-3b in neuroretinal cells (Plaza et al,
1999).
In contrast to retinal ganglial cells, most cells of the peripheral sensory ganglia 
undergo their final mitoses as early as embryonic day 13 (E13) (Altman and Bayer, 
1982). In view of the observation of the onset of Bm-3b expression by E13.5 in 
sensory ganglion cells, it is likely that this protein exerts its effects predominantly, if 
not exclusively, in post-mitotic, terminally differentiated neurons (Turner et al, 
1994). It is possible that cell specific factors in retina may be important in 
determining the effect of Bm-3b on a distinct subset of genes and hence its effects 
compared with other neurons, especially sensory neurons. Given the lack of gross 
abnormalities in the neurons of other regions of the CNS and PNS in Bm-3b 
knock-out mice, it has been difficult to elucidate its function in these areas and 
would require inducible model to study.
1.3.6.2.2 In vitro Brn-3b studies
The effects of Bm-3b appear to be complex. Whilst Bm-3b appears to be required 
for the survival and terminal differentiation of retinal ganglion cells, its effects in 
other cell types suggest a very complex role for this factor in cell fate 
determination. This was demonstrated in studies undertaken in cell lines and 
primary tissue materials which have attempted to highlight the role of Bm-3b in 
different cell types (see section 1.3.6.3).
65
Studies using the ND7 cell line have shown that actively proliferating cells grown in 
full growth medium express high levels of Bm-3b. Upon induction of differentiation 
by growth in defined medium (e.g. removal of serum or addition of cAMP), Bm-3b 
levels are dramatically decreased (Lillycrop et al, 1992; Budhram-Mahadeo et al, 
1995a). Similarly, studies using cell lines derived from human neuroblastoma 
tumours (IMR-32, SK-N-SH, SK-N-MC) have confirmed this change in Bm-3b 
levels, with higher levels detected in proliferating cells compared to the low levels 
detected after cells are induced to differentiate (Smith and Latchman, 1996). 
Interestingly, Bm-3b demonstrates a reciprocal expression pattern compared to 
the levels of Bm-3a in these cells. These findings suggest that Bm-3b is 
associated with a proliferation in these cells.
Further evidence for the role of Bm-3b in cellular proliferation has come from 
studies in which the expression of Bm-3b has been manipulated. Over-expression 
of Bm-3b in ND7 cells results in failure of neurite outgrowth even when the cells 
are grown in differentiation medium (Smith et al, 1997a). Interestingly, there is no 
effect on the number of cells bearing processes indicating that Bm-3b may act by 
inhibiting the neurite extension rather than their initial formation. The complexity of 
effects mediated by Bm-3b was also demonstrated by Ensor and colleagues 
(2001) who showed that its effects are altered depending on the time of expression 
during development. For example, over-expression of Bm-3b in trigeminal ganglia 
cultures taken from E11 and E12 embryos results in increased survival upon NGF 
withdrawal but this was not seen in cultures taken from older embryos (Ensor et al,
2001). Hence, it is possible that Bm-3b can substitute for Bm-3a during early 
trigeminal ganglia development but not at later stages, when there is significant 
loss of Bm-3a expression (Fedtsova and Turner, 1995). Moreover, Bm-3b 
represses many neuronal target genes associated with differentiation so its effects 
may change depending on target genes as well (discussed later in section 1.3.7). 
Therefore, the effects of Bm-3b expression are likely to depend on its temporal 
expression as well as the specific cell types.
Taken together the results using neuronal cell line models showed the opposite 
expression and sometimes anatagonistic effects of Bm-3b to Bm-3a in ND7 cells.
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This may suggest that there two factors are involved in a fine balance between 
proliferation and differentiation of neuronal cells depending on cell type.
1.3.6.3 Expression and function of Bm-3a and Bm-3b proteins 
in non-neuronal tissue and cancers
Even though Bm-3a and Bm-3b were originally detected in the developing and 
adult nervous system where they play a critical role in neural development, 
subsequent studies have demonstrated expression of both these transcription 
factors in non-neuronal cells. Hence, Bm-3a and Bm-3b have been detected in 
cervical epithelial cells (Lillycrop et al, 1992; Ndisang et al, 1997), in the testis 
(Budhram-Mahadeo et al, 2001), in human breast adenocarcinoma cell line, MCF7 
(Budhram-Mahadeo et al, 1998). Moreover, both Bm-3a and Bm-3b are expressed 
in primary breast tissue including the normal mammary cells, benign tumours, but 
high levels of Bm-3b has been detected in a subset of malignant tumours 
(Budhram-Mahadeo et al, 1999).
1.3.6.3.1 Cervical tissue
Reverse-transcriptase polymerase chain reaction (RT-PCR) assay has detected 
low levels of Bm-3a and Bm-3b mRNA expression in human cervical biopsies from 
individuals with no histologically detectable cervical abnormality, as well as in high 
grade cervical intraepithelial neoplasia type 3, CIN3, samples (Ndisang et al,
1997). More importantly, the mean level of Bm-3a expression is elevated 300-fold 
in CIN3 tissue compared with normal cervical tissue. In contrast, Bm-3b levels do 
not change significantly in these cells. Hence, there is a very large elevation in the 
Bm-3a:Bm-3b ratio in CIN3 compared with normal samples (Ndisang et al, 1997;
2000). This finding is particularly interesting in view of the ability of Bm-3a to bind 
and activate the upstream regulatory region (URR) of human papilloma viral 
genome (Morris et al, 1994). Conversely, Bm-3b also binds the same octamer 
motif in the URR of HPV but represses URR-driven transcription and negates 
activation by Bm-3a (Morris et al, 1994). HPV types 16 and 18 (HPV-16 and HPV- 
18) encode specific proteins, E6 and E7, which are able to transform cells to a 
malignant phenotype and it is now generally accepted that the production of these
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oncogenic proteins contribute to the development of cervical neoplasia (Schiffman 
et al, 1983; Burghardt E, 1984). Thus, the changes in the ratio of Bm-3a:Bm-3b in 
CIN3 cervical tissue may represent a critical role for these cellular regulatory 
factors, with Bm-3a, in particular, regulating the URR activity and, in turn, the 
progression of cervical cell transformation.
1.3.6.3.2 Testis
Immunocytochemical studies and in situ hybridisation studies in adult rat testis has 
demonstrated distinct expression patterns for Bm-3a and Bm-3b expression at 
specific stages of germ cell development. Thus, whilst Bm-3a is detected 
predominantly in spermatogonia around the periphery of the seminiferous tubules, 
high Bm-3b expression is observed in post-meiotic mature spermatids located 
centrally in the tubule (Budhram-Mahadeo et al, 2001). Interestingly, Bm-3a 
expression during germ cell development correlates with BRCA-1 expression in 
the testis and may represent one of the potential target genes regulated by Bm-3a 
in this tissue. In agreement with this hypothesis, BRCA-1 promoter has been 
shown to be activated by Bm-3a in the testis derived GH cell line. Hence, Bm-3a 
and Bm-3b may be important in specific stages of germ cell development in the 
testis. Interestingly, Bm-3b is found in more mature spermatids, suggesting a role 
in maturation, similar to its role in the retinal ganglion cells in the retina. However, 
confirmation of the precise role for Bm-3 protein in the testis requires analysis of 
testis development in mice lacking Bm-3b and in conditional/ inducible knock-out of 
Bm-3a models, where, at present, neonatal lethality of the knock-out animals has 
hindered such as a study.
1.3.6.3.3 Prostate
Both Bm-3a and Bm-3b has been detected in human prostrate tissue and cell 
lines. However, the expression of Bm-3a has been more intensively studied as it is 
expressed in the weakly invasive LNCAP cells but is found at lower levels in more 
metastatic cells PC-3 or PC-M cells (Diss J, personal communication). Moreover, 
overexpression of the short isoform of Bm-3a significantly increases the growth of
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PC-3 cells but reduces their invasiveness in vitro. More importantly, in primary 
prostate tissues, Bm-3a expression is significantly decreased in > 50% of prostrate 
cancers, hence paralleling the functional observed in vitro, and may play a role in 
growth and progression of prostate cancer.
1.3.6.3.4 Breast tissue
Bm-3b has been detected in breast epithelial cells with localization to ductal 
epithelium in sections of normal breast However, it is also expressed in the MCF7 
human breast adenocarcinoma cell line and its expression is increased in patients 
with breast cancers (Budhram-Mahadeo et al, 1998). Its relevance to this disease 
is highlighted by a number of findings. Firstly, Bm-3b functionally interacts with and 
enhance the transcriptional effect of oestrogen receptor (ER), which is associated 
with growth and proliferation in breast tissue (Budhram-Mahadeo et al, 1998; 
Endoh et al, 1999). Whereas both Bm-3a and Bm-3b interact with the ER, only 
Bm-3b can increase ER-mediated transcriptional activity on an oestrogen receptor 
element (ERE) containing promoter such as the vitellogenin gene promoter and an 
artificial ERE-containing promoter upon stimulation with the ligand 17-p-estradiol. 
In contrast, Bm-3a represses the ER mediated activation under similar conditions 
(Budhram-Mahadeo et al, 1998). The physiological relevance of this interaction is 
further confirmed by co-immunoprecipitation experiments using cellular extracts 
taken from rat brain and ovary which express both Bm-3b and ER, and in which 
Bm-3b and ER are found complexed. Furthermore, electromobility shift assays 
(EMSA) have shown that ER associates more readily with the ERE in the 
presence of Bm-3a and Bm-3b proteins.
Both these Bm-3 proteins have been detected in primary breast tissue but 
interestingly, the levels of Bm-3b, but not of Bm-3a, are elevated in tumours 
compared to the levels in normal mammary tissue (Budhram-Mahadeo et al, 
1999). Extensive studies have subsequently highlighted an important role for Bm- 
3b in breast tumourigenesis. In breast tumours, Bm-3b shows an inverse 
correlation with the levels of the breast cancer susceptibility gene, BRCA-1 
(Budhram-Mahadeo et al, 1999). In addition, artificial over-expression of Bm-3b
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with the BRCA-1 promoter in co-transfection assays produces a strong inhibitory 
effect on the BRCA-1 promoter, repressing its activity by approximately 20 fold. 
This suggests a direct regulation of BRCA-1 expression by Bm-3b (Budhram- 
Mahadeo et al, 1999). Being a tumour suppressor, BRCA-1 acts to halt cell 
proliferation in normal epithelial cells and therefore repression of such a protein by 
Bm-3b may enhance cell proliferation during transformation. Interestingly, BRCA-1 
mutations have been identified in a number of familial breast cancers (for review 
see Casey, 1997) but recent studies have shown decreased expression of the 
BRCA-1 gene both at mRNA and protein levels in non-familial sporadic cancers 
lacking BRCA-1 mutations (for review see Mueller and Roskelley, 2002). Thus, its 
inactivation either by mutations or repression by proteins such as Bm-3b may 
contribute to increased cellular proliferation. To date, Bm-3b is the first transcription 
factor reported to regulate BRCA-1 expression, supporting an important role for 
Bm-3b in regulating cellular proliferation.
To further explore the role of Bm-3b in breast cancer, Dennis and colleagues 
(2001) established stable cell lines that either over-expressed Bm-3b or had 
reduced expression of endogenous Bm-3b by using an anti-sense strategy. 
Results of these studies have demonstrated that over-expression of Bm-3b in 
MCF7 cells consistently increases their growth and proliferation rate compared to 
the vector control transfected cells which grow slower. In addition, Bm-3b over- 
expressing cells exhibit increased growth under anchorage independent 
conditions, suggesting that high levels of Bm-3b provides an advantage for tumour 
growth in vivo, compared to the control cells or cells with reduced levels of Bm-3b 
protein (Dennis et al, 2001). These results strongly support a role for Bm-3b in 
regulating mammary cell growth and proliferation, and suggest its elevation in 
breast cancer to be of functional significance.
Furthermore, Bm-3b has been shown to correlate positively with the cyclin- 
dependent kinase (CDK4) in human breast cancer cell lines and in tumour 
samples (Samady et al, 2004). Further analysis showed that Bm-3b could 
transactivate the CDK4 promoter. Since CDK4 is required for the G1 to S transition 
of the cell cycle, the ability of Bm-3b to activate its transcription suggests another 
mechanism by how this transcription factor gives rise to its effects of increased
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proliferation breast cells. Recently, Bm-3b has also been shown to repress the 
adhesion associated protein, plakoglobin, which might help to explain the elevated 
migration of breast cell with increased Bm-3b levels (personal communication, Dr. 
L. Samady, MMBU, ICH, UCL)
1.3.7 Promoters regulated by the Brn-3a and Brn-3b proteins
Alterations in the proliferation and/or differentiation status as demonstrated by Bm- 
3a and Bm-3b in different cell types require the reprogramming of gene expression 
that is predominantly brought about by the activity of transcriptional regulators 
within a cell. Transcription factors mediate their effects by associating with other 
proteins in transcriptional complex. As such factors that are co-expressed in 
specific cell types are likely to have significant impact on the effects of particular 
transcription factors.
A number of target gene promoters regulated by the Bm-3 transcription factors 
have been identified and characterized. The distinct roles demonstrated for Bm-3a 
and Bm-3b factors in neuronal cells in vivo and results showing differential 
expression of Bm-3a and Bm-3b in proliferating versus differentiated 
neuroblastoma cells is of particular interest since this reciprocal expression is 
paralleled by their antagonistic effect on several different gene promoters. Table
1.3.7 gives a summary of the various target gene regulated by Bm-3a and Bm-3b. 
This inverse correlation in the expression pattern of these two proteins is 
associated with their functional antagonism on many target promoters. Hence, a 
minimal promoter containing an octamer-related upstream elements was 
stimulated by Bm-3a whereas Bm-3b represses the transcription of this promoter 
and even inhibits the Bm-3a-mediated transcription (Gerrero et al, 1993; Budhram- 
Mahadeo et al, 1994; Morris et al, 1994). In general, Bm-3a seems to be involved 
in transactivation of genes associated with neuronal differentiation and cell cycle 
arrest which are repressed or unaffected by Bm-3b and will be discussed in the 
following sections (Budhram-Mahadeo et al, 1995; Morris et al, 1996; Smith et al, 
1997b).
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The expression of Bm-3a in the earliest post-mitotic neurons of the CNS and in 
adult sensory ganglia of the PNS as well as the promotion of neurite extension by 
this factor in ND7 cells suggests a role for Bm-3a in the differentiation of neurons. 
In depth analysis of the precise mechanisms by which Bm-3a mediates 
differentiation in neuronal cells has demonstrated that this transcription factor can 
regulate a number of genes whose protein products are critical for neuronal 
differentiation. For instance, Bm-3a directly activates the promoters of genes 
whose protein products are required at various stages of synaptic vesicle cycle 
and have been shown to be upregulated in Bm-3a overexpressing cells (Smith et 
al, 1997a). These include the SNAP-25, synaptotagmin 1 and synapsin I. 
Extensive promoter analyses confirm direct effects of Bm-3a on their regulation 
rather than a secondary consequence of differentiation events occurring in 
neuronal cells (Lakin et al, 1995; Morris et al, 1996). Subsequent search for other 
neuronal differentiation associated genes as possible targets for Bm-3a led to the 
identification of another gene, whose protein product plays a critical role in the 
radial growth of axons. The promoter of a-intemexin gene is strongly activated by 
Bm-3a in co-transfection experiments in ND7 cells (Budhram-Mahadeo et al, 
1995b). Moreover, Bm-3a is able to directly transactivate the promoters of all three 
neurofilament genes (NFH, NFM, NFL) whose proteins products have also been 
elevated in Bm-3a over-expressing cells (Smith et al, 1997b). This regulation of 
neurofilament genes by one transcription factor is interesting in view of the fact that 
neurofilament are obligate heteropolymers (Ching et al, 1993), and any decrease 
(or increase) in the expression of individuals subunits results in aberrant axonal 
size and transport (Eyer and Peterson, 1994; Sakaguchi et al, 1993). Hence, a 
common regulatory mechanism, allowing simultaneous expression of the three 
neurofilament genes in a spatio-temporal manner may be of critical importance for 
their correct functioning, making Bm-3a an attractive master regulator for 
controlling the expression of these in neurons which express this factor.
Interestingly, Bm-3b represses these Bm-3a target genes that are associated with 
differentiation of neurons, including SNAP-25 (Morris et al, 1996), the neuronal 
intermediate filament gene product a-intemexin (Budhram-Mahadeo et al, 1995), 
and promoters of all three neurofilament genes (Smith et al, 1997c). However, Brn-
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3b does activate the promoter of synapsin 1, in a manner similar to Bm-3a. This 
suggests that Bm-3b is able to compensate for Bm-3a in terms of transactivation of 
some but not all target genes in neuronal cells (Morris et al, 1996).
Bm-3a and Bm-3b have also been shown to regulate some non-neuronal target 
genes. For example, CDK4 is transcativated by Bm-3b in breast cancer cells while 
plakoglobin and BRCA 1 are repressed by Bm-3b, providing a mechanism by 
which Bm-3b promotes cellular proliferation and invasion in these cells (see earlier 
section 1.3.6.3.4). A member of the heat shock family of proteins, HSP 27, has 
also been shown to be transactivated by both Bm-3b and Bm-3a in both neuronal 
and breast cancer cells (Farooqui, S and Budhram-Mahadeo personal 
communication). Therefore, a theme that emerges from these studies of various 
gene targets of Bm-3a and Bm-3b is the complexity of effects on different targets, 
such that Bm-3a and Bm-3b can be an activator or repressor but effects depend 
on the specific target in specific cell types.
Studies using chimaeric constructs encoding different regions of Bm-3a and Bm- 
3b have identified two activation domains present in the longer Bm-3a (I), which 
regulates the ability of this protein to activate specific promoters (Budhram- 
Mahadeo et al, 1995; 1996; Morris et al, 1994). Thus, activation of a test promoter 
containing a Bm-3 binding site is dependent on the DNA-binding POU domain of 
Bm-3a as the isolated Bm-3a POU domain is enough for activation and so Bm- 
3a(s) and Bm-3a(l) can transactivate such promoters (Budhram-Mahadeo et al, 
1995; 1996; Morris et al, 1994). In contrast the activation of a-intemexin promoter 
requires the second activation domain located at the N-terminus of the protein and 
present only in Bm-3a(l) (Budhram-Mahadeo et al, 1995). Whilst Bm-3a(l) can 
activate the a-intemexin promoter, neither the isolated POU domain nor the 
shorter Bm-3a(s) isoform were capable of transctivating this promoter (Budhram- 
Mahadeo et al, 1995). Similarly, Bm-3a(l) but, neither Bm-3a(s) nor isolated POU 
domain, can transactivate the Bcl-2 promoter (Smith et al, 1998). Interestingly, 
although the a-intemexin promoter contains several Bm-3 consensus binding 
sites, Bm-3a is able to activate a minimal a-intemexin promoter, lacking any 
sequence closely related to the octamer motif (Budhram-Mahadeo et al, 1995).
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Similar effects are also observed on p 2 iQP1/WAF1 promoter (discussed later in this 
section). This suggests that Bm-3a may associate with the basal transcription 
machinery to mediate its effects.
Test promoters responsive to the isolated POU domain of Bm-3a are not activated 
by the corresponding POU domain of Bm-3b (Budhram-Mahadeo et al, 1995). 
Interestingly, this differential effect is associated with a single amino-acid difference 
found at position 22 of the POU homeodomains which is a valine residue in Bm-3a 
and an isoleucine residue in Bm-3b. This difference is located in the first a-helix of 
the POU homeodomain and is critical for the transcriptional effects on the target 
genes dependent on the POU domain of Bm-3a and Bm-3b. Thus, substitution of 
the valine residue at position 22 in Bm-3a with the isoleucine found in Bm-3b 
results in transcriptional repression of the promoters that are normally activated by 
wild-type Bm-3a (Smith et al, 1997). Conversely, substituting an isoleucine in Bm- 
3b with a valine residue at this position converts it into an activator of some target 
promoters tested (Morris et al, 1997; Dawson et al, 1996). Thus, the residue at 
position 22 may be critical for recruitement of a transactivator in the case of Bm-3a 
or a transcriptional co-repressor by Bm-3b on some neuronal target genes and 
alteration at position 22 may affect the protein-protein interactions by these factors 
(Dawson etal, 1998).
In addition to the direct transcriptional regulation of target genes by Bm-3a and 
Bm-3b, recent studies in our laboratory have also shown that these proteins can 
interact with other proteins, thus providing another mechanism by which these 
proteins can regulate gene transcription of diverse target genes. A well established 
phenomenon of POU family members is the ability to activate their target 
promoters via cooperative binding as homodimers and hetero-dimers with other 
proteins (Voss et al, 1991; Poellinger et al, 1989; Herr and Cleary, 1995). 
Budhram-Mahadeo and colleagues have shown strong interaction of Bm-3a and 
Bm-3b with other cellular proteins that can modulate transcription. In vitro and in 
vivo studies have shown a direct interaction of both Bm-3a and Bm-3b with the 
tumour suppressor p53. Interestingly, interaction of wild type p53 with Bm-3a 
antagonises the ability of Bm-3a to transactivate the Bcl-2 promoter (Budhram-
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Mahadeo et al, 1999). However, when tested on p53 target promoters the 
interaction of Bm-3a with p53 gives rise to differential effects on gene expression. 
Thus, Bm-3a cooperates with p53 to increase expression of the endogenous 
p21dPi/wafi protein levels (Budhram-Mahadeo et al, 2002; Perez-Sanchez et al,
2002), but decreases the expression of pro-apoptotic p53 targets Bax and Noxa 
(Budhram-Mahadeo, 2003). In support of this, co-transfection studies show that 
Bm-3a cooperates with p53 on p21ap1/wafl promoter but antagonizes p53 mediated 
transcription on Bax and Noxa promoters. Consequently, co-expression of Bm-3a 
and p53 results in enhanced survival and cell cycle arrest in G0/G1, resulting in cell 
cycle arrest/differentiation (Budhram-Mahadeo et al, 2002; Perez-Sanchez et al,
2002). These results support the role of Bm-3a in cell survival. Conversely, Bm-3a 
antagonises the p53-mediated effect on Bax promoter, thus enhancing cell 
survival. In support of this, analysis of Noxa and Bax protein levels in embryonic 
brain and spinal cord showed elevated Bax and Noxa in Bm-3a knock-out cells 
compared to the wild-type (Budhram-Mahadeo et al, 2003; Hudson et al, 2004). 
Therefore, these findings indicate that Bm-3a can mediate its effects in cell survival 
and differentiation, both directly and indirectly.
Another factor that associates with Bm-3a and Bm-3b is the proliferation- 
associated estrogen receptor (ER), which transactivates estrogen responsive 
element (ERE) containing promoter (Budhram-Mahadeo et al, 1998). In breast 
cancer cells Bm-3b/ER interaction results in greater induction of ERE containing 
promoters compared with Bm-3b alone. In contrast, upon binding of Bm-3a to ER 
there is a mild repression, suggesting a negative role for Bm-3a in cellular 
proliferation in these cells compared to the enhanced proliferative effect of Bm-3b 
in breast cancer cells (Budhram-Mahadeo et al, 1998).
Therefore, a number of different studies to characterize the effects of Bm-3a and 
Bm-3b on target gene promoters have highlighted the functional complexity of 
these transcription factors. It appears that cell specific factors and tissue of 
expression dictates the target and the nature of regulation by these factors. In 
addition, they can have a direct effect on gene regulation by binding to cis- 
regulatory elements of the target gene or associate with other proteins to exert 
their effect.
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Promoter Bm-3a Bm-3b Domain
a-internexin + -* N-term
SNAP-25 + POU
Synaptotagmin 1 + - POU
Synapsin 1 + + POU
NFH + POU
NFM + POU
NFL + POU
Bcl-2 + 0 N-term
Bcl-x + 0 POU
p 2 ic«pi/wafi + N.D. POU
Bax - N.D. POU
Noxa - N.D. POU
CDK4 N.D. + N.D.
Plakaglobin N.D. - N.D.
BRCA1 - N.D.
Vitellogenin 0 + POU
Table 1.3.7: Promoter regulation by Bm-3a and Bm-3b transcription factors 
Some of the known promoters regulated by Bm-3a and Bm-3b are given above. Activation 
of a promoter is indicated with a repression of a promoter is indicated with a no 
effect on the promoter is indicated with a 0. An indicates that Bm-3b not only represses 
the promoter, but also negates activation by Bm-3a. "Domain” indicates the Bm-3 protein 
domain responsible for the transcriptional effect.
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1.3.8 Regulation of Brn-3 proteins
While Bm-3 proteins control downstream targets, the factors that alter their 
expression in specific cells are also important Regulation of Bm-3a has been 
better characterized than Bm-3b. Expression of Bm-3a appears to be controlled by 
two distinct promoters (Frass et al, 2002). The first more distal upstream promoter 
is TATA-less and contains two bona fide mRNA start sites spanning over 500 base 
pairs 5’ of the ATG translation initiation and directs the expression of the long 
isoform of Bm-3a [Bm-3a(l)]. The second promoter, also TATA-less, has been 
identified in the first intron of the Bm-3a gene and has been shown to control the 
expression of the shorter isofbrm of Bm-3a [Bm-3a(s)], specifically in neuronal 
cells but not in epithelial cells. The existence of two different promoters may help to 
explain the differential expression of the Bm-3a gene with respect to cell specificity 
and developmental stage.
Analyses using a number of techniques have identified Bm-3a binding sites within 
the Bm-3a locus itself (Trieu et al, 1999). The distal binding site is found at -9 kb 
from the start site of transcription, and the proximal binding site is located at 
approximately at 5.4-5.6 kb. The proximal binding site can more effectively 
transactivate Bm-3a expression compared with the distal region. Thus, it appears 
that autoregulation plays an important role in maintaining Bm-3a expression, and 
hence provides a mechanism for the maintenance of differentiated neuronal 
phenotypes.
The co-expression of Bm-3a with Bm-3b in several sub-sets of neurons has led to 
a study determining the possible role of Bm-3b in regulating Bm-3a. Indeed, Bm- 
3b does exert a positive transcriptional effect on Bm-3a autoregulatory sequences, 
to similar levels to Bm-3a itself (Trieu et al, 1999). This suggests a convenient 
regulatory mechanism for the expression of Bm-3a in specific neurons where Bm- 
3b expression precedes that of Bm-3a such as in the retina, the inferior olivary and 
interpeduncular nuclei. Moreover, if this ability of Bm-3b to activate Bm-3a is 
mirrored during development, it may partly explain the severity of the retinal 
defects in Bm-3b null mutant mice, where the absence of Bm-3b results in the loss
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of Bm-3a expression (Erkman et al, 1996; Xiang et al, 1998), and effectively 
results in a mouse with defective expression of both Bm-3 factors.
At present not much is known about the regulation of Bm-3b expression but 
ongoing studies in our laboratory aim to characterize the Bm-3b promoter and 
determine whether it is regulated in a similar manner to Bm-3a.
1.3.9 Bm-3 expression in neuroblastomas
Even though no work to date has been carried out in primary neuroblastoma 
tumours to determine the expression levels of Bm-3a and Bm-3b, studies carried 
out in neuroblastoma cell lines have provided some due as to the possible function 
of these neuronal transcription factors in this cancer. As such, mouse cell line, 
ND7, and human neuroblastoma cell lines IMR-32, SK-N-MC, SK-N-SH have 
shown Bm-3a mRNA to be present to varying degrees in these cell lines, but is 
dependent on the cellular status (Smith and Latchman, 1996; Budhram-Mahadeo 
et al, 1995; Lillycrop et al, 1992). Interestingly, a dear pattern emerges when Bm- 
3a levels are compared to the levels of Bm-3b mRNA in each cell lines studied. 
Despite the variation in Bm-3a or Bm-3b levels, all nine proliferating 
neuroblastoma cell lines tested have a much higher Bm-3b to Bm-3a ratio than the 
rabdomyosarcoma and melanoma control cell lines. Moreover, Bm-3a levels rise 
dramatically following differentiation of these cells with different stimuli (Smith and 
Latchman, 1996). Hence, Bm-3a and Bm-3b expression appears to be assodated 
with the different cell fate in of neuroblastoma cells, with Bm-3a being strongly 
assodated with differentiation as cells withdraw from the cell cyde and enter a 
quiescent state. Conversely, high levels of Bm-3b in actively proliferating 
neuroblastoma cells which have lost their growth restraints, indicating that it may 
be more assodated with of cancer cells. Clearly, more research needs to be 
carried, espedally in primary human tumour samples, in determining the precise 
role of these proteins in tumourigenesis.
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The work described in this thesis is aimed at studying the role of Bm-3a and Bm- 
3b in human neuroblastoma cells in terms of initiation and progression of the 
tumourigenic characteristics of these cells.
1.4 Neuroblastoma
Neuroblastomas are malignant tumours of poorly differentiated neuroectodermal 
cells thought to be derived from the neural crest which are destined for the adrenal 
medulla and the sympathetic nervous system. Neuroblastoma represents the most 
common intra-abdominal malignancy of infancy and the most common extracranial 
solid tumor of childhood. It accounts for 8-10% of all paediatric malignancies, with 
an annual incidence of 1 per 7,000 live births. The median age at diagnosis is 
about 18 months, of which 40% of cases present by 1 year of age, 75% by 4 years 
and 98% by 10 years (Grovas et al, 1997; Miller et al, 1995; Brodeur and Maris,
2002).
The multiple anatomic sites where these tumours occur parallel the origin and 
migration pattern of neuroblasts during fetal development. For instance, 40% of 
tumors occur in the adrenal medulla, whereas 25% of tumours arise in paraspinal 
ganglia. Other primary sites of origin include the thoracic (15%), pelvic (5%) and 
cervical regions (3%). Metastases occurs in nearly 70% of patients, and the most 
common sites for distal spread being the bone marrow, bone, liver and skin. 
Secondary spread to lungs and brain has also been reported (Kellis et al, 1991; 
Shaw et al, 1992; Watts et al, 1996). The primary tumour site, as well as the 
pattern and frequency of metastatic spread, appears to be dependent on age. In 
infants the tumours usually arise in the thoracic and cervical areas, whereas older 
children frequently present with abdominal tumours.
Neuroblastoma tumours show remarkable clinical heterogeneity, ranging from life- 
threatening malignant tumours, to less aggressive tumours that mature to 
ganglioneuroblastoma or ganglioneuroma, and some more benign growth that 
show spontaneous regression of tumours. Highly malignant neuroblastomas are 
undifferentiated tumours, consisting of small, round cells called neuroblasts.
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However, ganglioneuroblastomas do exhibit moderate differentiation while 
ganglioneuromas are a sub-set of well-differentiated benign tumours that consist of 
dusters of mature neurons surrounded by stromal Schwann cells (for review see 
Brodeur, 1990,2003; Westermann and Schwab,2002 Schwab et al, 2003).
An international staging system (INSS) for neuroblastoma patients has been 
developed and is dinical factors such as sites of origin, other metastasis and 
histology of the tumour. The staging system allows dinical risk groups to be 
identified upon which other biologically-based risk factors can be determined. 
Together, these staging systems allow for predse diagnosis, prognosis and for 
rapid and effident therapy to be administered (Brodeur et al, 1993). High-risk 
tumours, dassed as INSS stages 3 and 4, indude disseminated disease or bulky 
tumours with gross genetic abnormalities, such as MYCN amplification. Patients 
within this group have a 5-year event-free survival (EFS) of 25-30%, despite multi­
modality treatment induding myelo-ablative chemotherapy. The intermediate risk 
group patients (INSS stages 2b-3) have characteristic large, unresectable localized 
tumours without structural genetic alterations. These patients have 5-years EFS of 
(60-80%) and show a more favourable outcome when treated with a combination 
of surgery and (neo-) adjuvant chemotherapy. INSS stages 1 and 2a represent the 
low risk patients with small tumours, which can be dinically managed by surgery 
alone, with 5 year EFS of greater than 90%. Finally, infants under 1 year of age at 
diagnosis, with small primary tumours and disseminated disease, represent INSS 
stage 4s. These patients have an excellent 5- year EFS of 70-90%, and exhibit a 
high frequency of spontaneous regression (van Noesel et al, 1997). Table 1.4 
summarises the main characteristics of different neuroblastoma risk groups.
For reasons unknown at present the age of the patients at diagnosis of 
neuroblastoma tumour also strongly influences the dinical prognosis and outcome 
of neuroblastoma treatment (Carlsen et al, 1986; Evans et al, 1987; Jereb et al, 
1984). Generally, infants diagnosed before 1 year of age and/or with localized 
disease are curable with surgery and little or no adjuvant therapy. Conversely, 
55% of neuroblastomas in older children (<l year) frequently have extensive 
hematogenous metastases at diagnosis, and most of them die from disease 
progression despite intensive chemotherapy.
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Tumour
characteristics
Low-risk Intermediate-risk High-risk
Clinical
Age Typically Typically Typically
<1 year >1 year >1 year
INSS Stage 1,2, 4s 3,4 3,4
5-year survival 95% 50% 25%
Genetic
Ploidy 3n 2n/4n 2n/4n
1p loss Rare Rare Frequent
11q loss Rare Frequent Rare
14q loss Rare Frequent Rare
17q gain Rare Frequent Frequent
MYCN Normal Normal Amplified
Molecular
TrkA High Low Low
TrkB Low Low High
TrkC High ? Low
Cyclin D1 ? ? ?
NM23 Low ? High
Table 1.4: Characteristics of neuroblastoma risk groups
Trk, tyrosine receptor kinase; International Neuroblastoma Staging System
(adapted from reference Brodeur, 2003)
81
1.4.1 Genetics of neuroblastoma
Most neuroblastomas occur spontaneously. Although the precise causes of 
tumour initiation and progression are still unclear, multiple somatic defects, such as 
gain of alleles, activation of oncogenes, loss of alleles or alterations in tumour- cell 
ploidy, have so far been identified in many neuroblastoma tumours. Several of 
these changes correlate with the different clinical manifestations of the disease. 
This has allowed a more accurate stratification of tumours at presentation, thereby 
allowing an appropriate selection of therapeutic strategies in individual patients 
(Table 4.0). Important genetic aberrations shown to contribute to the development 
of neuroblastoma are discussed in the following sections (for reviews, see 
Westermann and Schwab, 2002; van Noesel and Versteeg, 2004).
1.4.1.1 Changes in ploidy and chromosomal abnormalities
1.4.1.2 Ploidy
Aneuploidy (loss or gain of one or more chromosomes of a diploid genome) is 
frequent in neuroblastoma. The ploidy status of neuroblastoma is associated with 
the clinical heterogeneity (Look et al, 1991; Kaneko and Knudson, 1990). 
Cytogenetic analyses have distinguished four ploidy levels: near-diploid, near- 
triploid, near-tetraploid, and near-pentaploid tumours (Kaneko et al, 1987). The 
near-diploid and near-tetraploid tumours are observed in patients over 1 year of 
age, with structural chromosomal abnormalities such as the deletion of 
chromosome 1 and amplification of MYCN gene (discussed later in section 4.2.1). 
These genetic aberrations are associated with advanced stages of the disease, 
with rapid tumour progression and poor prognosis. The near-triploid tumours are 
characterized by three almost complete haploid sets of chromosomes, with few 
structural abnormalities, and are predominantly detected in patients under the age 
of 12 months (INSS stage 1, 2, and 4s), with favourable clinical outcome. Similarly, 
patients with near-pentaploid tumours have a good prognosis and prolonged 
disease free survival (Look et al, 1991; Kaneko et al, 1990; Oppedal et al, 1989; 
Kaneko et al, 1999; Cohn et al, 1990).
82
The genetic mechanisms leading to aneuploidy in neuroblastoma still remains to 
be determined conclusively. However, it has been suggested that aneuploid 
tumour cells in neuroblastoma might arise from tetraploidization and subsequent 
bipolar, tripolar, or tetrapolar divisions (Kaneko and Knudson, 2000). Increase in 
the number of centrosomes and aberrant spindle formation, resulting in aberrant 
chromosome segregation and multipolar cell divisions, has been implicated in the 
generation of aneuploid cells in many cancers, including neuroblastoma (for review 
see Brinkley, 2001; Sugihara et al, 2004). The incomplete segregation of 
chromosomes in a tetraploid cell undergoing a tripolar division could result in one 
near-triploid and one near-pentaploid daughter cell. In fact some neuroblastoma 
tumours comprising of more than one tumour cell clone, have been shown to have 
both near-pentaploid and near-triploid cells.
1.4.1.3 Trisomy of 17q
Trisomy for the long arm of chromosome 17 (17q) has been shown to occur in 
more than 80% of neuroblastomas, making it the most prevalent genetic 
abnormality in this disease. This trisomy can result from the gain of 17q in an 
unbalanced translocation, most commonly with chromosome 1p, followed by 11q, 
or as part of whole chromosome gain (Caron et al, 1994; Savelyeva et al, 1994; 
Lastowska et al, 1997; Meddeb et al, 1996; Plantaz et al, 1997; Stark et al, 2002). 
Trisomy 17 has been seen in near-triploid tumours with favourable outcome. In 
contrast selective gain of the long arm of chromosome 17 is associated with 
advanced stage disease, in tumours from children aged over 1 year, and 
correlates with 1p loss and MYCN amplification (Lastowska et al, 1997; Bown et al, 
1999).
The poor prognosis of neuroblastoma with an unbalanced translocation of 17q 
could result either from the fusion of a gene localised at the breakpoint, or caused 
by a dosage effect of gene(s) within the additions 17q region. The identifications of 
at least seven different breakpoints, but preferential gain of a region from 17q21.3- 
17qter, strongly favours the possibility of a dosage effect of one or more genes 
localized distal to the breakpoint rather than interruption of just a single gene, that
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may be responsible for the aggressive nature of these tumours (Lastowska et al, 
1997; 1998; 2002). Several genes have been proposed to be responsible for 
tumour growth characteristics in the common translocated 17q segment, but the 
most prominent candidates are survivin, NM23-H1 and NM23-H2.
Survivin is an anti-apoptotic protein which negatively regulates caspase 9 
expression. The gene for survivin has been mapped to 17q25, which is within the 
minimal region of chromosomal gain in neuroblastomas and, has been shown to 
correlate with unfavourable histology, adverse clinical factors, such as age and 
stage, and outcome (Adida et al, 1998). Over-expression of survivin in a 
neuroblastoma cell line results in inhibition of retinoic acid induced apoptosis, 
suggesting a functional role for this protein (Islam et al, 2000).
NM23-H1 maps to 17q22 which is within the common amplified region of 17q 
which correlates with poor prognosis and increased aggressiveness in non- 
Hodgkin’s lymphomas and other haematological malignancies (Aryee et al, 1996; 
Niitsu et al, 2000). Over-expression of NM23-H1 is observed in aggressive 
neuroblastomas. The closely related NM32-H2 co-localises at 17q22. Both NM23- 
H1 and NM23-H2 are up regulated by MYCN in neuroblastoma, suggesting that in 
tumours with MYCN amplification and gain of 17q, a synergistic mechanism may 
exist that leads to over expression of NM23-H1 and -H2. These two factors belong 
to a metastasis gene family. NM23-H1 promotes metastasis of neuroblastoma cell 
lines (Almgren et al, 2004). However, their precise pathogenetic role in 
tumourigenesis of unfavourable neuroblastoma remains to be fully established.
1.4.1.4 Deletion of 1p
Deletion of the short arm of chromosome 1 (1p) has been identified in 30-35% of 
neuroblastomas (White et al, 2001; 1995). Most studies have identified the 
smallest region of overlapping deletion (SRO) on chromosome 1 at 1p36 but as 
yet there is no agreement about the proximal and distal break points (Ejeskar et al, 
2001; Maris et al, 2001; Ohira et al, 2000). Loss of 1p is frequently associated with 
an unbalanced translocation with 17q t(1;17). However, no genes have been
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identified at the chromosomal break-points, as the breakpoints are highly variable 
on both chromosomes, and are dispersed throughout a large genomic region 
(Laureys et al, 1995; van der Drift et al, 1995). This implies the existence of more 
than one tumour suppressor gene at 1p. In the absence of genetic mutations, 
epigenetic silencing of potential tumour suppressor genes at 1p36 provides an 
alternative mechanism in neuroblastoma progression but this has not yet been 
investigated. Hence, due to the genomic complexity of the region and the large 
size of the deletions it has been difficult to elucidate the biological significance of 1p 
loss in neuroblastoma.
Cytogenetic and molecular analyses of large neuroblastoma tumour cohorts and 
cell lines have identified at least two different regions of overlapping deletion (SRO) 
and one region of homozygous deletion (HD). In one cell line, the region of HD has 
been mapped to chromosome 1p36.2, spanning approximately 500 kb. To date, 
no oncogenic mutations in this region have been identified (Ohira et al, 2000). In 
tumours with MYCN amplification, loss of heterogeneity of 1p seems to affect 
larger regions, often spanning to 1p32. The SRO for MYCN amplified tumours has 
been defined to 1p35-1pter (Caron et al, 1995; Schleiermacher et al, 1996; Spieker 
et al, 2001). This deletion correlates with grim prognosis. In contrast, the SRO for 
1p deletions in MYCN single copy tumours is smaller, and defined at 1p36.3 
(Caron et al, 2001; Bauer et al, 2001; White et al, 2001). These tumours are also 
often near-triploid and assodated with a better outcome. These different regions of 
deletion exhibiting varied biological outcome suggest that there may be more than 
one tumour suppressor genes localized to chromosome 1p.
The significance of del 1p as an independent predictor for survival is still debatable. 
Deletion of large regions of 1p is usually found in patients with advanced disease 
(INSS stages 3 and 4) and is strongly assodated with MYCN amplification, di- and 
tetraploidy, and gain of chromosome 17q (Caron et al, 1995; Spieker et al, 2001, 
Maris et al, 2000)). However, loss of 1p alone is not an independent prognosticator 
(Gehring et al, 1995).
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1.4.1.5 Deletion of 11q
Genetic aberrations at chromosome 11q include balanced translocation involving 
11q21 and 11q22, deletion of 11q23-ter, inversion 11q21-q23 and more frequently 
allelic loss (Koiffmann et al, 1995; Bown et al, 1993; Vandesompele et al, 1998). 
Loss of whole chromosome 11 (19% of neuroblastoma tumours) is associated with 
near-triploid low stage tumours whereas unbalanced translocations (22% of 
neuroblastoma tumours) are associated with patients over 1 year, stage 4 disease 
and unfavourable histology (Plantaz et al, 2001; Maris et al, 2001; Guo et al, 2000; 
Spitz et al, 2003; Guo et al, 1999; 2000). In many cases, unbalanced 11q deletions 
correlate with stage 4 neuroblastomas without MYCN amplification, and hence 
define a distinct sub-set of stage 4 tumours. This sub-group of patients also show 
gain of 17q, and losses of 3p, 4p and 14q, while exhibiting an inverse correlation 
with 1p deletion (Plantaz e al, 2001; Vandesompele et al, 2001).
Tumours without complete loss of chromosome 11 often demonstrate a common 
deleted segment between 11q14-23 (Maris et al, 2001). This suggests that one or 
more tumour suppressor gene(s) are possibly located at this position on 
chromosome 11, but these have yet to be elucidated. This hypothesis is supported 
by evidence showing that transfer of intact chromosome 11 into neuroblastoma cell 
line NGP lacking this chromosome, result in restoration of differentiation of the cells 
(Bader etal, 1991).
1.4.1.6 Other chromosomal deletions
Allelic losses in other chromosomes such as at 2p, 3p, 9p and 14q have been 
observed with variable frequency in neuroblastoma patients. Loss at 2q33 and is 
often associated with loss of expression of the caspase-8 which is localized to this 
chromosomal locus (Teitz et al, 2000; Takita et al, 1997). Capsase-8 is a member 
of the caspase family of proteolytic enzymes activated during apoptosis, thus its 
inactivation would lead to survival advantage (Teitz et al, 2000). Indeed, tumours 
cells with the loss of caspase-8 expression do not respond to tumour necrosis
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factor-related apoptosis (TRAIL) mediated apoptosis (Eggert et al, 2001; Fulda et 
al, 2000; Teitz et al, 2000). Loss of caspase-8 mRNA expression and protein levels 
has been observed in 13 out of 21 neuroblastoma cell lines studied and this 
correlates with a resistance to apoptosis which may be important for disease 
initiation, progression and resistance to chemotherapeutic agents. In primary 
patient samples, the loss of caspase-8 has been detected in 25-35% of high-risk 
tumours, and correlates with amplified MYCN (Teitz et al, 2000 van Noesel et al, 
2002). Some tumour cells also exhibit hypermethylation of caspase-8 gene, 
resulting in its inactivation (Banelli et al, 2002). Interestingly, treatment of 
hypermethylated caspase-8 tumours with demethylating agent, such as 5-aza-2’ 
deoxycytidine (5-AZA), reverts cellular responsiveness to TNF with resultant 
apoptosis (Fulda et al, 2001).
Loss of 3p25.3-p14.3, and is often found with loss of 11 q in localized tumours with 
MYCN single copy (Ejeskar et al, 1998; Spitz et al, 2003). As such these tumours 
are often associated with a poor clinical outcome. RASSF1A (Ras-association 
domain family 1) is a strong candidate gene believed to be lost by this deletion as it 
localizes to chromosomal band 3p21.3. RASSF1A is regarded as a tumour 
suppressor gene since re-expressing this gene in cancer cell lines decreases 
proliferation of the cells. Moreover, RASSF1A counteracts the oncogenic HRAS 
GTPase activity (Dammann et al, 2003). Moreover, RASSF1A also appears to be 
inactivated by hypermethylation in 86% of neuroblastoma cell lines and 40-55% of 
tumours (Astuti et al, 2001; Harada et al, 2002).
The loss of chromosome 9p occurs in a small number of tumours (Takit et al, 
1995). The tumour suppressor gene CDKN2A (encoding both p16INK4A and 
is localised to 9p21. Homozygous deletion of CDKN2A has been detected 
in 4 out of 46 neuroblastoma cell lines (Thompson et al, 2001). To date, the 
relevance of this chromosome change is unclear.
Delection of 14q23-32 occurs in 23% of localized tumours with a single copy of 
MYCN and is often associated with deletion 11q (Thompson et al, 2001).
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Therefore, a number of chromosomal abnormalities, resulting from loss or gain of 
genetic material, are found in neuroblastoma. Whilst some have diagnostic and 
prognostic values, the precise mechanism by which these lead to development 
and progression of neuroblastoma are still not fully understood.
1.4.2 Changes in gene expression associated with 
neuroblastoma
Aberrant gene expression in a normally tightly regulated cellular system will 
inevitably affect cellular growth and behaviour leading to tumourigenesis. 
Neuroblastomas exhibit alterations in gene expression and these are discussed in 
the following sections.
1.4.2.1 Amplification of MYCN oncogene
Amplification of the proto-oncogene, MYCN, is one of the most prominent 
abnormalities found in a sub-set of neuroblastomas. It occurs in 20-25% of all 
neuroblastomas but accounts for 50% of tumours classified as stage 3 and 4 
tumours (Brodeur et al, 1984; Caron et al, 1996). No mutations in the MYCN 
coding sequence has been detected in neuroblastomas. High levels of MYCN 
mRNA and protein expression are detected in MYCN-amplified tumours (Schwab 
et al, 1984; Wenzel et al, 1991). Since MYCN is recognized to induce neoplastic 
phenotype in embryonic rat cell cultures (Small et al, 1987), it is likely that a similar 
mechanism is operative in human neuroblastoma cells. This implies that the 
biological effects of MYCN in neuroblastoma tumours results from an increased 
dosage effect which contributes to tumourigenesis.
Patients with tumours that lack MYCN amplification have a 60% survival at five 
years, whereas only 10% of patients with highly amplified MYCN (greater than ten 
copies) survive for 1-year period (Seegar et al, 1985). Hence, a strong correlation 
exists between MYCN amplification and advanced stage disease and 
aggressiveness of tumours (Nakagawara et al, 1987; Brodeur et al, 1986; Berthold 
etal, 1997).
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The significance of the amplification of MYCN in terms of oncogenic effect has 
been shown in various experimental systems. For instance, transgenic mice 
engineered to over-express MYCN in neural crest-derived tissues develop 
neuroblastoma (Weiss et al, 1997). Similarly, overexpression of MYCN in 
neuroblastoma cells and post-mitotic neurons promotes S phase entry of cells 
(Lutz et al, 1996; Wartiovaara et al, 2002). In agreement, with these findings 
decreasing the levels of MYCN using anti-sense strategies reduces proliferation 
rates and/or induces differentiation of human neuroblastoma cell line (Whitesell et 
al, 1991; Schmidt et al, 1994). Moreover, over-expression of MYCN also over-rides 
G1 arrest after gamma-radiation in ex vivo primary untreated neuroblastoma 
tumours (Tweddle et al, 2001), and abrogates p53-mediated cell cycle arrest in 
MYCN amplified neuroblastoma cell lines (Tweddle et al, 2001). Recently, MYCN 
amplification in neuroblastoma cells has been shown to cause centrosome 
hyperamplification, which could result in increased frequency of multipolar mitotic 
spindles and imbalanced segregation of chromosomes into daughter cells, a 
hallmark of cancer cells (Sugihara et al, 2004).
The region of DNA that is amplified in MYCN-amplified tumours can range from 
100kb to >1 Mb, with a core region of 100-200kb domain, which encompasses the 
MYCN gene (Amler et al, 1989). Since the amplified region can often be much 
larger than the actual size of the MYCN gene, other genes co-amplified have been 
identified. For instance, the DDX1 gene, which maps to within 400kb upstream of 
MYCN, has been found to be co-amplified in approximately 50-70% of MYCN 
amplified tumours (Amler et al, 1996; Squire et al, 1995). Another gene, 
neuroblastoma amplified gene (NAG), is also co-amplified in 70% of MYCN- 
amplified neuroblastomas (Wimmer et al, 1999). Amplification of these two genes 
has not been detected without MYCN amplification, suggesting that MYCN 
maintains the 2p24-amplified DNA.
MYCN is a nuclear phosphoprotein that functions as a transcription factor (for 
review see Wenzel and Schwab, 1995). A direct transactivational target of MYCN 
is MCM7, which has been shown to be overexpressed both at mRNA and protein 
level in MYCN amplified neuroblastoma tumours and cell lines (Shohet et al, 
2002). MCM7 belongs to a family of DNA-binding proteins with a vital function in
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‘licensing’ DNA synthesis during transition from G1 to S phase of the cell cycle 
(Takisawa et al, 2000). Even though the precise role of MCM7 in neuroblastoma 
cells has not been determined, the transcriptional activation of this gene by MYCN 
oncoprotein could be a significant component of MYCN-induced tumourigenesis.
1.4.2.2 Expression of neurotrophin receptors
Neuroblastomas are thought to originate from neural crest precursor cells that 
normally mature and differentiate into sympathetic ganglia or the adrenal medulla. 
Development of the sympathoadrenal cell lineage requires the activation of specific 
signaling pathways linked to survival and differentiation which partly depends on 
neurotrophins that activate or interact with their tyrosine kinase receptors, Trk A, 
Trk B, and Trk C (for review see Patapoutian and Reichardt, 2001).
In the normal sympathetic nervous system, Trk B, and Trk C, are expressed at an 
earlier stage of neuronal development, whilst later on there is predominantly Trk A 
expression (Birren et al, 1993). Trk A is a transmembrane receptor that binds 
nerve growth factor (NGF) and is expressed at high concentration in mature 
neurons of the normal sympathetic ganglia. Nakagawara and colleagues (1993) 
studied the relationship between Trk A mRNA expression and patient survival in a 
series of neuroblastomas and ganglioneuromas. It appears that high expression of 
Trk A correlates with younger age of disease detection, early stage of disease and 
no MYCN amplification, and is therefore associated with a favourable outcome 
(Nakagawara et al, 1993; Suzuki et al, 1993; Kogner et al, 1993). By contrast, 
reduced Trk A expression is associated with poor prognosis and MYCN 
amplification (Kogner etal, 1993; Nakagawara etal, 1993).
In contrast to Trk A, the expression of TrkB receptor is strongly associated with 
higher stage tumours and MYCN amplification. These tumours often also express 
the Trk B ligand (BDNF), and this might represent an autocrine or paracrine loop, 
that enhances cell survival and confers a growth advantage to the cells 
(Matsumoto et al, 1995). High expression Trk B/BDNF is associated with
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angiogenesis and drug resistance (Eggert et al, 2000; Nakagawara et al, 1994; Ho 
etal, 2002).
In a cohort of 55 tumours, Trk C receptor were detected in 25% of 
neuroblastomas, with high levels found in stages 1, 2, and 4s and correlate 
negatively with MYCN amplified tumours. The exact function and role of Trk C in 
neuroblastomas remains to be elucidated. However, in vitro studies demonstrate 
that transfection of Trk C into neuroblastoma cells induces differentiation and this 
has suggested that, like Trk A, this neurotrophin receptor may also be associated 
with a favourable outcome in neuroblastomas (Yamashiro et al, 1996).
1.4.2.3 Expression of anti-apoptotic genes in neuroblastomas
Increased levels of anti-apoptotic gene BCL-2 and BCL-Xl have been detected in 
nearly 82 % of neuroblastoma tumours and majority of neuroblastoma cell lines 
tested (Ikeda et al, 1995; Ikegaki et al, 1995). High BCL-2 expression is associated 
with poor prognosis and correlates with MYCN amplification (Castle et al, 1993). 
Studies in neuroblastoma cell lines to analyse the mechanism by which BCL-2 
acts in these cells have shown that over-expression of BCL-2 can block TRAIL- 
induced apoptosis (Fulda et al, 2002). Similarly, over-expression of both BCL-2 
and BCL-Xl has been shown to block apoptosis in neuroblastoma cell lines 
exposed to chemotherapeutic agents such as cisplatin, doxorubicin and etoposide. 
The ability of these proteins to protect neuroblastoma cells from apoptosis may 
explain the drug-resistance that is exhibited by high-risk neuroblastoma tumours 
(Dole et al, 1995; Fulda et al, 1997). No structural abnormalities in BCL-2, Bel- Xl 
or any other genes involved in intrinsic apoptotic pathway have been detected in 
neuroblastomas (Teitz et al, 2002; van Noesel et al, 2003).
1.4.2.4 Cell cycle regulated genes in neuroblastomas
Altered expression in the positive and negative regulators of the cell cycle is a 
common event in virtually all types of human tumours. The involvement of factors
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that control cell cycle progression in neuroblastomas is discussed in the following 
sections.
1.4.2.4.1 Expression p53 family in neuroblastomas
p53, the protein product of TP53 gene, is a nuclear phosphoprotein which acts as 
a check point protein for the cell cycle. It is a ubiquitously expressed protein that 
monitors DNA damage and upon induction can either cause cell cycle arrest to 
allow for DNA repair to take place or induce apoptosis if damage is too severe or 
under unfavourable conditions. The TP53 gene is the most common genetic lesion 
in human cancers but in neuroblastomas this gene is rarely mutated (Vogan et al, 
1993). However, some studies have shown p53 to be inactivated in 
undifferentiated neuroblastomas by cytoplasmic sequestration, which results in 
loss of normal G1 checkpoint following DNA damage (Moll et al, 1995).
More recently, two p53 related proteins, p73 and p63, have been identified. This 
family has also been shown to be important for normal neuronal development (for 
review see Jacobs et al, 2004). p73 and p63 proteins have high homology to p53 
in some domains and share some effects on cell cycle arrest or apoptosis. For 
instance, the transactivator form of p73 (TAP73) behaves in a manner similar to 
p53 with respect to inducing cell cycle arrest or apoptosis depending on cellular 
conditions. Interestingly, the gene encoding p73 protein is located at 1p36.3, which 
is frequently deleted in neuroblastomas, therefore making it a possible candidate 
tumour suppressor gene lost in these tumours (Kaghad et al, 1997). However, no 
mutations in this gene have been reported in neuroblastomas.
A truncated anti-apoptotic isoform, ANp73, that lacks the transactivation domain in 
the amino-terminus of the protein has been identified and shown to be able to 
antagonize both p53 and p73 protein. In neuroblastomas, this ANp73 isoform has 
been detected as the predominant form of p73 and may provide a mechanism of 
inactivating wild-type p53 or p73. The clinical evaluation of a representative set of 
patients showed that the expression (or the lack of expression) of Tap73 is 
independent of clinical stage, age and survival (Romani et al, 1999). However,
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further investigations in larger cohorts need to be carried out before excluding a 
role for ANp73 in neuroblastoma tumourigenesis.
1.4.2.4.2 Cyclin D1 expression in neuroblastoma
The cyclin D1 gene (also referred to as CCND1, BCL1/PRAD1) was originally 
identified as an oncogene that was activated by chromosomal translocations in 
patients diagnosed with parathyroid adenoma (Motokura et al, 1991). It has since 
been found to be one of the most frequently over-expressed genes in a broad 
range of human neoplasms, including mantle cell lymphoma, head and neck 
squamous cell carcinoma, oesophageal, lung and breast cancer (Donnellan and 
Chetty, 1998; Diehl, 2002). This is not surprising when taking into account the 
functional role of cyclin D1 as a positive regulator of cell cycle progression through 
the G1 phase of the cell cycle (for review see Sherr, 1994). In most cancer types, 
cyclin D1 over-expression results from induction by oncogenic signals, rather than 
a clonal somatic mutation or rearrangement in the cyclin D1 gene (Hosokawa and 
Arnold, 1998).
Molenaar and colleagues (2003) have also shown very high expression of cyclin 
D1 at both the mRNA and protein levels in approximately two-third of 
neuroblastoma cell lines and primary tumours. However, this study showed no 
correlation between cyclin D1 expression and other prognostic factors such as 
stage of the tumour, age or MYCN status. More recent studies have shown that 
cyclin D1 is over expressed in up to 65% of neuroblastoma tumours. This seems 
to be associated with upstream regulation of expression as the gene itself does not 
appear to be amplified (personal communication, Dr. Huib N Caron, Dept, of 
Nuclear Medicine, The Netherlands Cancer Institute/Antoni van Leeuwenhoek 
Hospital, Amsterdam, the Netherlands).
The control of mammalian cell proliferation occurs largely during the G1 phase of 
the cell cycle and involves many regulatory proteins working in concert with each 
other to direct a timely and orderly progression through the cell cycle. To fully 
understand the role played by cyclin D1 in the cell cycle regulation, other proteins
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are required for its normal function. Thus, the progression from G1 to S phase of 
the cell cycle in mammalian cells is regulated mainly by the association of D-type 
cydins (D1, D2, D3). Cydin-dependent kinases 4/6 (CDKs) are involved in the 
early G1-late G1 phase transition in all proliferating cell types (Matsushime at al, 
1992; Meyerson et al, 1992), while the late G1-S phase is regulated through the 
interaction of cydin E with CDK2 (Dulic et al, 1992). The importance of normal cell 
cyde progression can further be appreciated by the superimposition of another 
group of regulatory proteins, the cydin-dependent kinase inhibitors (CDKIs), which 
compete with the cyclins to bind their CDKs and hence inhibit their activity.
The coordinated expression and/or assodation between the positive regulators, 
CDKs and D-type cydins, and inhibitors such as CDKIs, and the tumour 
suppressor protein, pRB, although relevant in the context of normal and malignant 
cells, has nonetheless received relatively little attention in neuroblastoma cells. In 
normal non-dividing cells, the presence of anti-mitogenic factors causes the cells to 
become quiescent as the cell cyde is halted in G0/G1 stage. During this phase the 
pRB protein is present in a hypo-phosphorylated state and bound to the general 
transcription factor, E2F. By sequestering E2F, pRB prevents transcription of 
genes whose products are essential for S phase entry (Chellappan et al, 1991). In 
addition to this, two other events ensure the maintenance of the quiescent state of 
a cell. First, the levels of cyclins in the cell are very low and secondly, CDKIs are 
assodated with CDKs, hence preventing them from phosphorylating pRB, which 
would then become dissociated from E2F and allow entry into S phase. However, 
upon extracellular mitogenic stimulus, there is a dramatic increase in the levels of 
specific D-cydins, depending on cell type, which interact with their respective 
CDK4/6 partners. This cyclin/CDK complex drives the phosphorylation and 
subsequent dissociation of pRB from E2F, thus allowing E2F to activate 
transcription of its target genes, for example, cyclin E (Figure 1.4.24.2) 
(Matsushime et al, 1991; 1994; Meyerson and Harlow, 1994).
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Figure 1.4.2.4.2: Schematic representation of constituents of the cell cycle. 
Transition from resting phase, G0 to Gi requires a coordinated expression of 
members of cyclin D (D1, D2 and D3) family, and their interactions with specific 
kinases (CDK4/6). Phosphorylation of retinoblastoma (pRb), p107 and p130, and 
their dissociation with E2F leads to transcriptional activation of a number of genes, 
allowing the progression past the restriction point (R) in Gi. During later phases of 
the cell cycle, E-type cyclins (E1 and E2) and CDKs are expressed with 
concomitant release of E2F and pRB. Cell cycle inhibitory proteins (p16, 15, 18, 
19) of the INK family (INK 4a, b, c, d) serve to inhibit the continued entry of cells in 
early phases of the cell cycle. Proteins of CIP/ KIP family (p21, 27, 57) also affect 
the cell cycle in both early and late phases.
The cyclin D1 gene is detected at very high levels in the developing CNS and PNS 
with significant elevations observed particularly in the developing sympathetic 
trunk, suggesting an important role for cyclin D1 in the nervous system (Sicinski et 
al, 1995). Moreover, the levels of cyclin D1 mRNA in the developing retina are
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higher than that observed in other tissues during a period when many embryonal 
tissues are known to be in a highly proliferative state (Kaufman, 1992; Sicinski et 
al, 1995). This high expression in retinal cells may act to overcome the high 
expression of Rb gene in this small, but highly specialized tissue when proliferation 
is required during normal development (Kaufman, 1992). Several lines of 
investigations have suggested cyclin D1 to be the one of most potent cyclins 
involved in the phosphorylation of pRb (for review see, Weinberg, 1995).
Manipulation of cyclin D1 in cell lines has further highlighted the critical role for this 
factor in G1/S transition. For instance, cells manipulated to over-express cyclin D1 
exhibit accelerated progress through the G1 phase of the cell cycle, suggesting 
that this cyclin might be the rate-limiting step for G1/S transition (Jiang et al, 1993; 
Resnitzky and Reed, 1995). Moreover, over-expression of cyclin D1 also appears 
to decrease cell size and dependency of the cell on mitogens (Ohtsubo and 
Roberts, 1993; Quelle et al, 1993; Resnitzky et al, 1994). These observations 
show that cyclin D1 levels can be rate-limiting for G1 progression in mammalian 
cells and suggest that the synthesis of this cyclin may be the target of physiological 
signals that control cell proliferation.
Homologous null mutants of cyclin D1 (cyclin D1-/-) generated have further 
highlighted the pivotal role of this gene in cellular proliferation (Sicinski et al, 1995; 
Fantl et al 1995). Mutant mice lacking cyclin D1 are viable but grow more slowly 
and majority die within the first month post-partum. The most obvious aberrant 
phenotype involves the nervous system as the mice exhibit retraction of their limbs 
towards the trunk as well as abnormal clasping of the limbs (Sicinski et al, 1995). 
This type of clasping of the limbs has been reported in several mutants generated 
by targeted disruption of genes that are known to be critical for the normal 
development and functioning of neurons (Urbanek et al, 1994).
Histopathological examination of cyclin D1-/- mice has shown changes particularly 
in retinal development with reduction in the number of cells in all the layers of the 
neural retina. This is thought to be due to the reduced ability of the cyclin D1-/- 
retinal cell precursors to proliferate during embryonic development (Sicinski et al,
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1995; Fantl et al, 1995). This retinopathy in cyclin D1 -/- mice is similar to that 
observed in Bm-3b null mutants (see 1.3.6.2.1).
Another phenotype observed in cyclin D1-/- mice is only apparent in female 
homozygous mutants after they give birth to litters. In normal mammary epithelium 
development, there are two phases of intense proliferation during two well-defined 
periods of development The first phase occurs during the ductal elongation at 
puberty and is directly stimulated by oestrogen, whilst the second phase involves 
the ductal side branching and lobuloalveolar formation during pregnancy in 
response to both oestrogen and progesterone (Haslam, 1988; Wang et al, 1990). It 
appears that mammary epithelium of cyclin D1-/- females develop normally during 
sexual maturation compared with wild-type mice. However, there is a clear 
impairment of pregnancy induced proliferation in cyclin D1 -/- females as the 
mammary epithelia fail to undergo the normal proliferation and expansion, resulting 
in lack of side branching and lubuloalveolar formation (Sicinski et al, 1995; Fantl et 
al, 1995). Since these changes are a prerequisite for lactation, these mutants fail to 
nurse their young. These results are further strengthened by the observation that 
cyclin D1 is the most abundantly expressed D-cyclin in normal mammary glands 
compared to the low levels of cyclin D2 and cyclin D3 (Yu et al, 2001). 
Interestingly, mammary glands of cyclin D1-/- mice have modestly elevated levels 
of cyclin D2 and D3, which might allow normal mammary development during 
puberty. As ovarian steroid hormones and their receptors are critical in stimulating 
mammary epithelium proliferation (Haslam, 1988; Wang et al, 1990), the failure of 
proliferation in mammary epithelium of cyclin D1-/- mice cannot be attributed to 
these factors as there is no significant difference observed in the mutant mice 
compared with the wild-type mice. Therefore, the lack of a proliferative response of 
the mutant mammary epithelial cells can be attributed directly to the loss of cyclin 
D1 (Sicinski et al, 1995).
As both cyclin D1 and oestrogens have an essential role in regulating proliferation 
of breast epithelial cells, it is not surprising that several studies have established a 
relationship between these two proliferative factors. Cyclin D1 has been shown to 
have a novel function in regulating growth of estrogen-responsive tissues by 
potentiating transcription of estrogen receptor (ER)-regulated genes (Zwijsen et al,
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1997; 1998; Lamb et al, 2000). Cyclin D1 mediates this activation independent of 
complex formation to a CDK partner. Cyclin D1 activates the ER-mediated 
transcription through increased binding of both liganded and unliganded receptor 
to ERE-responsive gene sequences (Zwijsen et al, 1997; 1998; Lamb et al, 2000). 
Cyclin D1 has been shown to bind directly to the hormone binding domain of the 
estrogen receptor, causing increased binding of the receptor to ERE, and thereby 
upregulating ER-mediated transcription (Zwijsen et al, 1997). Cyclin D1 gene is 
also amplified in approximately 20% of human breast cancers (Dickson et al, 1995) 
and protein over-expression has been detected in over 50% of human mammary 
carcinomas, and is associated with poor prognosis and lymph node metastases 
(Bartkova et al, 1994; Gillett et al, 1994, 1996). Over-expression of cyclin D1 
seems to have a causative role in breast cancer formation, as transgenic mice 
engineered to over-express cyclin D1 in mammary glands develop breast cancers 
(Wang et al, 1994).
Recent studies undertaken to elucidate the molecular pathways involved in cell 
cycle arrest and differentiation in neuroblastoma cells, have further highlighted the 
central role of cyclin D1 in the proliferation of these cells. For example, a significant 
decrease in cyclin D1 transcript levels is observed in neuroblastoma cells upon 
treatment with a differentiating agent, dibutyryl cyclic adenosine monophosphate 
(cAMP), which induces differentiation of these cells and correlates with growth 
retardation (Munoz et al, 2003). Similarly, treatment of neuroblastoma cells with 
retinoic acid induces differentiation, and results in a decrease in cyclin D1 level 
(Wainwright et al, 2001). Hence, these studies have suggested that the regulation 
of the cyclin D1 in neuroblastoma cells affect proliferative potential of 
neuroblastoma cells. In the work described in chapter 5 of this thesis, I have 
examined the regulation of cyclin D1 in human neuroblastoma cells.
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Aims
Brn-3a and Brn-3b are potent transcriptional regulators that are expressed in 
specific sub-set of neurons of the developing and adult nervous system. 
Studies carried out in mouse neuroblstoma cell lines, ND7, have shown that 
Bm-3a is highly expressed when these cells are induced to differentiate by 
serum withdrawal or cAMP treatment while Bm-3b levels dramatically 
decrease under these growth inhibitory conditions. Conversely, in actively 
proliferating mouse neuroblastoma cells, Brn-3a levels are detected at low 
levels while Brn-3b levels increase. Subsequent studies in our laboratory have 
shown these two transcription factors to have antagonistic effects on several 
neuronally expressed gene promoters, such as SNAP-25 and a-internexin. 
Based on these early studies, the aims of this thesis were to study the roles of 
these proteins in the growth and behaviour of human neuroblastoma cells and 
are summarized below:
(1) To manipulate the levels of Brn-3b transcription factor in human 
neuroblastoma cells, IMR-32, and study the effects on cellular events 
such as growth, proliferation, apoptosis, invasiveness as well as 
response to growth inhibitory signals (e.g. all-trans-retinoic acid).
(2) To over-express Brn-3a protein in IMR-32, and test whether increasing 
this factor reduces the growth and proliferation of these cells, whilst 
enhancing differentiation and cell survival.
(3) To identify and analyse target genes for Brn-3a and Brn-3b in human 
neuroblastoma cells, IMR-32, in order to provide some mechanistic 
understanding of how these transcription factors exert their effects on 
cellular proliferation and differentiation.
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2.0 MATERIALS AND METHODS
2.1 Materials
2.1.1 Suppliers
Analytical grade laboratory chemicals were obtained from Boehringer Maaheim 
(Lewes, East Sussex, U.K.), Merck Ltd., (Poole, Dorset, U.K.), or Sigma Chemical 
Company Ltd. (Poole, Dorset U.K.). Disposal plasticware was supplied by Greiner 
(Stonehouse, Gloucester, U.K.) or Sterilin (Stone, Staffordshire, U.K). Additional 
laboratory materials were obtained from the suppliers mentioned below (unless 
stated otherwise):
Amersham International pic. (Little Chalfont, Bucks., U.K.)
[Methyl-3H]Thymidine aqueous solution (70-95 Ci/mmol), Adenosine 5’-[y-32P] 
triphosphate triethylammonium salt (3000Ci/mmol), Rainbow™ protein weight 
marker, Hybond™-C membranes
Amersham Biosciences (Little Chalfont, Bucks., U.K.)
ECL Western blotting detection reagents and analysis system
BD Biosciences Discovery Labware (Bedford, MA, U.S.A.)
BD Biocoat™ Matrigel™ Invasion Chamber
Bio-Rad (Hemel Hempstead, Herts., U.K.)
Ammonium persulphate, N,N’-methylene-bis-acrylamide, N,N,N’N’- 
tetramethylethylene-diamine (TEMED)
Bio-Rad (Hercules, C.A., U.S.A.)
GS-250 Molecular Imager -  densitometer and phosphor imager, SmartSpec™ 
3000 spectrophotometer
Dako Ltd. (High Wycombe, Bucks., U.K.)
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All peroxidase conjugated secondary antibodies
Difco Laboratories (Basingstoke, Hants., U.K.)
Bacto-agar, Bacto-tryptone, Yeast extract
Gelman Life Sciences (Ann Arbor, Michigan, U.S.A.)
Disposable 0.2 and 0.45 pm sterile filters
Gibco-BRL Life Technologies Ltd. (Renfrewshire, Scotland, U.K.)
1kb DNA ladder, Lipofectin® reagent, all tissue culture solutions, media and 
supplements
Gibco, Invitrogen Corporation (Paisley, Scotland, U.K.)
Geneticin G-418 Sulphate, PBS tablets
Merck (Darmstadt, Germany)
TLC Aluminium sheets
Nunc (Roskilde, Denmark)
All tissue culture plasticware
Pierce Biotechnology, Inc., (Rockford, IL, U.S.A.)
BCA protein assay kit
Pharmacia
Turner TD-20e luminometer
Promega Corporation (Madison, Wisconsin, U.S.A)
All restriction and modifying enzymes and buffers 
Dual-Luciferase® Reporter Assay System
Qiagen (Crawley, West Sussex, U.K.)
Qiagen ‘midi/maxi-prep’ plasmid DNA extraction kits
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Roche (Mannheim, Germany)
Annexin-V-Fluos Staining Kit
Sigma (Saint Louis, Missouri, U.S.A)
Colchicine, 5-Fluorouracil, Hydroxyurea, MTT (Thiazolyl blue), all-trans 
retinoic acid
Sigma Chemical Company Ltd. (Poole, Dorset, U.K.)
Kodak X-OMAT imaging photographic film, Kodak Professional 64T colour 
film
Whatman International Ltd. (Maidstone, Kent, U.K.)
3MM chromatography paper
2.1.2. Standard buffers and solutions
The standard buffers and solutions used throughout are given below (all 
concentrations are expressed at 1X:
Luria Bertani (LB) media:
1% (w/v) Bacto®-tryptone
1% (w/v) NaCI
0.5% Bacto®-yeast extract
LB media was immediately autoclaved after preparation at 120°C for 20 
minutes at 10lb/square inch (psi).
Chloroform/isoamylalcohol:
96% (v/v) chloroform 
4% (v/v) isoamyl alcohol
Tris equilibrated phenol:
Liquefied phenol equilibrated twice with excess 0.1 M Tris-HCI pH 8.0
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TE:
10 mM Tris-HCI pH 8.0 
1 mM EDTA pH 8.0
Tris-Acetate Buffer (TAE):
400 mM Tris base 
200 mM Sodium acetate 
20 mM EDTA, pH 8.3
Tris Borate Buffer (TBE):
90mM Tris-HCI 
90mM Boric acid 
1mM EDTA pH 8.0
2.1.3 Description and source of E.coli strain
XL1-blue
Genotype: recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F’proAB Lacf 
ZAM15 Tn 10 (Tet)[]
Source: Stratagene Ltd., Cambridge U.K.
2.1.4 Description and sources of plasmids
pLTR poly
Description: Eukaryotic expression vector in which the MoMuLV promoter drives 
the expression of the target cDNA cloned into it 
Resistance: Ampicillin
Source/Reference: Dr.T.Moroy, Phillips University, Marburg, Germany. 
pLTR Bm-3a long
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Description: Eukaryotic expression vector under the control of the MoMuLV 
promoter, expressing the long form of Bm-3a. 3.5kb of the Bm-3a long cDNA is 
doned into the Sall/Nrul site of the pLTR poly vector.
Resistance: Ampidllin
Source/Reference: Dr.T.Moroy, Phillips University, Marburg, Germany. 
pLTR Bm-3b short
Description: Eukaryotic expression vector under the control of the MoMuLV 
promoter, expressing the short form of Bm-3b. 1.6kb fragment of the Bm-3b short 
cDNA is doned into the Sall/Hindlll site of the pLTR poly vector.
Resistance: Ampidllin
Source/Reference: Dr.T.Moroy, Phillips University, Marburg, Germany. 
pJ4 Bm-3b antisense
Description: Eukaryotic expression vector under the control of the MoMuLV 
promoter, expressing the first 300 antisense bases of Bm-3b. These first 300 
antisense bases of the Bm-3b short cDNA are doned in a reverse orientation into 
the Sal1/BamHI site of the pJ4 vector.
Resistance: Ampidllin
Source/Reference: Dr.M.Smith, University College London, U.K. 
pCi Neo
Description: Eukaryotic expression vector containing the gene for the neomydn 
phosphotransferase, allowing selection of stably transfected cells.
Resistance: Ampidllin, Neomydn
Source/Reference: Promega Corporation, Madison, Wisconsin, U.S.A. 
pCAT Basic
Description: Lacks eukaryotic promoter and enhancer sequences. It has a chimeric 
intron located 5’ of the chloramphenicol acetyltransferase (CAT) gene and a 
different polyadenylation site located 3’ of the gene. It provides a basis for the 
quantitative analysis of factors regulating mammalian gene expression.
Resistance: Ampidllin
Source/Reference: Promega Corporation, Madison, Wisconsin, U.S.A.
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pCycD1-CAT
Description: Cyclin D1 promoter-driven chloramphenicol acetyltransferase (CAT) 
vector, which has a 1.9 kb Pvu II (-1652 to +231) fragment from the 5’ flanking 
sequence of the human Cyclin D1 gene subcloned into a pCAT Basic background. 
Resistance: Ampidllin
Source/Reference: Dr. J. Nevins, Duke University Medical Centre, Durham, North 
Carolina, U.S.A.; Ohtani etal, 1995.
pGL3
Description: Provides a quantitative analysis of factors that may potentially regulate 
mammalian gene expression. It has a coding region for firefly (Photinus pyralis) 
ludferase, which allows detection of transcriptional activity in transfected eukaryotic 
cells.
Resistance: Ampidllin
Source/Reference: Promega Corporation, Madison, Wisconsin, U.S.A. 
pRL-TK
Description: Renilla Ludferase reporter vector, under a HSV-thymidine kinase 
promoter. pRL-TK contains cDNA encoding renilla ludferase, acts a control vector 
for transfection effidency.
Resistance: Ampidllin
Source/Reference: Promega Corporation, Madison, Wisconsin, U.S.A
2.1.5 Description and sources of cell lines used
IMR32
Description: Human neuroblastoma cells derived from an abdominal mass 
removed from a 13-month-old Caucasian male. The cell line was submitted to the 
American Type Culture Collection in the 36th passage.
Culture medium:
1X DMEM
10% (v/v) Foetal calf serum 
1% (v/v) Non-essential amino adds
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1% (v/v) Penicillin/streptomycin antibiotic 
Freezing medium: Culture medium + 10% DMSO
Source/Reference: ATCC, The Global Bioresource Centre™; Tumilowicz et al, 
1970.
2.1.6 Description and sources of antibodies used
Actin (1-19)
Immunogen: human actin carboxy-terminus 
Specificity: polyclonal
Concentration/dilution: affinity purified goat antiserum used at 1:2000 
Secondary: 1: 2000 HRP-conjugated anti-goat Ig 
Source: Santa Cruz Biotechnology, Inc., CA, U.S.A.
Bm-3a
Immunogen: mouse Brn-3a carboxyl-terminal domain 
Specificity: monoclonal
Concentration/dilution: mouse antiserum used at 1:1500 
Secondary: 1: 2000 HRP-conjugated anti-mouse Ig 
Source: Chemicon International, Temecula, CA, U.S.A.
Bm-3b
Immunogen: human amino acids 184-252 
Specificity: polyclonal
Concentration/dilution: crude rabbit antiserum used at 1:2000 
Secondary: 1: 2000 HRP-conjugated anti-rabbit Ig 
Source: BAbCo, Berkeley, CA, U.S.A.
Cleaved Caspase-3
Immunogen: peptide corresponding to residues surrounding the cleavage site 
of human caspase-3 
Specificity: polyclonal
Concentration/dilution: crude rabbit antiserum used at 1:1000
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Secondary: 1: 2000 HRP-conjugated anti-rabbit Ig
Source: Cell Signaling Technology™ (Cummings Center, Beverly, MA 01915) 
Cyclin D1 (DCS-6)
Specificity: mouse monoclonal; recognizes mouse, rat and human Cyclin D1 
Concentration/dilution: mouse antiserum used at 1:600 
Secondary: 1: 1200 HRP-conjugated anti-mouse Ig 
Source: Santa Cruz, Biotechnology, Inc., U.S.A.
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2.2. Methods
2.2.1. Bacterial Culturing Methods 
2.2.1.1 Propagation of bacteria
Bacteria were grown either on plates prepared from LB media containing 2% 
Bacto®-agar or in liquid media. Both media contained appropriate antibiotic for 
selection. Ampidllin was used at a final concentration of 100 pg/ml. Tetracycline 
was used at a final concentration of 12.5 (ig/ml in plates and 10 pg/ml in liquid 
cultures. Bacterial plates were incubated overnight at 37° C in an incubator. Liquid 
cultures were grown overnight at 37° C in a rotary shaker.
2.2.1.2 Long term storage of bacterial cultures
E.coli cells were grown as mentioned above to early log phase indicated by OD580 
of approximately 0.5. The bacteria were then pelleted by centrifugation in a Sorvall 
GS3 rotor (or its equivalent) at 3000 rpm for 15 minutes. The LB medium was 
removed and the bacteria were resuspended in fresh medium with the appropriate 
antibiotic containing 30% (v/v) sterile glycerol. The culture was then aliquoted at 
500 pi in autodaved vials. These glycerol cell stocks were slowly cooled to -70° C 
and stored at this temperature until ready for use.
2.2.1.3 Preparation of competent cells
Competent XL1-Blue cells were prepared using the calcium chloride technique 
(Sambrook et al, 1989). LB agar plates containing tetracydine were streaked from 
a frozen stock of XL1-Blue cells and incubated at 37° C overnight. A single fresh 
bacterial colony was picked and used to inoculate in 20 mis of LB. The cells were 
grown at 37° C overnight, shaking in a 500 ml sterile baffle flask. The following day 
cells were sub-cultured at a ratio of 1:50 into a litre of LB without tetracycline and 
grown to an OD580 of approximately 0.4. The culture was then chilled for 5 minutes 
on ice and spun in a Sorvall GS3 rotor at 4000 rpm for 10 minutes at 4° C. The
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cells were resuspended in 500 ml of 100mM CaCI2, pipetting up and down with a 
25 ml pipette. The cells were left on ice for a further 30 minutes, then spun at 5000 
rpm for 10 minutes at 4° C. The cell pellet was resuspended in 20 ml of CaCI2 and 
15% glycerol. 200 pi aliquots were made and left on ice for 1 hour, followed by 
storage a t-70° C.
2.2.1.4 Transformation of bacteria
Competent cells were transformed using the heat shock protocol. Competent XL1- 
B cells were thawed at room temperature and immediately placed on ice for 10 
minutes. Plasmid DNA of up to 2/5 volume of cells was added to the competent 
cells and incubated on ice for further 30 minutes. The cells were then heat 
shocked by incubating them at 42° C for 90 seconds and then returned to ice for 3 
minutes. 2-3 volumes of LB was added to each sample. The cell suspension was 
then incubated for 1 hour at 37° C in an orbital shaker. The cells were then plated 
out on appropriate antibiotic plates. The plates were incubated at 37° C overnight. 
The plate was stored at 4°C.
2.2.2 Preparation of plasmid DNA
2.2.2.1 Small scale plasmid DNA extraction from transformed 
bacteria
The DNA ‘mini-prep’ extraction method used was based on a standard alkaline 
lysis protocol (Bimboim & Doly, 1979). Single bacterial colonies were used to 
inoculate 3 mis of LB containing the appropriate antibiotic selection. Cultures were 
incubated overnight at 37° C with vigorous shaking in an orbital shaker. 1.5 ml of 
culture was pellet by centrifugation at 12,000g for 1 minute in a bench top 
microcentrifuge. The cell pellet was then resuspended in 100 pi of resuspension 
buffer (50 mM Tris-HCI pH 7.5, 10 mM EDTA pH 8, 100 pg/ml Rnase-A). Bacterial 
lysis was carried out in 200 pi of lysis buffer (200 mM NaOH, 1% (v/v) Triton X- 
100) and neutralised by the addition of 150 pi of neutralization buffer (3M sodium 
acetate pH 5.5). The cell lysate was centrifuged at 12,000g for 3 minutes at 4° C
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and the supernatant transferred to a fresh tube containing 500 pi of isopropanol. 
To pellet the DNA this supernatant was vortexed and centrifuged for 5 minutes at 
12,000g. The subsequent supernatant obtained during this step was discarded. 
The DNA pellet was washed with 500 pi of 70% ethanol, air dried and then 
resuspended in 100 pi of double distilled (ddH20) containing 20 pg/ml RNase A. 
The plasmid DNA was stored at -20° C.
2.2.2.2 Large scale plasmid DNA extraction from transformed 
bacteria
400 mis of LB containing the appropriate antibiotic selection was inoculated 
with a single colony from a bacterial plate or with approximately 50 pi of liquid 
bacterial culture. This was incubated overnight at 37° C with vigorous shaking 
(300 cycles/minutes on a rotary shaker). The overnight culture was then 
centrifuged at 4°C at 3000 rpm in a Sorvall GS3 rotor for 10 minutes. Plasmid 
DNA was then extracted from the bacterial pellet using the Qiagen maxi-prep 
kit following the manufacturer’s instructions. Typical yield of DNA obtained via 
this method was 100 pg, which was resuspended at a final concentration of 
1pg/pl in ddH20.
2.2.2.3 Phenol/Chloroform extraction and precipitation of DNA
To purify DNA, 400 pi of ddH20  and an equal volume of tris-equilibrated phenol 
were mixed. The mixture was vortexed and then centrifuged at 12,000g for 2 
minutes in a microfuge. The aqueous phase was removed and re-extracted with 
one volume of chloroform/IAA. The DNA in the aqueous phase was precipitated in 
0.1 volumes of 3M sodium acetate (pH5.5) and two volumes of ice-cold 100% 
ethanol. The pellet was washed with 70% ethanol and centrifuged at 12,000g for 5 
minutes in a microfuge. Finally, the ethanol was removed, the pellet dried and 
resuspended in ddH20.
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2.2.2.4 Restriction enzyme digestion
DNA analysis was carried out by restriction digests. These digests were performed 
in 20 pi total volume with approximately 1 pg of DNA. A maximum of 0.1 volumes 
of restriction enzyme(s) were added and the buffer recommended by the 
manufacturer was used at 1 X concentration. Digests were incubated at the 
appropriate temperature for 2 hours. The digested DNA was electrophoresed on 
an agarose gel of appropriate percentage and the products visualized on a UV 
illuminator. An undigested sample was run in parallel, allowing a reference against 
which to compare the enzyme cut samples.
2.2.2.5 Agarose gel electrophoresis
Depending on the expected size of DNA fragments, appropriate percentage 
agarose gels in 1 X TAE were cast For example, 1% gel was cast for fragments 
larger than 1kb, 1.5% for general purpose, and 2% to resolve DNA fragments less 
than 1kb. Ethidium bromide was added to a final concentration of 0.5 pg/ml. 
Approximately 0.1 volume of 10 X loading buffer (1 X TAE, 50% v/v glycerol, 
0.025% bromophenol blue) was added to DNA samples prior to loading. A DNA 
ladder corresponding to the sizes of the fragments being analysed was used, 
usually a Gibco 1 kilobase (kb) ladder. Electrophoresis of the DNA was carried out 
at 100 mA for 0.5 to 2 hours, allowing for a good resolution of bands. Finally, the 
bands were visualized on a long wave UV transilluminator and photographed using 
the Syngene gel doc system.
2.2.3 Protein Methods
2.2.3.1 Standard protein extraction from cultured cells
80% confluent well of a 6-well plate was washed in 1 X PBS and harvested in 100 
pi of standard protein sample buffer (5% (3-mercaptoethanol, 50 mM Tris-HCI pH 
8.0, 6% (v/v) glycerol, 2% (w/v) SDS, and 0.005% (w/v) bromophenol blue). The 
samples were immediately placed on ice and heated to 95°C for 5 minutes and
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placed on ice, and either loaded immediately onto a SDS-polyacrylamide gel or 
stored at -20°C.
2.2.3.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
Standard SDS-polyacrylamide gels were prepared with the composition for the 
stacking and resolving gels as described by Sambrook and colleagues (Sambrook 
et al, 1989). Protein samples were heated to 95° C for 5 minutes. 50-100 pg of 
protein from each sample and 5 pi of Rainbow marker were prepared and run in a 
vertical gel electrophoresis system (Sambrook et al, 1989). The gels were run at a 
constant voltage of 150 V in 1 X running buffer (25 mM Tris, 250 mM glycine and 
0.15 (w/v) SDS, pH 8.3). Gels were run until the protein of interest was sufficiently 
resolved as determined by the migration of the coloured molecular weight marker.
2.2.3.3 Equilisation of protein loading
2.2.3.3.1 Coomassie Blue Staining
In initial experiments in order to establish the integrity of proteins as well as check 
for variation in total protein concentration, SDS-PAGE mini-gels were run to 
separate the protein samples. The gel was then placed in Coomassie stain 
solution (2% (w/v) Coomassie brilliant blue R250, 50% (w/v) methanol, 50% (v/v) 
glacial acetic acid) for 30 minutes at room temperature on a shaker. Any unbound 
stain was removed by repeated replacement of destain solution (10% (w/v) glacial 
acetic acid, 30% (v/v) methanol). Any variation in different samples was observed 
by the intensity of the protein bands in each sample and densitometry was utilized 
to obtain values for various band intensities.
2.2.3.3.2 Bradford Chemistry
Protein concentration of triplicate samples was determined by Bradford chemistry 
using BCA Protein Assay Reagent from Pierce (Illinois, U.S. A.) according to the 
manufacturer’s instructions. Briefly, BCA Reagent A and BCA Reagent B were
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mixed at a ratio of 50:1. 300 fJ of this mixture was added to the appropriate 
number of wells of a 96-well microtitre plate. 1, 5, or 10 jJ of each protein sample 
of unknown concentration was added to the individual wells of the plate. 
Additionally, a titration series of known concentrations of bovine serum albumin 
were also added to individual wells containing the BCA mixture on the plate. This 
was carried out to generate a concentration standard curve. The plate was 
incubated at 37° C for 30 minutes and cooled to room temperature prior to 
exposure to the Smarts pec™ 3000 spectrophotometer (Bio-Rad) which was set to 
read the absorbance at 562 nm. The value of the absorbance of the blank was 
subtracted from all other values and a standard curve was generated from the 
absorbance readings obtained from the albumin titration. Finally, protein 
concentrations of the unknown samples were determined by comparing their 
values of absorbance to the albumin standard curve.
2.2.3.4 Transfer of proteins to nitrocellulose membranes 
(Western blotting)
Proteins of different sizes resolved by SDS-PAGE gels were transferred onto 
Hybond C membrane using a wet-transfer method as described by Sambrook and 
colleagues (Sambrook et al., 1989). Briefly, the nitrocellulose membrane and the 
SDS-PAGE gel were sandwiched between two sheets of 3 MM Whatman paper. 
The sandwiched gel was presoaked in transfer buffer (50 mM Tris, 380 mM 
glycine, 0.1% (w/v) SDS, and 20% (v/v) methanol) and a Trans-Blot TM Cell 
(BioRad) was assembled according to the manufacture’s instructions. The transfer 
was carried out overnight at 150 mA at 4° C.
2.2.3.5 Immunodetection of proteins on western blots
Following the transfer of proteins onto the nitrocellulose membrane, the membrane 
was then blocked to prevent subsequent non-specific binding by incubating it in 
5% (w/v) skimmed milk powder in 1 X PBS for 1 hour at room temperature with 
constant shaking. All subsequent incubations were also carried out at room 
temperature on a shaker unless specified otherwise. The membrane was then
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incubated with primary antibody diluted in the appropriate buffer stated by the 
manufacturers for 1 hour. All the antibodies used in this work, including their 
sources and the dilutions at which they were used, are listed in section 11.1.6. Any 
unbound, non-specific binding of antibody was removed by washing the 
membrane 3 X in wash buffer (1 X PBS, 0.1% Tween-20) for 15 minutes. The 
membrane was then incubated in an appropriate anti-IgG horseradish peroxidase 
(HRP) conjugated secondary antibody for 1 hour. The membrane was washed 
three times for 10 minutes each in wash buffer to remove any unbound antibody. 
The bound HRP was detected using an enhanced chemiluminescence system 
(ECL™) according to the manufacturer’s instructions. Finally, the membrane was 
exposed to X-ray film in order to capture the resultant light emissions. Depending 
on the strength of the signal, the exposure time varied from 1 second to 15 
minutes.
2.2.4 Cell culture
2.2.4.1 Culture conditions
For long term storage all cell lines were stored in liquid nitrogen at -180°C. During 
cultures the cells were maintained at 37°C in a 5% C02 incubator. All 
manipulations of cells were carried out under standard aseptic techniques.
2.2.4.2 Freezing and recovery of cell stocks
Cell stocks were prepared by resuspending the cell pellet from one 175 cm3 flask 
in 1.5 ml of 10% (v/v) dimethylsulphoxide (DMSO), 90% foetal calf serum (FCS). 
The temperature of the vials was gradually decreased to -70°C before being 
immersed in liquid nitrogen.
For growth from frozen stocks, cells were recovered by rapidly thawing the 
contents of one vial and transferring the cell suspension to a 25 cm2 flask 
containing 8 ml of pre-warmed medium. The medium was changed and cells 
passaged as required.
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2.2.4.3 Routine cell passage
Cells were grown in the appropriate growth medium until the flasks were -80% 
confluent when they were passaged as follows. The monolayer of IMR-32 cells 
was washed with Hank’s Balanced Salt Solution (HBSS) free of calcium and 
magnesium ions. 2-3 ml of trysin/versene (1:10) were added to detach the cells 
from the plastic ware and fresh flasks were seeded at a ratio of 1:10 in fresh 
medium.
2.2.4.4 Transient transfections using Lipofectin® 
reagent/peptide method
Transfections were carried out using the Lipofectin® reagent (GibcoBRL, Life 
technologies)/peptide (containing an integrin-targeting domain) complex (kind gift 
from Dr. S. Hart - ICH). IMR-32 cells were plated out at 1 X 10s cells per well in six- 
well plates and left overnight. The following day transfection complexes, sufficient 
for 6 pg plasmid per well in 6-well plate, were prepared in the following order and 
concentration: Lipofectin 4.5 pi (4.5 pg), peptide 240 pi (24 pg) and plasmid 600 pi 
(6 pg), respectively. The relative amount was scaled up as required for the number 
of wells being transfected. The complexes were allowed to form at room 
temperature for 30 minutes to 1 hour, and then diluted with serum free DM EM to a 
concentration of 6 pg DNA per 1 ml in wells of a 6-well plate. The full growth 
medium from the cells was removed and the cells were washed in 1 X PBS twice. 
1 ml of transfection complex was added to each well and the cells were incubated 
for 4 h at 37°C. The transfection medium was removed and replaced with the 
normal full growth medium. For reporter studies, the cells were left for 48 hours 
and then assayed for appropriate studies.
2.2.4.5 Construction of stable cell lines
IMR-32 cells were plated out at 1x 104 in six well dishes (Nunc, GibcoBRL, UK) 
and transfected using lipofectin transfection reagent as described in section 
II.2.4.D. Each plate was cotransfected with a 10:1 molar ratio of plasmid containing
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the Bm-3 constructs to that containing a neomycin selectable marker. The cells 
were grown in G418-containing medium to select for cells stably expressing the 
neomycin gene. It was assumed that cells exhibiting resistance to G418 were also 
stably expressing either the recombinant Bm-3b short, or Bm-3b anti-sense, or the 
empty pLTR vector (all under the control of Moloney Murine leukemia virus 
promoter). After 12 days (two days after 1(30% of the mock transfected cells had 
died under the G-418 selection process), individual colonies were picked by sterile 
pipettes using a Gilson P-1000 pipetteman under a microscope and transferred in 
volumes of 200 pi of medium to 96-well plates. Once the cells reached 70% 
confluency, they were transfected into 24-well plates, then into 6-well plates, and 
finally into 175 cm3. Cells from each coloney were split into two flasks and one 
flask grown for storage as a DMSO stock and the other for characterisation by 
Western immunoblotting.
2.2.4.6 Cellular growth curve studies
Two IMR-32 clonal cell lines representing each of the stably integrated constructs 
were grown to 80% confluency, trypsinised, counted and plated into 24-well plates 
using 1 ml of cells at 1 x 103 cells per ml. The number of wells seeded was 
determined by the number needed to allow 25 days of time points to be taken in 
triplicate at 48h intervals. The medium was changed every three days to 
supplement the cells with fresh growth medium containing G418 for 25 days.
2.2.4.7 Saturation density limitation growth studies
5 x 103 cells were plated in 24 well plates containing a 13 mm cover slip in each 
well. After 24 hours, the cover slips were transferred to six well plates containing 4 
ml of full growth medium. The medium was changed every 48 hours to ensure 
maximal growth conditions. After 5 days total cells were harvested and counted at 
48 hour intervals for ten days.
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2.2.4.8 MTT assay for measuring viability/proliferation of cells
MTT assay was carried out to measure live/proliferating cells in culture. IMR-32 
cells were grown in 6-well plates. The medium was removed from the cells and 
cells were washed in 1 X PBS. 500 pi of PBS was added to each well, followed by 
addition of 50 pi of MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide] (5mg/ml stock solution) to each well. Cells were incubated with this 
solution in a CO2 incubator for 2 hours at 37°C. Equal volumes (500 pi) of the 
solubilization buffer (0.1M HCI in 1 X PBS/ 0.1% Triton-X) was added to each well 
and incubated at 37°C incubator for 5 minutes, followed by cooling to room 
temperature. The absorbance of the converted dye was measured in disposable 
plastic cuvettes at a wavelength of 570 nm using a SmartSpec™ 3000 
spectrophotometer (Bio-Rad).
2.2.4.9 Tritiated thymidine incorporation proliferation studies
Two IMR32 clonal cell lines representing each of the stably integrated constructs 
were grown to 80% confluence, trypsinised, counted and plated in 96-well plates 
using 200 pi of medium containing cells at a density of 1 x 102 cells per well. Cells 
were grown in the normal growth medium containing G418. 24h post-plating, cells 
were pulsed with 10 pi of 50 pCi/ml [3H] thymidine for 1 hour. Cells were then 
trypsinised and harvested into glass filters, and washed using a Tomtec cell 
harvester. The glass filters were then treated with scintillant and counted on a 
Nuclear Enterprises NE10600 scintillation counter.
2.2.4.10 Anchorage independent growth studies
These studies were carried out in soft agar in 6-well plates where a base layer of 2 
ml of growth medium containing 0.7% agarose was topped with 1 ml of growth 
medium containing 0.35% agarose and 1 x 104 cells per ml. Finally, a top layer of 2 
ml of growth medium containing 0.7% agarose was added. Colonies were allowed 
to grow for 21 days after which time colonies comprising of at least 8 cells were
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counted using the Ziess axiovert microscope and images acquired using the 
Axiophot camera and AxioVision imaging sysytem.
2.2.4.11 Annexin V labelling for determination of apoptosis
1 x 106 IMR-32 were washed twice in 1 X PBS and scraped off the 6-well plates. 
Cell suspension was centrifuged at 200 X g for 5 minutes. The cell pellet was then 
resuspended in 100 pi of labeling solution (1000 pi of incubation buffer (10 mM 
Hepes/NaOH pH 7.4, 140 mM NaCI, 5 mM CaCI2), 20 pi of fluorescein 
isothicyante-conjugated Annexin-V (Roche Applied Science) and 20 pi Propidium 
Iodide (PI) (Roche Applied Science). This solution was incubated for 15 minutes in 
dark at room temperature. Following this time period, 400 pi of incubation buffer 
was added to the cells and immediately analysed on Beckman Coulter Epics XL 
(High Wycombe) flow cytometer. Analysis was carried out using 488 nm argon 
laser and bandpass filters of 515nm for Annexin V and 626nm for PI using Expo32 
software. Annexin V negative and PI negative cells were taken as live; Annexin V 
positive and PI negative were taken to represent apoptotic cells; Annexin V 
positive and PI positive were taken as necrotic; and finally, Annexin V negative and 
PI positive were nuclear debris. All the readings made on the FACS machine were 
carried out by Jo Buddie (UCL, London).
2.2.4.12 Matrigel invasion assay
For cell invasion assays, BD Biocoat™ matrigel™ Invasion Chambers were used 
and manufacturer's instructions followed for preparation of the membranes. Sub­
confluent IMR-32 cells were split from flasks using 0.02% EDTA solution without 
trypsin. The cells were resuspended in growth medium containing 0.1% foetal calf 
serum (FCS). 5 X 104 cells in 0.15 FCS were placed into the upper chamber while 
the lower chamber contained medium with 10% FCS, hence creating a serum 
concentration gradient. Cells were incubated at 37°C, 5% C02 for 12 hours. 
Following this time period, non-invading cells from the upper chamber were 
removed and the cells attached to the lower surface of the membrane were fixed in
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serial dilutions of 100% methanol. Cells were then stained with cresyl violet and 
counted using the Ziess Axiovert 200 microscope.
2.2.4.13 Retinoic acid treatment
IMR-32 cells were plated out at a density of 1 X 104 cells/ well in a 6-well plate and 
grown in full growth medium. 10 pM all trans-retinoic add (Sigma) dissolved in 
DMSO was added to the medium the following day and replenished every 48 
hours. Morphological analysis was carried out using the Ziess Axiovert 200 
microscope and images acquired using the Axophot camera and Axiovision 
imaging system.
2.2.4.14 Cisplatin treatment
IMR-32 cells were plated out at 1 X 106 cells/ well of a 6-well plate. The following 
day of plating, 33 pM Cisplatin was added to full growth medium. The cells were 
left for 48 hours under these conditions before harvested for either MTT assay, 
Annexin V analysis or Western immunoblotting. Simultaneously, controls cells 
grown in the absence of Cisplatin were grown at 1 X106 cells/well for 48 hours.
2.2.5 Gene Reporter assays
2.2.5.1 CAT assay
The transcriptional activity of transfected promoter constructs was measured by 
determining the activity of the chloramphenicol acetyltransferase (CAT) enzyme 
gene product which inactivates chloramphenicol by acetylating the drug at one or 
both of its two hydroxyl groups. This gene is not found in eukaryotes, and therefore 
eukaryotic cells contain no background of CAT activity. The enzyme activity was 
assayed using thin layer chromatography as described by Sambrook and 
colleagues (Sambrook et al., 1989). The cells were transiently co-transfected with 
the reporter and effector constructs and washed 48h post-transfection with 1 X 
PBS and harvested in 100 pJ of ice-cold 0.25M Tris-CI, pH 7.5. The cells were then
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lysed by five freeze-thaw cycles; centrifuged at 12,000g for 5 minutes at 4° C in a 
microfuge. The supernatant was transferred to a fresh eppendorf and cellular 
debris discarded. The supernatant was then stored at -20°C until the time for 
assay.
For CAT assays, the following mastermix was prepared: 2.0 pi of 200 pCi/mI [14C]- 
chloramphenicol (35 to 55 pmCi/mmol), 20.0 pi of 4mM acetyl CoA, 32.5 pi of 1M 
Tris-CI (pH 7.5) and 65.5 pi of H20. These amounts were used for one reaction for 
a 30 pi of extract. For each reaction 120 pi of the mastermix was aliquoted into a 
microcentrifuge tube. 30 pi of the extract was added to the tube and mixed gently. 
The tube was incubated at 37°C for 1h. 500 pi of ethyl acetate was added to the 
reaction and the tube was vortexed for 1 minute. The top layer (containing 
chloramphenicol and acetylated chloramphenicol in ethyl acetate) was transferred 
to a fresh microcentrifoge tube. The ethyl acetate sample was then dessicated in a 
Speedvac for 45 minutes and the sample was then resuspended in 15 pi of ethyl 
acetate. The sample was spotted onto a plastic-baked thin layer chromatography 
(TLC) plate. Meanwhile, a chromatography tank was equilibrated by putting 200ml 
of fresh 49:1 chloroform:methanol in the bottom and left for 2 hours. Finally, the 
TLC plate was placed in the tank taking care not to submerge the origin spot in the 
solvent. The chromatography was allowed to run for 2 hours or until the solvent 
front was close to the top. The TLC plate was removed from the tank and dried in a 
fume cupboard. It was then covered in plastic wrap and placed on film for 
autoradiography. For the quantification of CAT activity, the film was lined up with 
the plate and the location of the acetylated and non-acetylated spots determined. 
The resultant signal was analysed by densitometry. The ability of the expression 
vector containing the factor of interest to activate or repress the reporter construct 
was determined as a percentage of the conversion observed with the empty 
expression vector.
2.2.5.2 Luciferase assay
The promoter activity of transfected promoters in Luciferase vectors was measured 
by the amount of Firefly ludferase and Renilla ludferase activity. Firefly and Renilla
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luciferase are proteins that emit photons when provided with appropriate 
conditions and substrates. The Renilla luciferase acts as a control reporter gene 
for transfection efficiency. The pGL3-Basic vector lacks a eukaryotic promoter or 
any enhancer elements of its own, therefore, any promoter sequence inserted 
upstream of the luciferase gene could drive it, generate luminescence and hence 
be detected by this system. This assay was carried out using the commercially 
available Dual-Ludferase reporter assay system (Promega).
Cells were harvested 48 hours post-transfections, rinsed with PBS, and 200 pi of 
the 1X Passive Lysis Buffer (Promega) added to a well of a 6-well plate. The plates 
were left rotating on an oprbital shaker for 15 minutes at room temperature to 
ensure complete and even coverage of the cells. The cell lysate was then collected 
into an eppendorf and vortexed briefly. Following this, the samples were 
centrifuged at 12,000g for 5 minutes in a microfuge to pellet cell debris and 
supernatant collected into a fresh eppendorf.
All reagents and samples were thawed at room temperature prior to carrying out 
the assay. The readings were taken on the TD-20/20 Luminometer (Turner 
Designs). The luminometer was set to take dual luciferase readings (Firefly and 
Renilla luciferase), with a 5 second delay, followed by a 20 second 
integration/reading time. 50 pi of the Firefly luciferase reagent was added to 50 pi 
of the sample lysate, and the reading taken. Following this, 50 pi of the Stop ‘N’ 
Glo reagent (with 20 pl/ml of the Renilla luciferase substrate added) was added to 
the mix and another reading taken. Thus, providing two independent 
measurements and a final ration of promoter activity based upon the transfection 
efficiency.
2.2.6. Electrophoretic Mobility Shift Assay (EMSA)
EMSA is a technique employed to study protein-DNA interactions to determine if a 
particular protein binds to a specific DNA regulatory sequence. This assay is 
performed by incubating a cellular extract over-expressing the protein or purified in 
vitro translated protein with a radio-labeled DNA fragment or oligonucleotide that
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contains the putative binding site. The complex is then analysed on a non­
denaturing PAGE gel. Proteins that are bound to the labeled oligonucleotide will be 
visible by autoradiography.
2.2.6.1 Extraction of proteins under non-denaturing conditions
Cell extracts were prepared using a modified method of Dignam et al (1983). IMR- 
32 cells were scraped from 6-well plates and pelleted by centrifugation at 1000g for 
10 minutes at 4°C. The cell pellet was resuspended in 100-300 pi extraction buffer 
(50 mM Tris pH 8.0, 170 mM NaCI, 25 X protease inhibitor and 0.5% igepal). The 
cells were then lysed by three freeze-thaw cycles (-70°C/37°C) and centrifuged at 
12,000g for 10 minutes at 4°C to pellet debris. The supernatant was aliquoted in 50 
pi volumes and stored at -70°C. 4 to 6 pi was used in the bandshift reactions.
2.2.6.2 Annealing single-stranded oligonucleotides
Single-stranded oligonucleotides of specific regions of human Cyclin D1 promoter 
were reconstituted in dd-H20  at 1pg/pl. Equimolar amounts of complementary 
oligonucleotides were annealed by adding commercially available 1 X buffer C 
(Promega), heating to 80°C for 5 minutes and allowing the oligonucleotide mix to 
cool slowly to room temperature.
2.2.6.3 Labelling oligonucleotide probes
End-labelling of the oligonucleotides with T4 kinase was employed to label probes 
for the EMSA reaction. Typically, 100 ng of the annealed oligonucleotide was 
incubated with 20 pCi [“ PJ y-ATP, 50 mM Tris.CI (pH 7.6), 10 mM MgCfe, 5mM 
DTT, 0.1 mM EDTA and 5-10 units of T4 polynucleotide kinase (Promega). The 
reaction was carried out at 37°C for 30 minutes. Following this incubation period, 
50 pi of TE buffer was added to the reaction and the labeled DNA was purified 
from the unincorporated label by spin-eluting through a Sephadex G-25 column. 
The labeling efficiency was measured using a Geiger counter, comparing the 
eluate reading value to the radioactivity left on the column. The purified probe was
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typically at a concentration of 1 ng/pl in a final volume of 100 pi. The labeled probe 
was stored at -20°C for later use in a radioactivity designated area.
2.2.6.4 Gel Mobility Shift Assay
This procedure was modified from the method described by Theil et al., (1993) 
using the total cellular extracts obtained from actively proliferating IMR-32 cells. 
The following mastermix was prepared without the labeled double-stranded 
oligonucleotide: 3 pi of cellular extract, 2.0 pi 10 X EMSA buffer (10 mM Hepes (pH 
7.9), 60 mM KCI, 4% w/v Ficoll, 1 mM EDTA, 1 mM DTT), 2.0 pg poly (dl-dC) 
(Pharmacia), 50 -10 0  ng cold oligonucleotide (50 -1 0 0  fold molar excess specific 
competitor) or 50 ng non-specific (ERE oligonucleotide) and dd H20  to give a final 
volume of 20 pi. 1 ng of kinase labeled oligonucleotide probe was then added, 
mixed well and centrifuged at 12,000g for 5 seconds. The reaction mix was then 
incubated on ice for 1 hour.
The protein-DNA complex was resolved from the free probe by electrophoresis 
carried out on a pre-run 7% non-denaturing polyacrylamide gel run in 0.5% TBE at 
40 mA for 2 to 3 hours. Gels were carefully removed from the running apparatus 
and attached to two sheets of 3 MM paper, covered by cling film and vacuum dried 
at 80°C for 1hour on a gel drier. Finally, the dried gels were exposed to X-ray film 
overnight at 80°C.
2.2.7 Statistical Analysis
Data points were compared using Student’s T-test analysis and the level of 
significance of the test is given as p-value in the text. Microsoft Excel and Sigma 
plot 2001 were the softwares used for the analyses. Statistical help was provided 
by Dr. V. Budhram-Mahadeo and the statistician, Angie Wade (ICH, UCL).
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Results 1
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3.0 Growth and invasive characteristics of IMR32 cells 
with altered expression of Bm-3b
3.1 Introduction
The Bm-3 POU family of proteins represent a diverse and potent group of 
transcription factors. They were originally identified in the cells of the developing 
sensory nervous system where they regulate proliferation and neuronal 
differentiation (Lillycrop et al, 1992; He et al, 1989; Gerrero at al, 1993; Turner et al, 
1994).
The two closely related members of the Bm-3 family, Bm-3a and Bm-3b, are 
associated with distinct cellular phenotypes in ND7 neuronal cell line, which was 
derived by fusing non-dividing rat dorsal root ganglion cells with the N18 mouse 
neuroblastoma cells (Wood et al, 1990). ND7 can be maintained in a proliferative 
state when grown in full growth medium, containing 10% foetal calf serum 
(Lillycrop et al, 1992). Under these proliferating conditions, ND7 cells show high 
levels of expression of Bm-3b, but not of Bm-3a. However, upon serum 
withdrawal, when these cells cease to proliferate, withdraw from the cell cycle and 
undergo differentiation, Bm-3b levels decrease significantly with a concomitant 
increase in Bm-3a levels (Lillycrop et al, 1992; Smith et al, 1997). This differential 
expression has also been observed in the human neuroblastoma cell lines, IMR-32 
and SHSY5Y (Smith and Latchman, 1996), suggesting that these two transcription 
regulators are associated with different growth states in neuroblastoma cells. At a 
molecular level, Bm-3b was shown to repress the promoters of genes associated 
with neuronal differentiation, such as a-intemexin and neurofilaments (Smith et al, 
1997; Budhram-Mahadeo et al, 1994)
The association of Bm-3b with cellular proliferation is strengthened by other 
studies carried out in our laboratory in relation to breast tumourigenesis. Budhram- 
Mahadeo et al (1999) have shown elevated levels of Bm-3b in a significant 
number of breast cancer biopsies compared with levels in normal breast tissue. 
Moreover, modifying the levels of Bm-3b protein can alter the growth of breast
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cancer cell lines, MCF 7 (Dennis et al, 2001). It is interesting to note that these 
changes were achieved with the short isoform of Bm-3b protein (Bm-3b(s)). 
Furthermore, the proliferative effect of Bm-3b in breast epithelial cells is associated 
with its ability to suppress the expression of the tumour suppressor gene, BRCA1 
(Budhram-Mahadeo et al, 1999). In fact, Bm-3b is the first transcription factor 
shown to regulate the expression of BRCA1. Bm-3b is also known to functionally 
interact and enhance the proliferation associated with estrogen receptor in breast 
cancer cells (Budhram-Mahadeo et al, 1998).
Hence, the findings of elevated Bm-3b in proliferating neuroblastoma cell lines, led 
us to investigate the effect of altering the levels of this transcription factor in human 
neuroblastoma cells. Differences in cellular growth in vivo and in vitro, as well as 
changes in invasive properties associated with constitutively increasing or 
decreasing Bm-3b protein levels in human neuroblastoma cells, IMR-32, were 
analysed.
3.2 Results
3.2.1 Experimental strategy for alterating Brn-3b(s) levels in 
cells
Altering the expression of a specific protein in a cell line is a powerful tool for 
understanding its regulatory role in proliferation, differentiation and/or survival. 
Thus, cell lines with altered levels of a particular gene product have been created 
via homologous (Capecchi, 1989; Friedmann, 1989) or non-homologous (Scangos 
& Ruddle, 1981) recombination. In this study we have modified the gene 
expression of Bm-3b using non-homologous recombination in which constructs 
expressing short form of Bm-3b were used to generate constitutively over­
expressing cells. An anti-sense strategy was used to generate clonal cell lines in 
which Bm-3b levels were reduced.
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3.2.1.1 Human neuroblastoma IMR-32 cell line
The human neuroblastoma cell line, IMR-32, was used to generate stable clones 
with either elevated or reduced levels of Bm-3b. Similar to mouse neuroblastoma 
cells, ND7, IMR-32 cells also show changes in the levels of Bm-3a and Bm-3b 
depending on growth conditions so that high levels of Bm-3b are expressed when 
the cells are proliferating and low levels of Bm-3a are expressed when cells are 
induced to differentiate (Smith and Latchman, 1996), making it a good cell line for 
our studies of human neuroblastoma. This cell line was derived from a 
neuroblastoma tumour in a 13 months old Caucasian male, and exhibits properties 
such as antigen presentation, biochemical and tumour markers, neurotransmitter 
production, and ability to differentiate into neurons in response to stimulus such as 
retinoic acid (Tumilowicz et al, 1970).
3.2.1.2 Over-expression of Bm-3b short protein in IMR-32
Proliferating IMR-32 cells were transfected with the expression construct 
containing the cDNA encoding the short form of Bm-3b under the control of the 
Moloney murine leukemia virus (MoMuLV) promoter using Lipofectin®/peptide 
tranfection methodology (see section 2.2.4.4 of materials and methods). The 
empty expression vector pLTR was also transfected to provide a control for all 
subsequent studies undertaken with these manipulated cell lines. All transfections 
included pCi Neo at a 10-fold reduced concentration compared to the expression 
constructs. This allowed for selection of transfected clones exhibiting neomycin 
resistance in the presence of antibiotic, G418. Twenty independent G418-resistant 
clones were selected from each transfection, propagated and characterised by 
Western immunoblotting for Bm-3b levels.
3.2.1.3 Reducing Brn-3b protein levels in IMR-32
In the work described here, we utilised an eukaryotic expression vector encoding 
antisense cDNA for 300 bases of Bm-3b short. These 300 nucleotides of Bm-3b 
sequence do not cross-hybridise with the mRNA encoding other POU domain
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members, Bm-3a or Bm-3c mRNA. A pJ4 construct expressing the first 300 bases 
in a reverse orientation under the control of MoMuLV promoter was cotransfected 
in a 10-fold excess with a pCi Neo construct into IMR-32 cells using the 
Lipofectin<g>/peptide tranfection methodology (see section 2.2.4.4 of materials and 
methods). Selection was carried out in the presence of an antibiotic, Geneticin- 
G418 sulphate. Antibiotic resistance clones were further propagated and analysed 
for any decrease in endogenous Bm-3b protein levels in IMR-32.
3.2.2 Bm-3b expression in stable transformants
Stable cell transformants with increased or reduced levels of Bm-3b were 
established using the human neuroblastoma cell line, IMR-32. To determine 
changes in the Bm-3b protein expression in the selected clones, Western 
immunoblotting was carried out using an antibody that recognises both isoforms of 
this protein. Each of the donally selected cell line was harvested in cell lysis buffer. 
The cell lysates were equalised by Bradford Assay and 60 micrograms of total cell 
protein was run on a SDS/15% polyacrylamide gel and blotted onto a nitrocellulose 
membrane. These were incubated with Bm-3b specific antibody (see sections 
2.1.6 and 2.2.3 of materials and methods). In order to control for differences in 
protein loading, duplicate immunoblots were also incubated with an antibody 
specific for the invariant protein, p-actin.
As shown in Figure 3.2.2A, three of the selected Bm-3b over-expressing clones 
showed an increase in the short form of Bm-3b (33KDa) which was transfected 
into the cells but interestingly, there was also an increase in the expression of 
endogenous long form of Bm-3b (43KDa). This suggests an autoregulatory effect 
by which the short form of Bm-3b protein can induce the expression of the 
endogenous long form of Bm-3b. This effect has also been seen in studies using 
the breast cancer cell line, MCF7 (Dennis et al, 2001). Conversely, the anti-sense 
clones showed a reduction in the endogenous levels of both long and short forms 
(Fig. 3.2.2B) as expected since the anti-sense construct is derived from a region 
common to the mRNAs encoding both forms.
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3box1 3box2 LTR1 LTR2 3box3
Figure 3.2.2A: Western blot analysis of selected clonal IMR32 cell lines to assess 
for any increase in Bm-3b protein levels compared to empty vector cells 
Significant elevation in both the isoforms of Brn-3b (Brn-3b(l) and Bm-3b(s)) was 
observed in three over-expressing Bm-3b clones (3box1, 3box2, 3box3) compared 
with levels in the two empty vector controls (LTR1, LTR2). The blots were 
developed for only 30 seconds as longer exposure resulted in too strong a signal, 
making it difficult to discriminate bands in individual lanes. It is important to note 
that there was detection of Bm-3b(s) in LTR controls at longer exposure of 2 
minutes (not shown in the blot here). Therefore, it appears that there is a higher 
level of endogenous Bm-3b(l) than Bm-3b(s) in LTR controls. The level of the 
invariant (3- Actin protein in each cell line was used to control for variations in 
protein loading.
3bas1
Brn3b(l)
Brn3b(s)
Actin
LTR1 3bas2
Figure 3.2.2B: Western blot analysis of selected clonal IMR32 cell lines to assess 
for any decrease in levels of Brn-3b protein compared to empty vector clones 
Two anti-sense Bm-3b (3bas1, 3bas2) and one empty pLTR vector controls 
(LTR1) were tested for any decrease of Bm-3b protein in clonal cells transfected
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with the anti-sense construct There was a reduction of both, long and short 
isoforms of Bm-3b in the anti-sense cell lines compared with the LTR control. 
These blots were developed for 10 minutes, longer than the over-expressing 
clones to show endogenous levels of Bm-3b in IMR-32 celts and compare any 
decrease in the anti-sense clones with these basal levels. The level of the invariant 
P-Actin protein in each celt line was used to control for variations in protein loading.
3.2.3 Characterisation of growth and behaviour under 
differentiating stimulus of stable transfectants with different 
levels of Brn-3b
Having successfully obtained clones with variable expression of Bm-3b protein 
compared to the control cells, the effects of changing Bm-3b levels on cellular 
proliferation, response to differentiating stimulus and invasive properties were 
analysed.
3.2.3.1 Effects of manipulating Brn-3b levels on cellular 
growth in monolayers
Uncontrolled growth of cells is the underlying cause of neoplasia which can be 
caused due to an aberrant regulation of cellular growth pathways, or defects in 
differentiation and/or apoptotsis. Since, Bm-3b is associated with proliferation of 
neuronal cells (see section 1.3.6.2.2. of chapter 1), we investigated the changes in 
growth of IMR-32 neuroblastoma cell lines with increased or reduced levels of Bm- 
3b expression.
3.2.3.1.1 Effect of Bm-3b on cell growth over time
Cells were plated at a density of 1 X 104 cells per ml into 24 well plates (Nunc) and 
the number of cells counted using a hemacytometer every 48 hours in triplicates 
for 26 days. As shown in Fig. 3.2.3.1.1, IMR32 cells which constitutively 
overexpress Bm-3b showed the most rapid doubling time as well as cellular 
density at plateau phase compared to the empty vector control cell lines. In 
contrast two anti-sense cell lines with decreased Brn-3b showed slower growth
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compared to the control LTR clones. Thus, the Bm-3b over-expressing clones 
3box1 and 3box2 were the fastest growing, reaching average densities of 2.40 and 
2.75 X106 cells per cm2 respectively, after 26 days (624 hours). In comparison, the 
control clones LTR1 and LTR2 reached a plateau at an average density of 0.70 
and 0.75 X 10  ^cells per cm2 after the same time period (p < 0.05 using Student’s t 
test analysis). Moreover, statistically significant differences were observed as early 
as day 12 (288 hours), between cell numbers in both over-expressing 3box1 and 
3box2 cells compared with LTR 1/2 (p < 0.05). In contrast, the anti-sense clones 
with decreased levels of Bm-3b, 3bas1 and 3bas2, reached a plateau at an 
average density of 0.55 and 0.53 X106 cells per cm2 after 26 days. The anti-sense 
done, 3bas2, showed consistently slower growth compared with 3bas1, with 
significant differences compared with control cells observed by day 12 (p = 0.02 for 
LTR1 and 0.0001 for LTR2 compared with p = 0.25 for 3bas1 for LTR and 0.001 
for LTR2). Consistent statistically significant differences in growth were observed 
for 3bas1 compared with controls by day 18-22 (432-528 hours) (p = 0.009 and 
0.0007 for LTR1 and 2, respectively). These differences in the growth of the anti- 
sense done, 3bas1 and 3bas2, may be due to differences in the resultant loss of 
Bm-3b protein levels using the anti-sense strategy, with 3bas1 exhibiting lower 
Bm-3b loss than 3bas2 done.
Thus, changing the levels of Bm-3b protein significantly modify the growth 
properties of human neuroblastoma cell lines, with high levels of this protein giving 
rise to increased growth rate and lower levels having the opposite effects.
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Figure 3.2.3.1.1: Cellular growth curves comparing the rate of growth of stably 
transfected clonal IMR32 cell lines with different levels of Bm-3b 
Cells were plated out at a density of 1 X 104 cells per ml in 24-well plates and 
grown in full growth medium, and counted every 48 hours for a period of 26 days. 
Both the over-expressing clones (3box1, 3box2) showed significantly higher 
growth rate than the empty vector controls, LTR1 and LTR2, (p value < 0.05). In 
contrast, the two anti-sense clones (3bas1 and 3bas2) grew slower than the 
controls. In particular, the growth rate of 3bas2 was consistently and significantly 
lower than the two LTR controls (p value < 0.05 from day 12 {288 hours} for 3bas2 
and day 18-22 {432-528 hours} for 3bas1). The number of cells shown at each 
time point represents the mean of three independent experiments (six wells for 
each clonal cell line per experiment) +/- the standard deviation.
3.2.3.1.2 Saturation density in cells with different levels of 
Brn-3b
Towards the end of the log phase of cellular growth, the culture becomes confluent 
as all the available surface area of the substrate is occupied and the cells are in 
contact with each other. It is a measurement of the cell concentration in the plateau 
phase that is referred to as the saturation density. Contact inhibition, depletion of 
growth factors and nutrients in the medium contribute towards diminished growth 
observed at this stage and hence, it is important to try and promote cell density as
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the growth limiting factor rather than the limitation of medium nutrients to give an 
accurate measurement of cell numbers at the plateau phase. Therefore, we 
carried out a saturation density limitation growth assay to exclude the possibility 
that any differences in the saturation densities observed in the initial growth studies 
were due to slow growth or exhaustion of medium.
The significant differences in growth of each of the representative cell lines with 
different levels of Bm-3b were mirrored by differences in the cell density at the 
plateau phase of the cellular growth curves. A saturation density limitation growth 
study was carried out to exclude the possibility that the differences in the cellular 
densities observed in the initial studies were due to the slow growth or exhaustion 
of medium. For this study, 5X103 cells were plated in 24 well plates containing a 13 
mm coverslip in each well. After 24 hours, the coverslips were transferred to six 
well plates containing 4 mis of full growth medium. The medium was changed 
every 48 hours to ensure maximal growth conditions. After 5 days total cells in 
each well were harvested and counted at 48h intervals in triplicate for ten days.
As shown in Fig.3.2.3.1.2, similar to the effect seen in the growth curve, Bm-3b 
over-expressing celts continued to proliferate at higher densities compared with the 
control LTR cells with statistically significant differences between 3box1/ 2 and 
LTR1/2 (p<0.05). The anti-sense cells with decreased levels of Bm-3b grew at 
lower densities compared with controls, with 3bas2 showing a significantly greater 
growth reduction (p<0.05). Thus, the saturation densities for each clone were 
similar to their proliferation rate and at the plateau phase of growth curves. These 
results support our findings that over-expressing Bm-3b increases the cellular 
growth rate while decreasing its levels retards the proliferation of neuroblastoma 
celts.
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Figure 3.2.3.1.2: Saturation density of IMR32 cell lines with altered levels of Bm- 
3b
Cells were plated out on a coverslip in 24 well plates and transferred to a 6 well 
plate containing 4 ml of full growth medium. After 5 days total cells in each well 
were harvested and counted at 48 hour intervals for 10 days. The two over- 
expressing clones (3box1, 3box2) showed higher saturation density rate than the 
empty vector controls (LTR1, LTR2) and the two anti-sense clones, 3bas1 and 
3bas2 (p < 0.05). The number of cells shown at each time point represents the 
mean of three independent experiments (six wells for each clonal cell line per 
experiment) +/- the standard deviation of the mean.
3.2.3.1.3 Tritiated thymidine incorporation of cells with 
different Brn-3b levels
To further investigate if the differences in the cell numbers of different clonal cell 
lines were due to changes in their rate of proliferation, we measured differences in 
the rate of DNA synthesis. For this study the tritium (3H) labeled thymidine (3H- 
thymidine) was incubated with cells and the amount incorporated by replicating 
cells was used as a measure of proliferative activity. Cells were incubated with
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tritiated thymidine for 1h, then harvested and prepared as described in materials 
and methods. The incorporation of 3H-thymidine by different clones was measured 
using a scintillation counter. As shown in Fig. 3.2.3.1.3, the Bm-3b over-expressing 
cells showed a clear increase in the incorporation of labelled thymidine, compared 
with the empty vector controls (p < 0.05). In contrast, cells with decreased Brn-3b 
showed much lower tritiated thymidine incorporation rate compared to the controls 
(p value < 0.05). This confirmed our findings in the growth curve and saturation 
density studies, showing increased proliferation rates in cells over-expressing Brn- 
3b compared to controls while those with decreased levels of this protein grew 
slower.
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Figure 3.2.3.1.3: Tritiated thymidine incorporation by clonal IMR-32 cell lines with 
altered levels of Bm-3b
Cells were grown in full growth medium for 24 hours and pulsed with tritiated 
thymidine for 1 hour prior to harvesting. After the treatment, cells were trypsinised, 
harvested onto glass filters, and counts per minute from the glass filters were 
measured using a scintillation counter. The two Bm-3b over-expressing clones 
(3box1, 3box2) showed increased DNA synthesis, as reflected by the amount of 
3H-thymidine incorporation, when compared to the empty vector controls, LTR1 
and LTR2 (p value < 0.05). The two anti-sense clones (3bas1 and 3bas2) showed
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the slowest incorporation of the labelled thymidine with significant differences 
compared with the controls (p value < 0.05). The values shown represent the 
mean of three independent experiments (six wells for each clonal cell line per 
experiment) +/- the standard deviation. All statistical analyses were carried out 
using the student T-test
3.2.3.2 Effect of altering Bm-3b levels on growth, proliferation 
and apoptosis in response to a growth inhibitor (all-trans- 
retinoic acid)
Since Bm-3b appeared to have a profound effect on the proliferation of IMR-32 
neuroblastoma cells, we tested the effect of a growth inhibitory stimulus such as 
retinoic acid on the proliferation of cells with different levels of Bm-3b. It is 
recognised that the addition of retinoic acid to neuroblastoma cells leads to 
inhibition of proliferation and induction of apoptosis or differentiation (Haussler et al, 
1983; Sidell et al, 1983; Lovat et al, 1997). Therefore, we analysed any differences 
in the morphology, proliferation and apoptosis of Bm-3b manipulated cells in the 
presence and absence of all-trans-retinoic acid (RA).
3.2.3.2.1 Effect of 10pM RA on wild-type IMR-32 cells
We first tested the effect of 10pM RA on wild type IMR-32 neuroblastoma cells 
over five time points in order to determine the time at which this concentration of 
RA takes effect on the proliferation/vialibility of these cells. 1 x 104 cells / ml of IMR- 
32 were plated out in 6-well Nunc plates and after 24 hours, 10pM RA was added 
to the foil growth medium. Control cells were grown in parallel in the absence of 
RA. Cells were subsequently harvested at 6h, 12h, 24h, 48h and 72h, in triplicate 
for each time-point, and MTT assay carried out to measure changes in cell 
proliferation (see section 2.2.4.8 of chapter 2). In actively proliferating cells, 
mitochondrial succinic dehydrogenase metabolises the yellow tetrazolium salt [3- 
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-bromide], to yield a purple 
formazan reaction product. Hence, this reaction can be quantified 
spectrophotometrically. Conversely, in cells that are undergoing apoptosis, MTT 
metabolism decreases, reflecting the loss of cell viability. Therefore, the results
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arising from this assay can be interpreted as a measure of cellular proliferation, 
viability and/or cytotoxicity. For the purposes of the study described herein, the 
results obtained from this assay were used as a quantification of cellular 
proliferation and viability.
Figure 3.2.3.2.1 shows that the maximal effect of 10pM RA on proliferation and/or 
viability of IMR-32 cells takes place after 48h of RA addition, when a clear 
decrease is observed in the percentage of proliferating cells grown in RA 
compared with cells grown in the absence of RA. At 6, 12 and 24h post-RA 
treatment, there are no significant differences in the number of 
proliferating/surviving cells compared to the untreated control cells. Hence, 
subsequent studies to look at the effect of RA on IMR-32 cells were carried out at a 
time point after 48h of RA treatment, i.e. 72h, to observe any differences in cellular 
proliferation/viability of IMR-32 neuroblastoma cell line.
10 4
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Figure 3.2.3.2.1: Optimal time-point for observing decrease in cell numbers in 
response to 10juM RA in wild-type IMR32
Wild-type IMR-32 were plated out and 10 pM RA added to the growth medium. 
Cells were harvested in triplicate at 6h, 12h, 24h, 48h and 72h after addition of RA 
and MTT assay carried out, with absorbance measured at 570 nm. Untreated
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control cells grown in the absence of RA (red bars) were harvested in parallel at 
each time-point. The absorbance value is representative of the number of 
proliferating/viable cells. A significant decrease in the number of actively 
proliferating celts was detected at 48h post retinoic add treatment. A greater 
decrease in the number of cells was observed at 72 hours of RA treatment 
compared to untreated cells. The absorbance at 570 nm shown at each time-point 
represents the mean of 3 independent experiments (six wells for each donal cell 
line per experiment) +/- the standard deviation.
3.2.3.2.2 Morphology and growth in Brn-3b manipulated cells 
following 10pM RA treatment
To test whether the differentiating factor, retinoic add (RA), affected the 
morphology and growth of Bm-3b manipulated IMR32 cells, cells with different 
levels of Bm-3b were plated and grown in full growth medium either with or without 
10pM RA. Morphological analysis was carried out using the Ziess Axiovert 200 
inverted microscope. As shown in Figure 8A, 8B, there was a decrease in the 
number of LTR vector only control cells grown in the presence of RA compared 
with untreated cells as reflected by the density of the adherent cells. Moreover, 
following RA treatment the LTR control cells appeared flattened with extensive 
neurite processes (Figure 3.2.3.2.2B) similar to that observed upon differentiation 
of IMR-32 cells (Poongodi et al, 2002). The changes in cell numbers, together with 
the distinct morphological appearance, suggest that, following RA treatment, these 
cells had ceased to proliferate and undergone differentiation or apoptosis as 
reflected by the decrease in cell numbers.
Conversely, Bm-3b over-expressing cells continued to exhibit higher density 
following treatment with RA compared with LTR control. Figure 3.2.3.2.2A shows 
that Bm-3b over-expressing clones, 3box1 and 3box2, failed to show decrease in 
cell numbers upon RA treatment, with the numbers remaining similar to the 
untreated cells at 48 and 72 hours. Moreover, morphological analysis revealed that 
the RA treated Bm-3b over-expressing cells did not exhibit the flattened 
morphology and neurite processes, observed in the control cells, and remained 
similar to the untreated Bm-3b over-expressing cells. This suggests Bm-3b over­
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expressing IMR-32 cells overcome the growth inhibition secondary to RA 
treatment
As shown in Figure 3.2.3.2.2C, the antisense clones, 3bas1 and 3bas2, showed a 
decrease in celt number, as well as an extensive neurite outgrowth, in the 
presence of RA compared to the untreated control antisense clones. Interestingly, 
the morphological appearance of these antisense clones is distinct from the LTR 
control or over-expressing cells as they appear to have smaller cell body with 
distinctive branching patterns.
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-RA 3box1 +RA
-RA 3box2 +RA
Figure 3.2.3.2.2A: Photomicrographs showing the effect of 10 pM retinoic acid 
on the growth and morphology of Brn-3b over-expressing clones 
The Bm-3b over-expressing cells, 3box1 and 3box2, were plated in six-well plates 
in full growth medium either with or without RA for 72 hours. Morphological 
analysis was carried out 72 h post-treatment using a Ziess Axiovert 200 inverted 
microscope and photomicrographs taken at 10 X magnification. The left-hand 
panels represent untreated cells (-RA) while the right-hand panels are cells treated 
with 10pM RA (+RA). There appeared to be no significant difference in cell 
numbers or morphology between the treated and untreated cells of each clone. 
These photomicrographs represent one set of three independent experiments 
carried out.
141
-RA LTR 1 +RA
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Figure 3.2.3.2.2B Photomicrographs showing the effect of retinoic acid on LTR 
control IMR-32 cells
The LTR vector only control (LTR1 and LTR2) was grown in full growth medium 
either in the presence or absence of RA. All left hand panels represent cells grown 
in the absence of RA (-RA) and all the right hand panels are photomicrographs of 
cells grown in the presence of 10pM RA (+RA) for 72h time-points. There are 
significant differences in the number of cells in the treated compared to the 
untreated cells of each clone at each time point. RA treated cells were lower in 
numbers and exhibited flattened morphology with neurite processing. These 
photomicrographs represent one set of three independent experiments carried out.
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Figure 3.2.3.2.2C: Photomicrographs showing the effect of retinoic acid on anti­
sense IMR-32 cells
The Bm-3b anti-sense cells, 3bas1 and 3bas2, were grown in full growth medium 
either in the presence or absence of RA. The cells grown in the absence of RA (- 
RA) or presence of 10pM RA (+RA) were photomicrographed at 10X 
magnification, 72 hours post-treatment. Cells treated with RA showed significant 
decrease in cell numbers and exhibited neurite processing which was absent in 
their untreated counterparts. These photomicrographs represent one set of three 
independent experiments carried out
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3.2.3.2.3 Effect of RA on growth and viability of cells with 
different levels of Brn-3b
Since RA did not result in the growth reduction of Brn-3b over-expressing cells 
compared to the untreated control cells grown in the absence of RA, we tested the 
effect of RA on cell survival/proliferation using the MTT assay (see section 2.2.4.8 
of chapter 2). Bm-3b over-expressing, LTR controls and anti-sense cells were 
plated in triplicate and grown in the presence or absence of 10 pM of RA. The cells 
were harvested after 48 hours of plating and MTT metabolism measured. As 
shown in Figure 3.2.3.2 3, a significantly larger number of Brn-3b over-expressing 
cells were proliferating/viable, following RA treatment compared to control LTR (p 
value < 0.05 for 3box1and 3box2), while anti-sense cells did not exhibit any 
differences compared to controls (p value = 0.73 to 0.8). These results suggest 
that cells with high levels of Bm-3b continue to proliferate and/or survive even in 
the presence of RA.
"140 --------------------------------------------------------------------------------------------------------------------------------------------------
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3box1 3box2 LTR2 3bas1 3bas2
Figure 3.2.3.2 3: MTT assay to observe cell survival/proliferation of Bm-3b 
manipulated cells following treatment with 10pM RA
Cells were grown in the presence or absence of 10pM RA for 48h and 
subsequently assayed for conversion of yellow MTT salt to purple formazan 
crystals, which was measured spectrophotometrically at 570 nm wavelength. The 
data represents the ratio of conversion of MTT in treated (RA+) compared with 
corresponding untreated (RA-) controls for each clonal cell lines. Both Brn-3b over-
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expressing clones, 3box1 and 3box2, had a higher percentage of 
proliferating/surviving cells expressed as a percentage of untreated cells compared 
with the LTR control (p value < 0.05). In contrast the anti-sense clones, 3bas1 and 
3bas2, showed no significant difference compared with control cells (p value = 
0.73 and 0.8 for 3bas1 and 3bas2, respectively).
3.2.3.2.4 Effect of RA on Bm-3b mediated proliferation/ 
survival
The sustained increase in cell numbers seen in the MTT assay in the Brn-3b 
over-expressing cells in the presence of RA, compared to the control cells 
may either result from continued proliferation and/or reduction in apoptosis. To 
elucidate whether these differences seen in cells with higher levels of Bm-3b 
were due to increase in the rates of proliferation, we directly measured the 
rate of DNA synthesis in replication cells by quantifying the incorporation of 
labelled nucleotide tritiated thymidine (3H-thymidine). For this study, cells were 
exposed to 10pM retinoic acid for 48h, then incubated for 1h with the 3H 
thymidine prior to harvesting, and uptake of the label measured using a 
scintillation counter (see section 2.2.4.8 of chapter 2). As shown in Figure 
3.2.3.2.4, Brn-3b over-expressing cells demonstrated significantly higher 
incorporation of labelled nucleotide in untreated as well as RA treated cells so 
that 3H thymidine incorporation in treated and untreated cells were not 
significantly different (p value = 0.025 for 3box1 +/- RA and 0.28 for 3box2 +/- 
RA). Conversely, there was a significant difference in 3H thymidine 
incorporation between RA treated and untreated control LTR cells (p value < 
0.05 for +/- RA). Similarly, anti-sense cells also demonstrated a statistically 
significant difference in the incorporation of 3H-thymidine between RA treated 
and untreated controls (p value < 0.05 for both 3bas1 and 3bas2 +/- RA). 
Thus, in agreement with the previous morphological and growth/viability 
analysis, these results suggest that both LTR control and anti-sense cells fail 
to proliferate in the presence of RA, while Bm-3b over-expressing cells 
continue to proliferate.
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Figure 3.2.3.2.4: Effect of manipulating Bm-3b levels on the proliferation of 
neuroblastoma cells in response to retinoic acid of neuroblastoma cells 
Each clonal cell line was grown in full growth medium with and without 10|jM RA 
for 48 hours. Cells were treated with tritiated thymidine for 1 hour, trypsinised, 
harvested onto glass filters, and counts per minute from the glass filters were 
recorded by a scintillation counter. Cells from the two over-expressing clones 
(3box1 and-2) demonstrated continued proliferation even in the presence of RA 
(red boxes), as reflected by the amount of 3H-thymidine incorporation. Proliferation 
rates between RA treated and untreated 3box1 and -2 cells did not differ (p value = 
0.025 for 3box1 +/- RA and 0.28 for 3box2 +/- RA). In contrast, the control cells 
and anti-sense cells showed a significant decrease in proliferation in the presence 
of RA compared to their corresponding untreated control cells (p value < 0.05 for 
LTR2 +/- RA and for both 3bas1 and 3bas2 +/- RA). The values shown represent 
the mean of three independent experiments (twelve wells for each clonal cell line 
per experiment) +/- the standard deviation.
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3.2.3.2.5 Effect of changing Brn-3b levels on retinoic acid
induced apoptosis
To determine if the increased number of surviving Bm-3b ceils in the presence of 
RA was not just associated with increased proliferation, but also decreased 
apoptosis, we analysed the percentage of apoptosing cells of different clonal cell 
lines in response to RA. Apoptosis is characterized by a variety of morphological 
features such as loss of membrane asymmetry and attachment condensation of 
the cytoplasm and nucleus, and intemudeosomal cleavage of DNA. One of the 
earliest indications of apoptosis is the translocation of the membrane phospholipid 
phosphatidylserine (PS) from the inner to the outer leaflet of the plasma 
membrane. Once exposed to the extracellular environment, binding sites on PS 
become available for Annexin V, a 35-36 kDa, Ca 2+-dependent, phospholipid 
binding protein with a high affinity for PS. The translocation of PS precedes other 
apoptotic processes such as loss of plasma membrane integrity, DNA 
fragmentation, and chromatin condensation. As such, Annexin V conjugated to 
biotin or a fluorochrome such as FITC, PE, APC, Cy5, or Cy5.5, can be used for 
identification of cells in the early stages of apoptosis using flow cytometry.
Because PS translocation also occurs during secondary necrosis, Annexin V is not 
an absolute marker of apoptosis. Therefore, it is often used in conjunction with vital 
dyes such as 7-amino-actinomysin (7-AAD) or propidium iodide (PI), which bind to 
nucleic adds, but can only penetrate the plasma membrane when membrane 
integrity is breached, as occurs in the later stages of apoptosis or in necrosis 
(Koopman et al, 1994). Hence, together Annexin V and PI staining can measure 
for early apoptosis, late apoptosis and necrosis in cells.
Cells from each donal cell line with different levels of Bm-3b were plated in 6 well 
plates at a density of 1 X 106 cells / well and grown either in RA+ or RA' medium, 
and harvested 48 hours later for FITC-Conjugated Annexin V antibody and PI 
staining (described in section 2.2.4.11 of chapter 2). As shown in Fig 3.2.3.2.5, 
similar levels of apoptosis was observed in Bm-3b over-expressing cells compared 
with control or anti-sense cells. These results suggest that Bm-3b does not affect 
the survival of these cells and hence any increase in cell numbers observed in RA
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treated Brn-3b over-expressing cell lines compared to controls were not 
necessarily due to increased survival in these cells. Together with the results 
discussed in section 3.2.2.1.D4, the increase in cell numbers in Bm-3b over­
expressing cells is likely to be due to an increase in cellular proliferation and not 
due to decreased apoptosis. Similarly, the lower cell numbers observed in LTR 
controls and anti-sense clones in the presence of RA compared to their respective 
untreated counterparts, is likely to be due to a decrease in proliferation rather than 
increased apoptosis.
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Figure 3.2.3.2.5: Effect of RA on apoptosis of Bm-3b manipulated cells
Clonal cell lines with different levels of Bm-3b were grown in full growth medium 
with and without 10pM RA for 48 hours. Cells were harvested and incubated with 
FITC-conjugated Annexin V antibody and stained with propidium iodide (PI), and 
analysed on a flow cytometer. The cells were dual labelled with FITC-Annexin V 
and PI to discriminate between apoptotic and necrotic cell populations. The data 
represents the percentage of Annexin V positive RA treated cells divided by the 
percentage of Annexin V positive untreated cells. There is no significant difference 
between the Brn-3b over-expressing (3box1, 3box2), empty vector control (LTR2) 
and anti-sense IMR-32 cells (3bas1, 3bas2). The data represents the mean of 
three independent experiments, +/- the standard deviation.
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3.2.3.3 Effect of manipulating Brn-3b levels on cellular growth
under anchorage independent conditions
The ability of cells to grow independently of anchorage is a hallmark of transformed 
cells and is an important property that allows tumour growth in vivo. We tested 
whether manipulating levels of Bm-3b could modify the ability to these 
neuroblastoma cells to grow in an anchorage independent manner, by forming 
colonies in soft agar. Thus, cells with different levels of Bm-3b were grown in full 
growth medium containing 0.35% agarose. These were observed regularly and 
after approximately 15 days, colonies greater than eight cells were counted using 
an inverted microscope (see section 2.2.4.9 of chapter 2). As shown in Fig 
3.2.3.3A, the number of colonies arising from Bm-3b over-expressing clones was 
significantly larger when compared to the vector only LTR controls (p value < 
0.05). Anti-sense clones with decreased Bm-3b levels grew fewer colonies 
compared to control LTR cells (p value < 0.05). In addition, the Bm-3b over­
expressing cells gave rise to colonies that were consistently larger in size than the 
empty vector control and anti-sense colonies (Fig 3.2.3.3B, 3.2.3.3.C, 3.2.3.3D). 
Therefore, increasing the levels of Bm-3b in neuroblastoma cells not only 
increases their proliferative rates but also enhances their ability to grow in an 
anchorage-independent manner.
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Figure 3.2.3.3A: Effect of manipulating Bm-3b levels on the ability of 
neuroblastoma cells to grow in soft agar under anchorage independent 
conditions
Cells were plated in full growth medium containing 0.3% low-melting-point 
agarose. After 15 days, colonies comprising of greater than 8 cells were counted. 
Bm-3b over-expressing clones 3box1 and 3box2 gave rise to greater number of 
colonies on soft agar compared with the vector only controls LTR1, LTR2 (p value 
< 0.05). In contrast cells with decreased levels of Bm-3b, 3bas1 and 3bas2 grew 
fewer colonies compared with control cells (p value < 0.05). The number of 
colonies counted for each Bm-3b manipulated cell line represents the mean of 
three independent experiments (three wells for each clonal cell line per 
experiment) +/- the standard deviation.
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3.2.3.3B: Anchorage independent colonies on soft agar arising from cells with elevated levels of 
Brn-3b (3box1 and 3box2)
Single cell suspensions from each clonal cell line were grown in full growth medium containing 0.3% 
low melting point agarose. Cells were allowed to form colonies for 15 days. These representative 
photomicrographs were taken on day 15 post-plating using a Ziess Axiovert 200 inverted 
microscope at 20X magnification. Bm-3b over-expressing clones, 3box1 and 3box2, exhibited a 
greater ability to grow colonies in soft agar, forming much larger and denser colonies compared with 
the LTR controls or the anti-sense cells (see facing pages for Figure 13C and 13D).
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3.2.3.3C: Anchorage independent colonies on soft agar arising from empty vector LTR control 
(LTR1 and 2)
Single cells were grown in full growth 0.3% agarose medium for 15 days. These representative 
photomicrographs were taken using a Ziess Axiovert 200 inverted microscope at 40X magnification. 
LTR cells gave rise to significantly fewer and smaller colonies compared with the Bm-3b over­
expressing cells.
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3.2.3.3D: Anchorage independent colonies on soft agar arising from I MR-32 cells with decreased 
Bm-3b levels (3bas1 and -2)
Single cells from each clonal cell line were grown in full growth 0.3% agarose medium for 15 days. 
These representative photomicrographs were taken using a Ziess Axiovert 200 inverted microscope 
at 40X magnification. The anti-sense clones, 3bas1 and 3bas2, gave rise to the smallest and the 
least number of colonies on soft agar compared with Bm-3b over-expressing cells and the LTR 
control cell lines.
153
3.2.3.4 Effect of Bm-3b on invasive potential of neuroblastoma
cells
Invasion and metastatic growth can profoundly affect the course and outcome of 
neuroblastoma tumours. Preliminary results of studies using breast cancer cells in 
our laboratory suggested a role for Bm-3b in regulating expression of genes 
associated with invasion and / or metastasis (Dennis J et al, unpublished data). 
We, therefore, investigated whether changing Bm-3b expression could modify the 
invasive potential of IMR-32 neuroblastoma cells. Wildtype I MR-32 cells have been 
shown to be relatively invasive (Zaizen et al, 1998). We further compared the 
ability of cells with elevated (3box1 and 3box2) or lower Bm-3b (3bas1 and 3bas2) 
levels to migrate through an artificial Matrigel Basement Membrane (BD Biocoat 
Matrigel™) in the presence of a serum gradient with wildtype or control LTR vector 
cells.
We analysed cells migrating due to a serum gradient through the matrix of a BD 
Biocoat Matrigel™ to the lower surface of the membrane after 12 hours. Following 
plating of 5 X 104 cells of each clonal cell line in 0.1% serum in the upper chamber, 
the cells that had migrated to the lower chamber containing medium with 10% 
serum were stained and counted (see section 2.2.4.12 of chapter 2). As shown in 
figure 3.2.3.4, there was a clear and significant increase in the number of migrating 
cells from both Bm-3b over-expressing clones, 3box1 and 3box2, compared with 
the wild-type IMR-32 control cells or the vector LTR control clones (p value < 0.05). 
Interestingly, the number of anti-sense cells, particularly 3b-as2, migrating in this 
assay was slightly lower than the wild-type IMR-32 or LTR control cells (p value for 
3bas1 = 0.02 and 0.01 and p value for 3bas2 = 0.001 and 0.01 with LTR and wild­
type IMR-32, respectively), indicating that the loss of Bm-3b may decrease the 
invasiveness of these cells. These results suggest that Bm-3b affects the ability of 
neuroblastoma cells to migrate through a matrix, hence affecting the invasive 
properties of these cells, implicating a role for this transcription factor in pathways 
associated with tumour progression.
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Figure 3.2.3 4: Invasion assay using the BD Bioquote Matrigel™ chamber to test 
the effect of manipulating Brn-3b expression on migration of neuroblastoma cells 
Cells were plated in medium containing 0.1% foetal calf serum (FCS) in the upper 
chamber of a BD Biocoat Matrigel™ plate and allowed to migrate to the lower 
chamber containing medium with 10% serum for 12 hours. Cells in the lower 
chamber were stained and counted. Cells in the upper chamber were also counted 
and used to determine total cell numbers at the end of the 12 hour incubation 
period, which appeared to remain the same as at the time of plating for each clone 
(data not shown). Both clones over-expressing Bm-3b (3box1 and 2) showed 
increased invasiveness with significantly larger number of cells migrating through 
the membrane compared with the wildtype IMR-32 cells, LTR control (p 
value<0.05). Lower number of anti-sense cells of clone 3bas2 migrated through 
the matrix compared with LTR and wild-type IMR-32 controls (p value = 0.02 to 
0.001). Anti-sense clone, 3bas1, did not show any significantly different migratory 
ability compared to the controls (p > 0.05). These results were obtained from four 
independent counts.
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3.2.3.5 Tumour growth of Brn-3b manipulated cells in vivo
In vitro studies dearly suggested that modulating Bm-3b expression had a 
significant effect on the growth characteristics and behaviour of IMR-32 
neuroblastoma cells. Thus, elevating the levels of Bm-3b increased the cellular 
growth and proliferation both in monolayer as well as in conditions of anchorage- 
independent growth while decreasing this protein in IMR-32 cells retarded their 
growth under similar conditions. We also observed that manipulating the levels of 
Bm-3b affected the invasive properties of IMR-32 neuroblastoma cells, with larger 
numbers of Bm-3b over-expressing cells migrating through the serum gradient 
compared to LTR control and anti-sense cells. We further analysed whether these 
in vitro results would be paralleled in a physiologically more relevant system. 
Hence, we tested whether manipulating Bm-3b in IMR-32 neuroblastoma cells 
could affect their ability to form tumours in vivo.
3.2.3.5.1 Tumour growth in athymic nude mice
For initial studies, we utilised xenograft mice models, in which 1 X 106 cells of each 
done were injected subcutaneously into the flanks of athymic nude mice. Sets of 
six mice were used for each done. The mice were observed everyday for signs of 
ill health as well as changes in the volume of the tumour. When the tumours 
reached a maximum size of 1 cm3, the experiment was terminated, keeping in 
compliance with UKCCCR Guidelines for the Welfare of Animals in Experimental 
Neoplasia. The injection and monitoring of mice was kindly carried out by Dr. 
Barbara Pedley.
As shown in Fig. 3.2.3.5.1, mice injected with cells over-expressing Bm-3b had 
detectable tumour mass at earlier time points of days 7 and 11 respectively, 
compared with the LTR control clones, in which tumours were detected by days 15 
and 17 respectively. The Bm-3b over-expressing dones grew faster than control 
cells with significant differences seen by day 8 after injection (p<0.05). Tumours 
arising from 3box2 clones reached volumes of 0.9-1 cm3 by 10 days and by 14 
days for 3box1 cells. The rate of growth of the Bm-3b over-expressing cells, once
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established, was rapid in both sets of experiments. Interestingly, in this study all 
mice injected with Bm-3b over-expressing clones showed that the rapid increase in 
tumour volume was associated with evidence of invasion into the skin and 
surrounding tissue at the site of the tumour upon reaching a volume of 0.9-1 cm3, 
so these groups had to be terminated by days 10 - 14. In comparison, mice 
injected with the LTR control cells had tumours reaching similar sizes by 18 to 24 
days for LTR1 and 2 respectively. Moreover, unlike the tissue invasion seen with 
tumours resulting from the over-expressing cells, the control cells and anti-sense 
cells resulted in more discrete tumours with less tissue invasion. Tumour arising 
from the anti-sense cells, in particular 3bas2, grew more slowly than tumours 
arising from control cells and were much smaller after 24 days with an average 
volume of 0.5 cm3 for 3bas2 and 0.8 cm3 for 3bas1. As with the in vitro studies on 
growth, LTR2 cells grew more slowly and were the only other surviving control 
group remaining with sets of animals injected with anti-sense cells at 24 days. At 
this stage, while the tumour arising from the anti-sense cells remained small, this 
LTR2 control group resulted in tumours with mean volume of 1.2 cm3, which was 
statistically significant compared with the anti-sense cells (p<0.05).
These results paralleled the findings of in vitro studies, suggesting that 
manipulating the levels of Bm-3b in IMR-32 neuroblastoma cells affected their 
growth rate with cells expressing elevated levels of Bm-3b promoting tumour 
formation in vivo while reduction of Bm-3b retarded tumour growth.
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Fig. 3.2.3.5.1 Tumour growth in athymic nude mice injected with Bm-3b 
manipulated IMR-32 cells
Comparison of in vivo tumour growth resulting from cells with different levels of 
Bm-3b used as xenograft in nude mice models. Groups consisted of six nude mice 
for each clonal cell line. 1 X 106 cells from each clone were injected 
subcutaneously into the flank of the animal. Mice were observed daily for signs of 
ill-health and tumour volume measured following the appearance of a tumour 
mass. Cells with elevated Bm-3b (3box1 and 2) grew tumours more rapidly 
compared with control cells, LTR1 and 2 so that significant differences were 
observed by day 8 post injection (p value = 0.04). The Bm-3b over-expressing 
tumours resulted in tissue necrosis around the site of tumour growth so that these 
groups of mice had to be sacrificed at much earlier time points. In contrast, 
tumours arising from the anti-sense cell lines with lower Bm-3b, 3bas1 and 3bas2, 
resulted in smaller, slower growing tumours compared with LTR controls. As seen 
in in vitro studies, anti-sense clone, 3bas2, grew slower than 3bas1, reflecting 
differences in the levels of Bm-3b in these different clones (p value for 3bas2 = 
0.009 by day 15 compared with the p value for 3bas1, day 21 = 0.005). This study 
was carried out in three independent experiments.
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3.2.3.5.2 Tumour growth in immunosuppressed mice
We also tested whether similar effects dependent on the Bm-3b levels would be 
observed in a different strain of immunocompromised mice. For this study, we 
utilised a genetically different strain of mice to the nude mice used in the previous 
study, and compared any difference in tumour formation after injecting different 
Bm-3b manipulated clonal cells into these animals. These mice are RAG -/-, 
common gamma chain -/- and complement C5 -/- (i.e. homozygous knock-out for 
these three separate alleles). They have no T, B or Natural Killer cell function and 
also exhibit innate immunity defects caused by the complement dysfunction, 
rendering the animals immuno-compromised.
As with nude mice, sets of six mice were used for each Bm-3b manipulated cells 
as well as normal IMR-32 cells. The mice were observed everyday for signs of ill 
health as well as changes in the volume of the tumour. In this experiment, the 
tumours were allowed to grow to a maximum of 2 cm3 size before terminating the 
experiment keeping in compliance with UKCCCR Guidelines for the Welfare of 
Animals in Experimental Neoplasia. The injection and monitoring of mice was 
kindly carried out by Dr. John Anderson.
As shown in Fig. 3.2.3.5.2, mice injected with cells over-expressing Bm-3b (3box1 
and 3box2) showed the fastest tumour growth compared to the controls (p<0.05), 
with 3box2 reaching 20 mm3 within 18 days post-injection and 3box1 reaching a 
maximum of 15 mm3 during the same period. In sharp contrast mice injected with 
the empty vector control cells and normal IMR-32 cells had barely detectable 
tumour size after 18 days, and only reached a maximum size of 12.5 mm3 and 6 
mm3 after 21 days of injection. Moreover, there was a complete failure of the anti­
sense cells, 3bas2, to grow over a period of 21 days while 3bas1 cells also 
showed retarded growth, reaching a maximum tumour size of only 2.5 mm3 at 21 
days. The difference in the growth of antisense cells was statistically significant 
compared with the control cells (p<0.05). Hence, these results suggest that over­
expression of Bm-3b enhances tumour growth in vivo, while reducing the levels of 
Bm-3b retards tumour growth.
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Fig. 3.2.3 5.2: Tumour growth in immunocompromised mice injected with IMR-32 
cells with altered levels of Bm-3b
1 X 106 cells of each clone with different levels of Bm-3b were injected 
subcutaneously into the flank of immunocompromised mice. Groups consisted of 
six immunocompromised mice for each clonal cell line. Mice were observed daily 
for signs of ill-health and following the appearance of a tumour mass, tumour 
volumes were measured. Cells with elevated levels of Bm-3b (3b1 and 3b2) gave 
rise to tumours more rapidly compared with the control cells, LTR1 and 2 (p value
< 0.05). In contrast, antisense cells either failed to give rise to tumours (3bas2) or 
resulted in smaller, slower growing tumours compared to the LTR controls (p value
< 0.05).
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3.3 Discussion
It has previously been shown that high levels of Bm-3b have been observed in 
proliferating, as opposed to differentiated, neuroblastoma cell lines (Latchman 
2001, Smith et al, 1998). At the molecular level, Bm-3b represses the promoters 
of neuronal genes such as a-intemexin and neurofilaments, which play an 
important role in neuronal differentiation (Smith et al, 1997; Budhram-Mahadeo et 
al, 1994). Similarly, Bm-3b has been shown to have a strong proliferative effect in 
breast cancer cell lines (Dennis et al, 2001), and functionally interacts with the 
proliferation associated estrogen receptor in these cells (Budhram-Mahadeo, 
1998). Moreover, this protein has been shown to be over-expressed in several 
cases of sporadic breast cancer compared to its levels in normal mammary 
epithelium. These breast cancer samples with increased levels of Bm-3b show 
reduced levels of the anti-oncogene BRCA1, which may act to halt cellular 
proliferation in normal tissue (Budhram-Mahadeo et al, 1999). In view of this strong 
proliferative potential of Bm-3b, we investigated its role, if any, in human 
neuroblastoma cell line.
In this chapter the cellular growth, proliferation and invasive characteristics of 
human neuroblastoma cells with altered levels of Bm-3b is reported. The 
establishment and confirmation of cell lines which either stably over-expressed the 
exogenous Bm-3b short or decrease the endogenous levels of both long and short 
forms of this protein has been confirmed by Western immunoblotting. Over­
expression of the short form of Bm-3b in IMR-32 cells was accompanied by an 
increase in the endogenous longer isoform of this protein. This is suggestive of a 
possible auto-regulatory mechanism where the short form of the protein causes an 
increase in the long isofbrm.
Transfection of the anti-sense construct caused a decrease but not total loss of 
Bm-3b protein. Antisense strategies are valuable tools to inhibit the expression of a 
target gene in a sequence-specific manner. The general principle of antisense 
methodology is based on DNA or RNA oligonucleotides binding a complementary
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sequence within a specific mRNA and thereby preventing translation into protein. 
At present three types of anti-sense mRNA strategies are in use.
(1) Introduction of a DNA-antisense oligonucleotide into the cell, where it binds to 
its complementary target mRNA and either creates a substrate for endogenous 
RNase H, leading to directed cleavage of the mRNA (Dash et al, 1987, Dagle et al, 
1991) or possibly the oligonucleotide: RNA duplex inhibits translation by steric 
blockade of the ribosome (Fire 1999). However, the effect of use of 
oligonucleotides in preventing protein production is only transient.
(2) Use of mRNA-cleaving ribozymes strategy is based on mutating the 5’ four -  
base nucleotide sequence in order to bind complementary sequences on the 
target mRNA to be cleaved (Doudna and Cech, 2002). The disadvantages of this 
method is because the specificity is based on only four bases, mismatches are not 
uncommon (Colman, 1990) and the catalytic activity of ribozymes varies on 
different target sequences (Cantor et al, 1996).
(3) In the last two years, after the onset of the study described in this thesis, the 
discovery of RNA interference (RNAi) has further improved the antisense field of 
research. RNA interference is initiated by long double stranded- RNA molecules, 
which are processed into 21-23 nucleotide long RNAs, which act as small 
interfering RNAs (siRNA). They are then incorporated into the RNA-induced 
silencing complex, a protein RNA complex, and guide a nuclease, which degrades 
the target RNA (Yu et al, 2002).
In order to achieve efficient methods for gene silencing that are less transient than 
oligonucleotides treatments, more specific than ribozymes, expression vectors 
encoding antisense DNA which acts as a template for the synthesis of antisense- 
mRNA in vivo are used (Colman, 1990). In the work described here, we utilised an 
eukaryotic expression vector encoding antisense cDNA for 300 bases of Bm-3b 
short. These 300 nucleotides of Bm-3b short do not cross-hybridise with the other 
POU domain members, Bm-3a or Bm-3c mRNA. A pJ4 construct construct 
expressing the first 300 bases in a reverse orientation under the control of 
MoMuLV promoter was cotransfected in a 10-fold excess with a pCi Neo construct 
into IMR-32 cells using the LipofectirKSVpeptide method of transfection as
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described in chapter 2. Selection was carried out in the presence of an antibiotic, 
Genetidn-G418 sulphate. Antibiotic resistance clones were further propagated and 
analysed for any decrease in endogenous Bm-3b protein levels in IMR-32.
The results in this chapter have clearly shown that manipulating the levels of Bm- 
3b in IMR-32 cells had profound effiects on the cellular growth, proliferation and 
invasive characteristics of these cells. Over-expression of Bm-3b levels resulted in 
increased growth rate in monolayer of neuroblastoma cells, reflected in increased 
proliferation, saturation densities, and tritiated thymidine incorporation compared to 
the empty vector control cells. This finding was further strengthened by the 
decrease in growth rates observed in cells with reduced levels of this protein. 
Additionally, elevating levels of Bm-3b protein in neuroblastoma cells also 
significantly enhanced growth under anchorage independent conditions, an 
essential requirement for tumour cells to gain autonomy and progress. As 
expected, cells with lower levels of Bm-3b protein, inhibited growth of colonies on 
soft agar under anchorage independent conditions.
Altering the levels of Bm-3b also affects the invasive ability of these human 
neuroblastoma cells. A significantly higher number of invading cells are observed 
from clones with elevated Bm-3b levels while decreasing Bm-3b reduces the 
invasiveness of IMR-32 cells. This suggests that high levels of Bm-3b may 
profoundly affect not just the growth but also invasion and progression of 
neuroblastoma cells.
Another hallmark of tumour cells is their ability to override growth inhibitory or 
differentiating signals. Our results described herein have shown that cells with 
enhanced Bm-3b levels exhibited continued proliferation even in the presence of 
growth inhibitory all-trans retinoic acid (RA). Moreover, IMR-32 cells with 
decreased levels of Bm-3b proteins as well as the empty vector control cells 
showed significantly reduced proliferation when grown in the presence of RA. The 
anti-sense cells with lower levels of Bm-3b exhibited flattened morphology with 
distinct branching patterns. These morphological differences in IMR-32 cells with 
altered levels of Bm-3b, and previous studies showing its ability to negate the 
effect of a differentiation associated protein, Bm-3a, on the expression of some
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neuronal structural genes (Smith et al, 1997; Budhram-Mahadeo et al, 1994), 
suggests a possible indirect involvement of Bm-3b in a complex structural 
mechanism.
In order to ascertain whether the enhanced growth rate of neuroblastoma cells with 
high levels of Bm-3b observed in in vitro experiments could be mirrored at an in 
vivo level, we used two different xenograft models in which cells over-expressing 
Bm-3b as well as those with decreased levels of this protein and LTR controls 
were injected. The aim was to observe any differences in tumour growth rate and 
size. In keeping with the in vitro growth and proliferation studies, Bm-3b over­
expressing cells grew tumours of significant size in these mice models in a shorter 
time period than control cells. Further evidence supporting the role of Bm-3b in 
proliferation and growth of neuroblastoma tumours emerged with the observation 
that IMR-32 cells with decreased levels of Bm-3b resulted in slower rate of tumour 
growth and much smaller size in in vivo mice models. Moreover, not only was the 
size of the tumours arising from Bm-3b over-expressing cells significantly larger 
than the controls but there was tissue invasion, not observed in mice injected with 
vector only controls or anti-sense cells. Similar results were obtained from 
immunocompromised mice in which Bm-3b over-expressing cells injected grew 
larger tumours in a shorter period of time compared to the controls. However, mice 
injected with Bm-3b antisense cells showed a much lower growth compared to the 
over-expressing cells and control cells, with one clone failing to grow into a tumour 
of considerable size. In fact, the anti-sense cells injected into immunocomromised 
cells grew to a smaller size compared to same cells injected into nude mice. This is 
possibly due to the difference in the genetic background of the mice models.
It is clear that the effects of manipulating the levels of Bm-3b in IMR-32 cells gives 
rise to significant effects on proliferation, growth and behaviour of human 
neuroblastoma cells both in vivo and in vitro. It is, however, necessary to elucidate 
the pathways and transcriptional mechanisms affected by altering Bm-3b levels in 
neuroblastoma tumours. Chapter 5 investigates the role of Bm-3b transcription 
factor in the progression of the cells through the cell cycle and its effect on an 
important cell cycle regulatory protein, cyclin D1.
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4.0 Growth and apoptosis in IMR-32 cells with altered levels of 
Bm-3a
4.1 Introduction
The POU domain transcription factor, Bm-3a, is expressed in the developing and 
adult nervous system (Gerrero et al, 1993; Lillycrop et al, 1992; He et al, 1989; 
Turner et al, 1994; Ninkina et al, 1993). Bm-3a expression defines the earliest 
post-mitotic neurons to appear in the central nervous system whereas in the 
peripheral nervous system, Bm-3a expression is initiated just before the neurons 
exit the cell cycle (Fedtsova et al, 1995; 1996). Bm-3a is also expressed in the 
neural crest derived cells (Greenwood et al, 1999), which are associated with 
neuroblastoma formation (Brodeur and Castleberry, 1993).
Bm-3a is associated with differentiation and survival of sensory neurons. The 
critical role for Bm-3a in vivo is paralleled by its ability to activate transcription from 
various promoters of neuronally expressed genes such as the neurofilaments 
(Smith et al, 1997), the related neuronal intermediate filament a-intemexin 
(Budhram-Mahadeo et al, 1995), the synaptic vesicle proteins, involved in the 
process of neurite outgrowth, SNAP-25 and synaptophysin (Lakin et al, 1995; 
Morris et al, 1997; Smith et al, 1997). It also activates the anti-apoptotic protein 
Bd-2 (Smith et al, 1998), while down-regulating the pro-apoptotic Bax (Budhram- 
Mahadeo et al, 2002). Two isoforms of the Bm-3a, generated from alternative 
promoter usage, confer two distinct functions of this protein. Whereas the long 
isoform of Bm-3a (Bm3al) is required for survival, both the long and the short 
(Bm3as) isoforms are associated with differentiation.
Over-expression of Bm-3a in ND7 mouse neuroblastoma cell line stimulates 
neurite outgrowth under normal growth conditions, whereas reduction in the levels 
of Bm-3a via anti-sense strategy results in inhibition of process formation in these 
cells (Smith et al, 1997c). Moreover, upon differentiation of ND7 cells by serum 
removal, endogenous Bm-3a levels are elevated compared to actively proliferating 
cells with low Bm-3a levels (Budhram-Mahadeo et al, 1994). Similar changes in 
Bm-3a levels, in differentiating versus proliferating cells, are observed in human
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neuroblastoma cells such as IMR-32, SKN-MC and SK-N-SH (Smith and 
Latchman, 1996). Hence, in vitro studies using various neuroblastoma cell lines 
have highlighted a potential role for Bm-3a in the transition from proliferating 
neuroblasts to quiescent differentiated sensory neurons, thus suggesting Bm-3a to 
be a factor associated with differentiated neuronal cells.
Bm-3a is well documented to be involved in cell survival in neuronal cell lines and 
primary sensory culture, providing an explanation for the profound wave of 
neuronal apoptosis observed in Bm-3a null mutant mice (McEvilly et al, 1996; 
Xiang et al, 1996; Huang et al, 1999). For example, over-expression of Bm-3a in 
mouse neuronal cell line, ND7 cells and primary cultures of trigeminal and dorsal 
root ganglia protects these cells from apoptotic stimuli such as the withdrawal of 
nerve growth factor from the medium (Smith et al, 1998b; Ensor et al, 2001). In 
agreement with this survival role for Bm-3a, ND7, trigeminal and dorsal root 
ganglia with decreased Bm-3a expression, achieved via anti-sense strategies, 
exhibited enhanced death (Ensor et al, 2001; Smith et al, 1998b). In addition, Bm- 
3a over-expressing cells have been shown to express high levels of Bd-2 (Smith 
etal, 1998a; Ensor etal, 2001).
An important phenomenon observed in lower stage neuroblastoma tumours in 
infants is the frequent spontaneous regression in which the tumour cells become a 
non-malignant ganglioneuroma (Brodeur 2003). The molecular mechanisms 
leading to regression are ill-defined and it is reasonable to postulate that alterations 
in the expression of genes that regulate apoptosis and/or differentiation may 
underlie the spontaneous conversion of a neuroblast to a non-malignant 
ganglioneuroma. High expression of Bm-3a in differentiating neuroblastoma cells 
compared to proliferating cells has led us to hypothesise that aberrant expression 
of this gene might result in dysfunctional differentiation pathway, and hence lead to 
continued proliferation of cells that is observed in neuroblastomas.
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4.2 Results
In this study, we tested whether altering the expression of Bm-3a would change 
the growth characteristics of human neuroblastoma cells, IMR-32. As with Bm-3b 
(discussed in Chapter 3), stable cell lines were generated in which Bm3a(l) protein 
was constitutively over-expressed. We utilised the IMR-32 cell line for these 
studies because, similar to ND7 cells, the levels of Bm-3a(l) are low in these cells 
when they are actively proliferating but are elevated upon differentiation of cells 
(Smith etal, 1996).
4.2.1 Establishment and confirmation of stable cell lines over­
expressing longer Brn-3a(l) isoform
Proliferating IMR-32 cells were transfected with the expression construct 
containing the cDNA encoding the mouse Bm3a(l), or antisense construct to 
decrease Bm-3a expression, under the control of Moloney Murine Leukemia Virus 
(MoMuLV) promoter using the Lipofectin/peptide method of transfection (see 
section 2.2.4.4 of chapter 2). Simultaneously, control cell lines, expressing the 
empty expression vector pLTR, were also generated in IMR-32 cells. All 
tranfections include pCiNeo expression constructs, thus allowing selection of 
neomycin resistant transfected cells in the presence of G418 antibiotic. A number 
of independent G418-resistant Bm-3a or LTR (vector-only control) transfected 
clones were selected and grown up for evaluation for any changes in the levels of 
Bm-3a protein by Western immunoblotting as described in materials and methods. 
In brief, 25 pg of total cellular protein from each done was separated on a 
SDS/10%/Polyacrylamide gel, blotted onto a nitrocellulose membrane, and 
incubated with Bm-3a specific antibody. The membrane was then stripped in 
200mM NaOH and re-incubated with an antibody spedfic for the invariant protein, 
(3-Actin, thus allowing any differences in protein loading to be deteded.
When these stable cells were being generated, the cells that were transfected with 
Bm-3a(l) gave rise to colonies with different charaderistics. While some cells 
proliferated to give rise to large colonies that could be propagated further, others 
failed to proliferate and subsequently, died in culture. As such of the twenty Bm-3a
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overexpressing clones that were obtained, only four survived and could be grown 
and three of these were further characterised. Strikingly, the G418-resistant 
colonies arising from cells transfected with Bm-3a by anti-sense plasmid grew to 
form small colonies but died soon after and, therefore, could not be propagated for 
any further studies.
As shown in Figure 4.2, four of the selected Bm-3a(l) over-expressing clones 
showed expression of the exogenous mouse Bm-3a(l) protein (43KDa) but this 
band was absent in pLTR control cell lines.
Bm-3a
3-Actin —►
Figure 4.2: Western blot analysis of selected clonal IMR-32 cell lines to 
determine increase in the levels of Bm-3a over-expressing clones compared to 
cells transfected with the empty vector
High levels of exogenous mouse Bm-3a(l) protein was observed in four of the 
selected clones (3al1, 3al2, 3al3, 3al4) compared with no exogenous expression of 
this protein in two empty vector control cell lines (LTR1 and LTR2). The antibody 
used is specific for mouse Bm-3a and does not cross react with endogenous 
human Bm-3a protein. Differences in protein loading were determined by 
analysing the levels of the invariant (3-actin protein in each cell line.
3al1 LTR1 LTR2 3al2 3al3 3al4
—
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4.2.2 Characterisation of stable transfectants with increased 
levels of Bm-3a
Having successfully obtained clones that over-expressed Bm-3a protein compared 
to the control cells, we carried out an analysis of the changes on cellular growth, 
proliferation and invasive properties of these cells.
4.2.2.1 Effects on cell growth in monolayers
As Bm-3a is involved in events associated with cellular differentiation, we 
investigated whether increasing Bm-3a changes the growth characteristics of 
human neuroblastoma cell lines when grown in a monolayer using the standard 
growth parameters as described below.
4.2.2.2 Analysis of growth and proliferation of IMR-32 cells 
with different levels of Bm-3a protein
Three clonal cell lines constitutively over-expressing Bm3al and two empty vector 
LTR controls were studied to determine effects on cellular growth. For the growth 
curve study, cells were plated at a density of 1 X 104 cells per ml into 24 well-plates 
(Nunc) and the total number of cells counted on a haemocytometer at 48 hour 
intervals for 26 days. As shown in Fig. 4.2.2.2A, all three over-expressing Bm-3a 
cells grew at a similar rate to the empty vector control cell lines and exhibited 
similar cellular densities at the plateau phase. Thus, Bm-3a over-expressing 
clones 3al1, 3al2 and 3al3, reached average densities of 0.63, 0.69 and 0.65 X 106 
cells/cm2 respectively, after 26 days. Similarly, the control clones LTR1, LTR2 and 
LTR3 reached a plateau at an average density of 0.67, 0.72 and 0.68 X106 cells 
per cm2 after 26 days of plating. On the basis of these findings it appears that 
clones with high Bm-3a did not exhibit different growth rates compared to controls.
In order to evaluate whether the similar growth rates observed between Bm-3a 
over-expressing clones and LTR controls were associated with the actual 
proliferation rather than any other parameters such as cell death or differentiation, 
not excluded in the previous analysis of gross cellular growth, we measured the
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rate of DNA synthesis in different clones. To this end, the cells were incubated with 
tritium (3H) labeled nucleotide thymidine (3H-thymidine) for 1 hour prior to being 
harvested. The incorporation rate was taken as a measure of proliferative activity 
and measured by a scintillation counter as described in materials and methods. As 
shown in Fig. 4.2.2.2B, the Bm-3a over-expressing cells showed a similar rate of 
incorporation of 3H-thymidine as the empty vector controls. This experiment further 
confirmed our findings in the analysis of growth rate that increasing Bm-3a levels in 
these cells did not significantly alter cellular proliferation compared to controls. It is 
important to note that these analyses were carried out in parallel to growth 
experiments on Bm-3b manipulated clones (discussed in results chapter 3) where 
significant differences were observed compared to controls, showing that 
experimental set up was reliable to determine any possible differences.
48 96 144 192 240 288 336 384 442 480 520 576 624
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Fig. 4.2.2.2A: Growth curves of clonal IMR-32 cell lines with increased levels of 
Bm-3a protein
Each clonal cell line was grown in full growth medium and counted every 48 hours 
for 26 days. Analysis of the total number of cells in three Brn-3a over-expressing 
clones (3al2, 3al3 and 3al4) compared with two empty vector controls, LTR1 and 
LTR2, showed no statistically significant differences in growth rate (p value >0.05). 
The number of cells at each time point represents the mean of three independent 
experiments (six wells for each clonal cell line per experiment), +/- the standard 
deviation.
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Fig. 4.2.2.2B: Tritiated thymidine incorporation by clonal IMR-32 cell lines with 
altered levels of Bm-3a
Cells from each clonal cell lines were incubated with 3H-thymidine for 1 hour prior 
to being harvested and the incorporation rate measured by a scintillation counter. 
The three over-expressing Bm-3a clones (3al2, 3al3 and 3al4) showed no 
statistically significant difference in the rate of DNA synthesis compared with the 
empty vector controls (LTR1 and LTR2), as reflected by the amount of 3H- 
thymidine incorporation (p value >0.05). The values shown represent the mean of 
three independent experiments (six wells for each clonal cell line per experiment), 
+/- the standard deviation.
4.2.2.3 Effect on growth, proliferation and apoptosis of 
neuroblastoma cells in response to a growth inhibitory 
stimulus, 10 pM all-trans-retinoic acid, RA
Although Bm-3a did not appear to reduce growth of these neuroblastoma cells, we 
next assessed whether increased Bm3a(l) could modify the survival and 
differentiation of IMR-32 cells. This is because previous in vivo and in vitro studies 
showed that elevated Bm-3a increases survival as well as differentiation of 
neuronal cells. Artificial over-expression of Bm-3a in mouse neuroblastoma ND7
cells and primary cultures of trigeminal and dorsal root ganglia protects cells from 
apoptotic stimuli such as the withdrawal of nerve growth factor (NGF) from the 
medium (Smith et al, 1998b; Ensor et al, 2001). Furthermore, enhanced apoptosis 
occurs in cells where endogenous Bm-3a expression is decreased by an 
antisense strategy (Ensor et al, 2001; Smith et al, 1998b).
The effect of retinoic acid on neuroblastoma cell lines has been widely studied and 
shown to induce differentiation and apoptosis (Chu et al, 2003; Chambon P, 1996; 
Minucd and Ozato, 1996; Mangelsdorf et al, 1992; Theil et al, 1988). Retinoic acid 
has also shown to affect the differentiation, proliferation and adhesion of human 
neuroblastoma cells (Voigt et al, 2000). RA inhibits cell cycle progression in G1 
phase by up-regulating transcription of the CDK inhibitor P2 iapi/WAF1 through 
retinoic add responsive elements present in the p2 i GIP1/WAF1 promoter (Liu et al,
1996).
4.2.2.3.1 Measurement of growth, proliferation and survival on 
Brn-3a over-expressing cells by MTT assay, 3H-thymidine 
incorporation and Annexin V labelling
The effect of retinoic add on cellular growth, viability and survival of different Bm- 
3a over-expressing cells was analysed using the MTT assay, 3H-thymidine 
incorporation and Annexin V labelling as described in materials and methods. For 
these assays, cells were plated in triplicate for each donal cell line and grown 
either in the presence or absence of RA (10 pM, the optimal concentration shown 
to have effect on IMR-32 -  discussed in results chapter 3). Similarly, controls were 
set up in parallel for each donal cell line.
For MTT assays, the cells were harvested at 24h and 48h intervals after plating 
and MTT conversion measured by spectophotometry. To determine changes upon 
treatment with RA the value for cells treated with RA were expressed as a 
percentage of untreated. As shown in Fig 4.2.2.3.1A, there was no significant 
difference in the percentage of Bm-3a over-expressing cells proliferating/surviving 
following ATRA treatment compared to control LTR cells.
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Fig. 4.2.2.3.1A: MTT assay to determine the percentage of surviving/proliferating 
cells with enhanced levels of Brn-3a(l) in response to treatment with all-trans- 
retinoic acid
Each clonal cell line was plated out in full growth medium either with or without 
10pM RA for 48 hours. Subsequently, a MTT assay was carried out to determine 
whether increasing Bm-3a could alter survival/proliferation of these cells when 
grown in the presence of RA compared to untreated controls. The data is 
represented as absorbance units (at 570 nm) which is taken as a measure of cell 
number upon treatment with RA compared to untreated cells. The three Brn-3a 
over-expressing cells (3al2, 3al3 and 3al4) did not exhibit any statistically 
significant changes in the percentage of surviving/proliferating cells compared to 
the empty vector controls (LTR1 and LTR2) (p >0.05). The values shown 
represent the mean of three independent experiments +/- the standard deviation.
This finding was further supported by 3H-thymidine incorporation studies which 
directly measures DNA synthesis. Cells were grown in medium with or without 10 
pM RA for 48h (the optimal time to allow cell arrest and/or differentiation in I MR-32 
by RA discussed in described in results chapter 3). The 3H-thymidine was added to 
the growth medium for 1 hour prior to harvesting and the amount of incorporation
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measured. As shown in Fig. 4.2.2.3.1B, Bm-3a over-expressing cells showed 
decrease in 3H-thymidine incorporation upon treatment with RA compared to their 
untreated counterparts. However, there was no significant difference in the 
proliferation rate of Bm-3a over-expressing cells treated with RA compared to LTR 
controls. Therefore, both Bm-3a(l) over-expressing and LTR control cells fail to 
proliferate in the presence of RA and the growth retardation induced by RA is to 
the same extent in both donal cell lines. These results suggest that Bm-3a(l) does 
not enhance differentiation or survival of cells compared to the empty vector cell 
lines in the presence of the growth inhibitor, retinoic acid.
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Figure 42.2.3.1B: Effect of over-expressing Bm-3a protein levels on the 
proliferation of human neuroblastoma cells in response to all-trans-retinoic acid 
Cells with different levels of Bm-3a protein were grown in full growth medium either 
with or without 10pM RA. 3H-thymidine incorporation was used as a measure of 
cell proliferation. The three untreated Bm-3a over-expressing IMR-32 clones (3al2, 
3al3 and 3al4) showed similar rates of proliferation as the untreated LTR controls 
(p > 0.05) while addition of RA resulted in a significant decrease in the proliferation 
of Bm-3a over-expressing cells, similar to that seen in treated controls, LTR1 and 
LTR2 (p < 0.005). Therefore, there was no statistical difference in cellular 
proliferation in response to RA between Bm-3a over-expressing cells and controls. 
The values shown represent the mean of three independent experiments +/- the 
standard deviation.
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In order to determine whether over-expression of Bm-3a increased the survival of 
human neuroblastoma cells in the presence of RA, we looked at the changes in 
the number of cells undergoing apoptosis upon treatment with 10 pM RA 
compared with untreated cells and LTR controls (treated and untreated). FITC- 
Conjugated Annexin V antibody staining was carried out as described in materials 
and methods. As shown in Fig. 4.2.2.3.1C, similar levels of apoptosis were 
observed in Brn-3a over-expressing cells compared with the control cells. These 
results suggest that Bm-3a does not affect the survival of these cells in the 
presence of RA. Hence, IMR-32 cells with manipulated levels of Bm-3a(l) do not 
exhibit any differences in their growth/proliferation, viability and survival compared 
with control cells in response to 10 pM RA.
3al2 3al3 3al4 LTR1 LTR2
Fig. 4.2.23.1C: Effect of RA on apoptosis of Bm-3a over-expressing cells 
Each clonal cell line with different levels of Bm-3a was grown in full growth medium 
either with or without 10pM RA. After 48 hours cells were harvested and incubated 
with FITC-conjugated Annexin V antibody and stained with PI to determine if RA 
had any effect on the apoptosis of IMR-32 cells over-expressing Bm-3a. The 
values represented in the graph above give the percentage of RA treated apoptotic 
cells (RA+) divided by the percentage of apoptotic cells that were not treated with 
RA (RA-). The three over-expressing clones (3al2, 3al3, 3al4) showed similar 
levels of apoptotic cell death as the controls (LTR1, LTR2) (p > 0.05). The values 
shown represent the mean of three independent experiments +/- the standard 
deviation.
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4.2.2.4 Effect of cisplatin on cell survival/apoptosis of
neuroblastoma cells
ds-Ratinum(ll)diamminedichloride (cisplatin), is an important chemotherapeutic 
agent which is used to treat a variety of human cancer, including neuroblastomas 
(Yaris et al, 2004). It is generally believed that cisplatin mediates its effect by 
binding to the DNA, causing structural alterations such that DNA replication is 
prevented. Subsequently, intracellular transduction pathways are triggered that are 
involved in regulating the cellular equilibrium between apoptotic death and the cell 
cycle (for review see Boulikas and Vougiouka, 2003). Genes upregulated following 
cisplatin treatment of the cells include the pro-apoptotic p53, and its target genes 
p2 iCipi/wafi Qr ^  pro-apoptotic factors such as Bax. Not surprisingly, the anti- 
apoptotic protein, Bd-2, is downregulated following cisplatin treatment (Donzelli et 
al, 2004). Since the anti-apoptotic effects of Bm-3a are mediated via its up- 
regulation of Bd-2 gene, we sought to elucidate the potency of this effect in IMR- 
32 cells in the presence of a Bcl-2 down-regulator, cisplatin.
4.2.2.4.1 Measurement of survival/proliferation and apoptosis 
in Brn-3a stable cell lines by MTT assay, Annexin V labelling 
and caspase-3 activation
We first tested the optimal time to observe effects of dsplatin on the 
viability/proliferation of IMR-32 cells. To this end, wild-type IMR-32 cells were 
plated and grown in the presence of dsplatin for 6 different time-points (4h, 8h, 
12h, 24h, 48h, 55h) and harvested at spedfic times for MTT assay as described in 
materials and methods. Untreated cells were harvested at each time-point as 
controls. We used 33pM dsplatin as other researchers in our laboratory have 
shown this concentration to be optimal for indudng apoptosis in neuronal cells 
(personal communication Smith MP; Ensor L; Hudson C). As shown in Fig. 
4.2.2.4.1A, there was no difference in spectrophotometric values between dsplatin 
treated and untreated IMR-32 cells after 4h, 8h, 12h and 24h exposure to the drug. 
However, a statistically significant difference in the absorbance at 570nm 
wavelength (indicative of mitochondrial activity in living cells) was observed 
between treated and untreated cells after 48h of exposure to dsplatin. Hence, for
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further analyses to determine the effect of cisplatin on Bm-3a manipulated IMR-32 
cells, all assays were carried out after 48 hours of cells being grown in the 
presence of cisplatin.
0.25
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Fig. 4.2.2.4.1A: Effect of cisplatin on IMR-32 cells over time determined by MTT 
assay
IMR-32 cells were grown in full growth medium supplemented either with (C+) or 
without (C-) 33pM cisplatin. Cells were harvested over the indicated time periods 
(4h, 8h, 12h, 24h, 48h and 55h) and determined the mitochondrial dehydrogenase 
activity in viable cells by spectrophotometrically measuring the cleavage of 
tetrazolium rings of the yellow MTT to purple formazan crystals. Readings at 
570nm wavelength indicated that cisplatin exerts its cytotoxic effect only after 48 
hours in IMR-32 cells.
We tested the effect of cisplatin on cell survival/proliferation using the MTT assay. 
Bm-3a over-expressing and control cells were plated at a density of 1 X 106 cells / 
well in full growth medium. The following day 33pM cisplatin was added to the 
medium. Untreated cells from each clone were grown in parallel. All cells were 
harvested after 48 hours of plating and MTT assay carried out as described in 
materials and methods. As shown in Figure 4.2.2.4.1B, there was no significant
178
difference in the survival/proliferation of Brn-3a over-expressing cells in the 
presence of cisplatin compared with empty vector control cells. These results 
suggest that Brn-3a did not protect IMR-32 human neuroblastoma cells against 
cisplatin induced death.
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Fig. 4.2.2.4.1B: MTT assay on cisplatin treated IMR-32 clonal cell lines
Clonal cell lines with different levels of Bm-3a were grown in full growth medium in 
the presence or absence of 33pM cisplatin and harvested 48 hours after treatment. 
MTT assay was carried out to determine whether increasing Bm-3a altered the 
survival of cells when grown in the presence of cisplatin compared to control cells. 
All three Brn-3a over-expressing IMR-32 clones (3al2, 3al3 and 3al4) exhibited a 
significant decrease in survival/proliferation in the presence of cisplatin compared 
to their corresponding untreated counterparts (p value >0.05). The empty vector 
control cell lines (LTR1 and LTR2) also exhibited a similar reduction in their 
survival/proliferative rates in the presence of cisplatin (p value >0.005). However, 
the extent of cell loss between cisplatin treated Bm-3a over-expressing clones and 
the two empty vector control cells was not significantly different (p value > 0.05). 
The values shown represent the mean of three independent experiments +/- the 
standard deviation.
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To directly test the effect of cisplatin on apoptosis of Bm-3a manipulated IMR-32 
cells, Western blot analysis was carried out to measure the levels of activated 
caspase-3 in treated and untreated Bm-3a over-expressing cells and LTR controls. 
Caspase-3 is a key down-stream protease that is critical for apoptosis and its 
activation requires proteolytic processing of its precursor protein in the cytoplasm 
to yield a heterodimer of p17 and p12 subunits (Tewari et al, 1995). Activation of 
caspase-3 occurs rapidly following the onset of apoptosis induced by various 
signals. Hence, detection of active caspase-3 protein is a reliable indicator of 
apoptosis in its irreversible stages. Therefore, we analysed for the presence of 
active caspase-3 protein in the various clonal cell lines treated with cisplatin. Cells 
were harvested 48 hours after treatment in whole cell lysis buffer for Western 
immunoblotting as described in materials and methods. As shown in Fig 
4.2.2.4.1C, activated caspase-3 was readily detected in cisplatin treated cells as 
shown by the presence of two bands, indicated as p17/p12, which were not seen 
in the untreated controls. However, there was no difference in the amount of 
activated caspase-3 detected in the treated Bm-3a over-expressing cells and
treated LTR controls, suggesting that increasing Bm-3a in these cells does not
prevent apoptosis induced by cisplatin.
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Fig. 4.2.2.4.1C Detection of activated caspase-3 protein in cisplatin treated Bm-3a 
over-expressing IMR-32 cells
Clonal cell lines with different levels of Bm-3a were grown in full growth medium 
supplemented either with (C+) or without (C-) 33pM cisplatin. Total cellular proteins were 
harvested from Brn-3a over-expressing cells (3al2, 3al3) and empty vector clones (LTR1, 
LTR2) and analysed by Western immunoblotting for activated caspase-3 protein following 
cisplatin treatment. Similar levels of activated caspase-3 were detected in cisplatin treated 
Bm-3a over-expressing cells and LTR controls. In contrast, activated caspase-3 proteins 
were not detected in untreated cells of either the Bm-3a over-expressing or LTR control cells.
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4.3 Discussion
The role of the POU domain transcription factor, Bm-3a, has been extensively 
studied in mouse neuroblastoma cell line, ND7. ND7 cells can be induced to 
differentiate to a non-dividing neuronal phenotype bearing numerous neurite 
processes by removal of serum from the growth medium or treatment with cyclic 
AMP (cAMP) (Wood et a, 1990; Suburo et al, 1992). Dramatic increase in the 
levels of Bm-3a was observed in ND7 cells induced to differentiate to a non­
dividing phenotype while levels of the closely related factor, Bm-3b, were virtually 
undetectable under these conditions (Budhram-Mahadeo et al, 1994). Moreover, 
over-expression of Bm-3a in ND7 cells resulted in enhancement in the proportion 
of cells bearing neurites, an event associated with differentiation of cells into 
mature neurons (Smith et al, 1997). In actively proliferating cells, the ratio of Bm-3a 
to Bm-3b is reversed. Similar changes are observed during the in vitro 
differentiation of human neuroblastoma cells such as IMR-32, SKN-MC and SK-N- 
SH, with levels of Bm-3a rising dramatically whilst those of Bm-3b fall (Smith and 
Latchman, 1996). Hence, these studies have shown Bm-3a to be associated with 
neuronal differentiation while Bm-3b to be active in proliferating cells.
In the experiments described in this chapter, we set out to study the effects of 
modifying Bm-3a levels in human IMR-32 neuroblastoma cells. We generated cell 
lines that over-express the long isofbrm of Bm-3a protein. However, of the twenty 
clonal cells arising following the transfections to over-express Bm-3a, only four of 
these (3al1, 3al2, 3al3 and 3al4) survived and could be propagated. This 
suggested that in other clones, Bm-3a may be inhibiting proliferation, thereby 
preventing colony growth.
Three of the constitutively over-expressing Bm-3a clones (3al2, 3al3 and 3al4) 
were used in to study the effects on growth, proliferation and response to 
therapeutic drugs such as all-trans-retinoic acid and cisplatin, and compared with 
empty vector transfected cells (LTR1, LTR2). Results of proliferation assays 
confirm that over-expressing Bm-3a in IMR-32 cells did not significantly alter the 
cellular growth or proliferation compared to cells containing the empty vector alone.
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Moreover, previous studies in ND7 cells engineered to over-express Bm-3a 
exhibited striking morphological changes such as neurite outgrowth even in serum- 
containing medium which would not normally promote differentiation (Smith et al,
1997). However, similar analyses in human neuroblatoma IMR-32 cells over- 
expressing Bm-3a did not show any enhancement in the proportion of cells 
bearing processes or in the length of the processes compared to the control cells 
(data not shown).
We also tested whether Bm-3a affected survival of these cells since in addition to 
its effect on neuronal differentiation, high levels of Bm-3a has been shown to 
protect ND7 cells as well as primary cultures of trigeminal and dorsal root ganglia 
from apoptotic stimuli such as the withdrawal of nerve growth factor (NGF) from 
the medium (Smith et al, 1998b; Ensor et al, 2001). In vivo studies also 
demonstrated that increasing Bm-3a expression protected dorsal root ganglia 
following sciatic nerve lesion (Smith et al, 2001). Conversely, increased death has 
been observed in ND7, TG and DRG neurons in cultures where endogenous Bm- 
3a expression is decreased using an antisense strategy (Ensor et al, 2001; Smith 
et al, 1998b). Subsequently, Bm-3a was shown to regulate survival by enhancing 
expressing of anti-apoptotic genes associated with survival in neuronal cells either 
directly or indirectly upon association with p53 protein. These include activation of 
the Bd-2 P2 promoter (the predominant promoter that is active for this gene in 
neuronal cells) (Smith et al, 1998a; 1998b; Ensor et al, 2001). Moreover, Bm-3a 
has been shown to repress p53 mediated activated of pro-apoptotic factors Bax 
and Noxa (Budhram-Mahadeo et al, 2002; Hudson et al, 2004). Therefore, given 
this protective role of Bm-3a in neuronal cells and the failure to propagate cells 
containing the Bm-3a anti-sense plasmid, we tested if IMR-32 cells over­
expressing this factor exhibited any protection to apoptosis following all-trans- 
retinoic add (RA) or ds-Platinum(ll)diamminedichloride (dsplatin) treatment. Both 
of these agents are known to induce apoptosis in IMR-32 and have been used as 
chemotherapeutic agents to treat children with neuroblastoma (Nitschke et al, 
1981; DeBemadi et al, 1992; Reynolds et al, 2003). However, no statistically 
significant difference in the number of apoptotic/differentiating cells was observed 
between Bm-3a over-expressing and control cells. This was determined by
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different methods such as MTT assays, Annexin V antibody staining and activated 
caspase-3 analysis.
The failure of Bm-3a to alter growth or survival of these cells is surprising given 
that previous studies have shown Bm-3a to promote neuronal differentiation as 
well as survival against a number of apoptotic stimuli both in vivo and in vitro. In 
addition, the significant effects observed in the studies using the Bm-3b 
manipulated IMR-32 cells (discussed in chapter 3) which employed many of the 
assays used in the studies with Bm-3a over-expressing cells discussed here, 
would suggests that the experiments were adequately set up and functional. As 
such the lack of differences in survival and proliferation in the IMR-32 over- 
expressing cells compared with controls may have resulted from the limitations of 
constitutively altering Bm-3a gene expression in these cells. Since previous 
studies have shown that increasing Bm-3a enhances differentiation and hence 
prevents cellular proliferation, it is feasible to accept that we might only have 
propagated cell lines that have growth advantage either due to the site of 
integration of the Bm-3a plasmid or other cellular changes that could overcome the 
effects of Bm-3a in these cells. Even though we tested three different Bm-3a cell 
lines, these were selected out of twenty original colonies, most of which failed to 
proliferate in culture and were subsequently lost As such analysis of the 
parameters that would normally be affected by Bm-3a (survival and differentiation) 
did not give rise to the expected effects.
Another possible reason to explain the lack of effects seen in IMR-32 over­
expressing Bm-3a might be due to the heterogenous population of IMR-32 cells. 
These human neuroblastoma cell lines consist of two types of cells of neuroblasts 
and neurofibroblasts. It is possible that while selecting the clonal cells transfected 
with Bm-3a plasmid, we actually might have selected neurofibroblasts rather than 
neuroblasts.
Additionally, we also attempted to generate IMR-32 cells with reduced levels of 
Bm-3a. However, cells transfected with Bm-3a anti-sense construct gave rise to a 
number of colonies but all of these died early after transfections. This is attributable 
to the established role of Bm-3a as a surviving factor in neuronal models and
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abolishing its expression in knock-out studies results in enhanced cell death of 
specific neurons (Smith et al, 1998a; 1998b; Ensor et al, 2001; McEvilly et al, 
1996; Xiang et al, 1996; Huang et al, 1999). These problems observed in both the 
constitutively over-expressing and anti-sense IMR-32 Bm-3a clones can be 
overcome in the future by establishing an inducible expression system to generate 
Bm-3a stable cell lines such that the gene of interest is expressed only when 
induced. This could be achieved by, for example, constructing a Bm-3a cDNA 
construct that is under the control of a tetracydin inducible promoter so that it is 
only expressed after the addition of a spedfic substrate such as tetracydine or 
doxycydin.
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5.0 Functional effect of Brn-3b in neuroblastoma cells
5.1 Introduction
We have shown that over-expressing of Bm-3b in IMR-32 neuroblastoma cells 
dearly increased proliferation (see chapter 4). This finding lead us to further 
investigate how this transcription factor mediates its effects by identifying putative 
target genes regulated by Bm-3b in these cells.
One of the hallmarks of transformed cells is their ability to grow uncontrollably. 
Cancer cells either do not require mitogenic stimulation to proliferate or their 
requirements are far less stringent compared to those of normal cells. Similarly, 
cancer cells do not exit the cell cyde to enter a quiescent state in response to 
growth inhibitory signals. These acquired properties often result from alterations in 
growth regulatory pathways, which may either directly or indirectly involve cell 
cyde regulation. Some of the proteins most often altered in human cancers are 
those involved in the control of G1/S transition of the cell cyde at a time when a 
cell becomes committed to a cell division. In particular, the alterations of members 
of the cascade assodated with cydin-dependent kinase (CDK)-cyclin D/CDK- 
4/retinoblastoma (pRB)/E2F (described in section 4.4 of introduction) have also 
been found in more than 80% of human cancers. Such changes arise either 
because of mutations within the genes or in the regulators that control their 
expression in specific cells. In this study, we investigated cydin D1 as a possible 
candidate gene regulated by Bm-3b.
Cydin D1 expression is normally increased in early G1 when it complexes with and 
activates CDK4. Hence, cydin D1 is critical for cell cyde progression and 
commitment to cell division. Interestingly, cydin D1 knock-out mice (Sidnski et al, 
1995) share significant phenotypic features with Bm-3b homozygous null mutants 
(Gan et al, 1996). Thus, similar to Bm-3b homozygous mutants, cydin D1-/- mice 
develop to foil term but exhibit drastic reduction in the retinal cell numbers due to 
inability of retinal cell precursors to develop during embryogenesis. In addition, 
Bm-3b has been implicated in the proliferation of mammary epithelial cells
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(Budhram-Mahadeo et al, 1999; Dennis et al, 2001) and it is interestingly to note 
that cydin D1-/- females are unable to nurse due to failure of pregnancy- 
assodated mammary proliferation. Additionally, independent studies have 
demonstrated that cydin D1, like Bm-3b, is over-expressed in human breast 
cancers (Buckley et al, 1993; Wang et al, 1994; Budhram-Mahadeo et al, 1998).
A recent study has shown high expression of cyclin D1 at both the mRNA and 
protein levels in approximately two-third of neuroblastoma cell lines and primary 
tumours (Molenaar et al, 2003). However, amplification of cydin D1 gene was 
found only in one neuroblastoma cell line and four neuroblastoma tumours, 
suggesting that the increased cydin D1 result from altered expression of the gene 
thus implicating upstream mechanisms controlling its expression. Furthermore, a 
significant decrease in cydin D1 transcript levels is observed in neuroblastoma 
cells upon treatment with a differentiating agent dibutyryl cydic adenosine 
monophosphate, which induces differentiation of these cells and correlates with 
their growth retardation (Munoz et al, 2003). Similarly, treatment of neuroblastoma 
cells with retinoic add induces differentiation into neuronal cells, and a decrease in 
cydin D1 level (Wainwright et al, 2001).
We have previously shown that the POU-domain transcription factor, Bm-3b, 
promotes cellular proliferation in human neuroblastoma cell lines (discussed in 
chapter 4). The changes in levels of this protein in differentiating versus 
proliferating cells, lead us to investigate whether the in vivo and in vitro functional 
overlap between Bm-3b and cydin D1, reflects some common underlying 
molecular mechanism that regulate cell proliferation. It is possible that the potent 
proliferative effect of Bm-3b in IMR-32 is mediated via its direct ability to 
transcriptionally increase cyclin D1 expression, causing rapid cell cyde 
progression in neuroblastomas. Therefore, we undertook studies to investigate the 
possible role of and inter-relationship between Bm-3b, cydin D1, and proliferative 
kinetics of IMR-32 cells with altered levels of Bm-3b.
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5.2 Results
5.2.1 Cyclin D1 protein levels in Bm-3b overexpressing IMR-32 
cells
Proteins were extracted from manipulated IMR-32 cells with altered levels of Bm- 
3b. Immunoblotting was carried out to determine the levels of cyclin D1 in the Bm- 
3b overexpressing cells, and compared to levels in anti-sense cells with decreased 
Bm-3b, and vector control cells using densitometry. Total cellular protein from each 
cell line was harvested at 60% confluency of 6-well plates and loaded onto a 
15%/SDS/PAGE gel for resolution of different proteins, which were then 
transferred onto a nitrocellulose membrane, and probed with an anti-cydin D1 
antibody. Membranes were stripped and reprobed with the invariant protein actin 
to control for any differences in protein concentrations.
As shown in Fig. 5.2.1 A, the levels of cydin D1 protein were significantly increased 
in Bm-3b over-expressing cell lines compared to the control cells whilst reduced 
levels were detected in the Bm-3b anti-sense cells. This correlation of cydin D1 
levels with Bm-3b protein levels in neuroblastoma cells was observed in at least 
three independent experiments as shown on the graph (Fig. 5.2.1B).
The correlation of Bm-3b protein levels with cydin D1 protein in Bm-3b 
manipulated IMR-32 cells could reflect either a direct effect of Bm-3b in 
transactivating the cydin D1 gene promoter or an indirect effect assodated with 
altered proliferation rates of these cells.
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Fig. 5.2.1: Levels of cyclin D1 protein in Bm-3b over-expressing cell line (3box1) 
compared to the antisense (3bas1) and empty vector control (LTR1)
(A) Proteins were extracted from IMR-32 cells with altered levels of Bm-3b and Western 
immunoblotting carried out to determine the levels of cyclin D1 protein in the Bm-3b over- 
expresssing cells (3box1), empty vector control (LTR1), and anti-sense Bm-3b cells 
(3bas1). Higher levels of cyclin D1 protein were detected in 3box1 compared to LTR1, and 
even lower levels were found in 3bas1. Invariant (3-Actin protein was used as an internal 
control for differences in protein concentration.
(B) Densitometric analysis on three sets of independent Western immunoblotting 
experiments (+/- the standard deviation) confirmed the differences in the cyclin D1 protein 
levels in Bm-3b manipulated cells. Statistical analysis using Student’s T-test revealed 
significant increase in 3box1 compared with LTR (p£0.05) and decrease in 3bas1 (p 
value£0.05). The values have been normalized using (3-actin as an internal control on three 
sets of independent experiments +/- the standard deviation.
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5.2.2 Effect of Bm-3b on cyclin D1 gene promoter
To elucidate whether Bm-3b directly regulates cyclin D1 expression In 
neuroblastoma cells by transactivating the cyclin D1 promoter, we tested the effect 
of Bm-3b on this promoter in co-transfection assays. An expression vector 
containing the cDNA encoding Bm-3b was co-transfected into IMR-32 cells with a 
reporter construct in which the 1.9kb fragment from the 5’ regulatory region 
upstream of the human cyclin D1 gene was cloned into pBLCAT reporter so that it 
drives the expression of chloramphenicol acetyl transferase (CAT) reporter gene (a 
kind gift from Dr. J.R. Nevins). To provide an internal control, a second reporter in 
which the thymidine kinase minimal reporter drives the expression of the renilla 
gene, was also transfected and its activity was used to equalize for different 
transfection efficiencies in different experiments. Renilla DNA was tranfected at 
1:10 total DNA ratio in each well. The cells were harvested 48h post-transfection 
and CAT assays were carried out using cell extracts as described in materials and 
methods whilst thymidine kinase-renilla values were used to equalize for variability 
in transfections.
As shown in Fig 5.2.2, co-transfection with Bm-3b(l) resulted in approximately 3.5- 
4 fold increase in the promoter activity of cyclin D1 gene compared to control 
transfections where empty LTR vector was co-transfected with the promoter 
construct. Similarly, Bm-3b(s) activated the promoter by 2.2-2.7 fold. Hence, Bm- 
3b can directly transactivate the cyclin D1 promoter resulting in significant increase 
in promoter activity (p<0.05).
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Fig. 5.2.2(H) Effect of Bm-3b(l) and Bm-3b(s) on full length cyclin D1 promoter 
determined in a CAT reporter construct
IMR-32 cells were co-transfected with 2.7 pg of Bm-3b(l) or Bm-3b(s) or LTR DNA 
and 2.7 (jg of CAT reporter construct DNA encoding 1.9 kb of the 5’ regulatory 
region of cyclin D1 gene. A control in which minimal thymidine kinase promoter 
drives the expression of the Renilla gene was also transfected at 1:10 total DNA 
ratio in each transfection in order to equalize for variability between different 
transfections. Cells were harvested 48h post-transfections and CAT assays carried 
out to determine the expression levels of the reporter gene. Bm-3b(l) increases the 
activity of cyclin D1 promoter by approximately 4 fold (p<0.05), whereas the Bm- 
3b(s) increases it by about 3 fold compared to the empty vector LTR control 
(p<0.05). The data represents the mean of three independent experiments (carried 
out in triplicate in each experiment), +/- the standard deviation.
5.2.3 Effect of Brn-3b on cyclin D2 and cyclin D3 promoters
To determine whether the ability of Brn-3b proteins to transactivate the promoter of 
cyclin D1 gene was specific for this gene promoter, we tested its effect upon co­
transfection with reporter constructs containing the promoters of other D-type 
cyclins, namely cyclin D2 and cyclin D3. Using a similar approach described for
191
cyclin D1, the full length promoters of cyclin D2 and D3 in pCAT Basic vector 
(Promega) (a kind gift from Dr. J.R. Nevins, Duke University, North Carolina, 
U .SA) were co-transfected with Bm-3b expression vector and the internal control 
renilla vector. The transactivation of test promoters were determined by CAT 
assays as described in materials and methods.
As shown in Fig. 5.2.3, both isoforms of Bm-3b [Bm-3b(l) and Bm-3b(s)] strongly 
transactivated the cyclin D1 promoter but had little effect on cyclin D2 and cyclin 
D3 promoters. These results suggest that Bm-3b induces the transcription of cyclin 
D1 but not D2 or D3.
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Fig. 5.2.3: CAT assays showing transactivation of cyclin D1 promoter, but not 
cyclin D2 or cyclin D3, by Bm-3b proteins
IMR-32 cells were co-transfected with 2.7pg of Bm-3b(l) or Bm-3b(s) DNA and 2.7pg CAT reporter 
constructs containing the promoters of cydin D1/cydin D2/cydin D3 DNA. Thymidine kinase Renilla 
minimal reporter was also transfected at 1:10 total DNA ratio in order to provide an internal control for 
differences in transfections effidencies of different experiments. Cells were harvested 48 hours post­
transfection and CAT assays carried out to determine the acetylation at one or both of the hydroxyl 
groups of chloramphenicol by chloramphenicol acetyltransferase (CAT) gene product resulting from 
activation of the cydin D1 promoter. Panel (A) shows the activation of the promoter and consequent 
high expression of the CAT gene product, resulting in both mono- and di-acetylated 
chloramphenicol, which reflects a significant transactivation of cyclin D1 promoter upon co­
transfection with the long isofbrm of Bm-3b(l) (3bl + pCD1). However, the absence of acetylated 
produds on cydin D2 (3b! + pCD2) and cydin D3 (3bl + pCD3) promoters suggests that Bm-3b(l) 
does not transactivate these D-type cyclins. Panel (B) shows similar results of with the short isoform 
of Bm-3b (3bs) with reporter vectors containing the different D-type cydins. Therefore, both isoforms 
of Bm-3b (Bm-3b(l) and Bm-3b(s)) are able to transactivate the cydin D1 promoter but not the cydin 
D2 or cyclin D3 promoters.
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5.2.4 Isolation of the promoter region of Brn-3b required for its 
transctivation of cyclin D1 promoter
In order to determine the specific region of the cyclin D1 promoter that is required 
for transactivation by Bm-3b, we tested the effect of Bm-3b(l) and Brn-3b(s) on the 
activity of various deletion constructs of cyclin D1 promoter in which there was a 
step-wise deletion of the 5’ region of the promoter, (see figure 5.2.4(i)). The full 
length promoter (CD1-944) and the deletion constructs which contained different 
regions of the regulatory sequences of cyclin D1 (referred to as CD1-848, CD1- 
567, and CD1-69) were cloned into the pGL2 luciferase vector to facilitate easier 
analysis of the promoter activity (see materials and methods). These constructs 
were a kind gift from Dr. R. Gerard, Saint-Antoine Hospital, Paris.
CD1-848
-567 +49
CD1-567
-69 +49
CD1-69
Fig. 5.2.4(i): Diagrammatic representation of cyclin D1 promoter deletion 
constructs
Step-wise deletions of the 5’ end of the cyclin D1 promoter (CD1-944) gave rise to 
constructs lacking 96 (CD1-848), 377 (CD1-567) and 875 (CD1-69) bases. These 
deletions were cloned into pGL2 luciferase vector and used in co-transfection 
studies with Bm-3b expression vectors.
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5.2.4.1 Brn-3b requires sequences between -567 and -69 of 
cyclin D1 for transactivation
As can be seen in Fig. 5.2.4(H), Bm-3b(l) is able to activate the full length cyclin D1 
promoter (CD1-944) by 4-5 fold compared to the empty LTR vector (p<0.005). 
Similarly, Bm-3b(s) activates this CD1-944 promoter by approximately 3 fold 
(p<0.005). Ability of both Bm-3b(l) and Bm-3b(s) to transactivate the full length 
cyclin D1 promoter cloned into the luciferase reporter construct parallels the effect 
seen using the cyclin D1 CAT reporter construct, thus further supporting Bm-3b as 
a regulator of the cyclin D1 promoter activity and validated using these deletion 
constructs for further analysis.
Similar studies undertaken with CD1-848 construct which lacks 96 bases showed 
that co-transfection with Bm-3b(l) or Bm3b(s) continued to transactivate by 5- and
2.5 to 3- fold respectively compared to the empty vector control (p<0.05). Similarly, 
both isoforms of Bm-3b proteins could transactivate a shorter reporter construct 
lacking 377 bases (CD1-567). Although there appeared to be slight but 
insignificant decrease in the effect of Bm-3b(l) on CD1-567 construct, there was 
still a 4-fold induction compared to the empty LTR vector control (p<0.05), while 
Bm-3b(s) continued to activate this construct by approximately 3-fold.
Co-transfection of Bm-3b expression vectors with a shorter promoter construct 
(CD1-69), lacking 875 bases, resulted in the loss of ability of Bm-3b proteins to 
transactivate this promoter. These results suggest that the regulatory element 
required for Bm-3b to transactivate the cyclin D1 promoter resides within the 
region of -567 and -69.
It is important to note that the basal transcriptional activity is still intact in the 
shortest CD1-69 construct, as determined by the relative luciferase activity of 
different promoter constructs when transfected alone into IMR-32 cells. The basal 
activity of CD1-69 was similar to that observed with the full-length (CD1-944) and 
another deletion construct (CD1-848) (Fig.5.2.4(iii)), suggesting that the loss of this 
region of the promoter in the sequentially deleted constructs studied does not 
affect the basal transcription.
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Fig. 5.2.4(H) Fold induction of cyclin D1 promoter activity by Bm-3b proteins 
Co-transfection experiments were undertaken in which the Bm-3b(l) or Brn-3b(s) 
or LTR control vector were introduced into human neuroblastoma cells, IMR-32, 
with Firefly luciferase reporter constructs containing the full-length cyclin D1 
promoter or different deletions constructs (as indicated on the graph). The values 
shown were standardized using TK-Renilla. Each experiment was performed in 
triplicate in three independent experiments. The error bars represent the standard 
error of the mean. Brn-3b(l) and Bm-3b(s) activates cyclin D1 full-length promoter 
constructs (CD1-944), as well as deletions CD1-848, and CD1-567 between 3-5 
fold. However, neither isoforms of Bm-3b could activate the CD1-69 deletion 
construct compared to the empty vector LTR control (p<0.05).
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Fig. 5.2.4(iii): The basal transcriptional activity of the full length cyclin D1 
promoter and two deletions constructs (CD1-848 and CD1-69) when transfected 
into IMR-32 cells.
The data indicates the relative promoter activity of each construct normalized to 
TK-Renilla. The basal promoter activity of the shortest deletion construct (CD1-69) 
is similar to the full-length promoter (p value >0.05), indicating that basal 
transcription is still intact on this promoter.
5.2.5 Determining whether Brn-3b regulates cyclin D1 by 
binding directly to the cyclin D1 promoter by electrophoretic 
mobility shift assay
We next attempted to elucidate whether Bm-3b transactivated the cyclin D1 
promoter by interacting directly with cis-regulatory DNA sequences. Analysis of the 
cyclin D1 promoter from -567 to -69 for putative Bm-3b consensus binding 
sequences revealed an A/T rich region with sequence homology to common 
preferential binding site for POU domain proteins. This region was identified 
between position -248 to -228 of the promoter. In fact, online Matlnspector search 
results identified an octamer binding motif within this site. Based on this 
observation, an oligonucleotide was synthesized (5’-CGA TTT GCA TTT CTA 
TGA AAA-3’) and used in electrophoretic mobility shift assay (EMSA) (described in
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materials and methods) to test whether the Bm-3b protein could bind to this region 
of the cyclin D1 promoter.
-944 -848 -567 -248-227 -69 +1
5’- CGA TTT GCA TTT CTA TGA AAA -3’
Fig. 5.2.5(i): Schematic representation of the cyclin D1 promoter
The Brn-3 octamer binding site is positioned between -248 and -227. The
sequence of the promoter in this region is highlighted in bold.
Fig. 5.2.5(ii) shows the result of an EMSA in which the radiolabelled 
oligonucleotide, corresponding to the putative Bm-3 binding site, in the cyclin D1 
promoter (see above) was incubated with protein extract obtained from IMR-32 
cells over-expressing the Bm-3b protein (3box1), giving rise to protein/DNA 
complexes that form retarded bands that can be separated by electrophoresis. 
Hence, incubation of cell extract obtained from IMR-32 expressing high levels of 
Bm-3b with labeled oligonucleotide probe resulted in the formation of a number 
of protein-DNA complexes (lane 2) but only two of these complexes were 
competed by addition of increasing molar concentration of unlabelled Bm-3 binding 
site (lane 3, 4, 5) but not by a non-specific oligonucleotide (lane 6). This suggests 
the presence of proteins that strongly and specifically bind to the DNA probe so 
that they are only competed by the addition of the specific oligonucleotides. The 
presence of two bands with different mobility could suggest that the protein may be 
bound in different conformation, for example, smaller complex may represent 
monomers of Bm-3b whilst larger complex may be associated with dimers of Bm- 
3b. We failed to super-shift any of these complexes with Brn-3b specific antibody 
(data not shown), perhaps due to the masking of the epitope once the protein is 
bound to the sequence. Therefore, to confirm that Brn-3b protein was present in 
these complexes, wild type probe was incubated with SAOS 2 cells that lack Brn- 
3b (personal communication Perez-Sanchez C). Lane 1 shows that both these 
complexes were specific to Bm-3b as they were absent in SAOS2 cells. Hence, it
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is likely that Brn-3b protein is able to bind to the cyclin D1 at promoter sequence 
located between -248 and -228 from the transcriptional start site.
1 2 3 4 5 6
Fig. 5.2.5 (ii) Electrophoretic mobility shift assay (EMSA) using a radioactively 
labeled oligonucleotide (oligo) probe containing the putative Brn-3b binding 
sequence (CD1 Bm-3b).
The oligonucleotides were designed to correspond to the putative Bm-3b binding 
site within the cyclin D1 promoter and labeled with 32P. The labelled oligos were 
subsequently incubated with cell lysate prepared from SAOS 2 which lacks 
endogenous Brn-3b or IMR-32 cells over-expressing Bm-3b (3box1). The reaction 
complex was then analysed on a non-denaturing PAGE gel and visualised by 
autoradiography.
Lane 1: SOAS 2 cell lysate + labeled oligo
Lane 2: 3box1 cell lysate + labeled oligo
Lane 3: 3box1 cell lysate + unlabeled CD1 Bm-3b (50-foki molar excess) + labeled oligo
Lane 4: 3box1 cell lysate + unlabeled CD1 Bm-3b (100-foid molar excess) + labeled
oligo
Lane 5: 3box1 cell lysate + unlabeled CD1 Brn-3b (200-foid molar excess) + labeled 
oligo
Lane 6: 3box1 cell lysate + Non-specific competitor (ERE) + labeled oligo
Non-specific complexes
Brn-3b/cyclinD1 
oligo complex
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5.2.6 Identification of the specific bases required for the 
binding of Brn-3b to the cyclin D1 promoter
Since we identified the DNA sequence in cyclin D1 promoter that was recognized 
by Bm-3b, we next attempted to determine the specific bases required by Brn-3b 
to bind the cyclin D1 promoter sequence tested earlier. Two A/T rich regions were 
found within the putative binding site so we tested the requirement of these sites 
for binding of Brn-3b protein. As such these sites were mutated and tested for 
binding of Bm-3b using EMSA assays. Two variants of the wild-type sequence 
were synthesized, each containing changes in different base pairs as shown 
below:
Wild-type (WT/CD1): 5’-CGA TTT GCA TTT CTA TGA AAA- 3’
3’-GCT AAA CGT AAA GAT ACT TTT- 5’
Mutant 1 (M1/CD1): 5’-CGA TTT GCA GGG CTA TGA AAA- 3’
3’-GCA AAA CGT CCC GAT ACT TTT- 5’
Mutant 2 (M2/CD1): 5’-CGA TGG GCA TTT CTA TGA AAA- 3’
3’-GCT ACC CGT AAA GAT ACT TTT- 3’
The wild-type and the mutant oligonucleotides were labeled (see materials and 
methods) and an EMSA carried out. Fig. 5.2.6 shows the differences in binding by 
Bm-3b protein on the three oligonucleotides. As also shown previously, incubation 
of 3box1 cellular extracts with 32P labeled oligonucleotide probe corresponding to 
the wild-type probe (WT/CD1) resulted in formation of a specific complex (lane 1). 
Interestingly, incubation of labeled M1/CD1 mutant probe with neuroblastoma 
cellular extract (3box1) did not give rise to any specific Bm-3b protein/DNA 
complex (lane 2, 3, 4). However, incubation of 3box1 cellular extract with the 
second mutant (M2/CD1) resulted in a specific complex formation (lane 5), similar 
to the WT/CD1. This was further confirmed by the addition of specific competitor 
(lane 6) and non-specific competitor (lane 7). These results indicate that 5’- TTT -3’ 
in this sequence is critical for binding of the Bm-3b protein to the cyclin D1 
promoter and suggests that the sequence 5’- A TTT CTA T -3’ is likely to be the
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consensus octamer site bound by this protein in the cyclin D1 promoter. However, 
further studies will need to be undertaken to confirm the significance of these 
findings by testing the effect of inserting such mutations in the full length promoter 
using co-transfection studies.
Brn-3b/cyclin D1 complex -
Non-specific
complexes
Free probe ►
Fig. 5.2.6: EMSA undertaken to test whether Bm-3b binding to cyclin D1 
promoter was compromised by mutating two ATT hch sub-sites within the putative 
Bm-3b site
Wild-type (WT/CD1) and mutant (M1/CD1; M2/CD1) oligonucleotides were labeled 
with 32P and then incubated with neuroblastoma cellular extract over-expressing 
Bm-3b (3box1). The complex was then analysed on a non-denaturing PAGE gel 
and radio-labelled oligonucleotides then visualised by autoradiography.
Lanel: 3box1 cell lysate + labeled WT/CD1 
Lane 2: 3box1 cell lysate + labeled M1/CD1
Lane 3: 3box1 cell lysate + labeled M1/CD1 + unlabelled M1/CD1 (150-fold molar excess) 
Lane 4: 3box1 cell lysate + labeled M1/CD1 + unlabelled M1/CD1 (200-fold molar excess) 
Lane 5: 3box1 cell lysate + labeled M2/CD1
Lane 6: 3box1 cell lysate + labeled M2/CD1 + unlabelled M1/CD1 (100-fold molar excess) 
Lane 7: 3box1 cell lysate + labeled M2/CD1 + non-specific competitor ERE
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5.3 Discussion
One of the acquired characteristic of tumour cells is their ability to divide 
uncontrollably. Several lines of evidence have shown a strong correlation of the 
POU domain transcription factor, Bm-3b, with proliferation both in neuroblastoma 
cells (Lillycrop et al, 1992; Budhram-Mahadeo et al, 1995a; Smith and Latchman, 
1996; chapter 4 of this thesis) and breast cancer cells (Budhram-Mahadeo et al, 
1998; Dennis et al, 2001). Hence, in these cell types high Bm-3b levels are 
observed in proliferating cells and increasing this factor has been shown to be 
associated with accelerated rate of cell proliferation.
In terms of its effect in neuroblastoma cells, Bm-3b has been shown to be involved 
in the maintenance of undifferentiated state by repressing the promoters of genes 
involved in neuronal differentiation. Thus its ability to repress expression of genes 
involved in synaptic vesicular function and structural genes, namely SNAP-25 
(Morris et al, 1996), a-intemexin (Budhram-Mahadeo et al, 1995) and all three 
neurofilament gene promoters may provide one mechanism by which Bm-3b can 
give rise to its effects in these cells (Smith et al, 1997c).
In the breast epithelium, Bm-3b has been shown to mediate its potent proliferative 
effect by directly activating the expression of CDK4 in breast cancer cells (Samady 
et al, 2004) whilst repressing the anti-proliferative BRCA-1 gene (Budhram- 
Mahadeo et al, 1999). However, Bm-3b can also modify gene expression by 
increasing the estrogen-receptor mediated transcriptional activity on estrogen- 
receptor-element containing promoter (Budhram-Mahadeo et al, 1998). Moreover, 
recently Bm-3b has been shown to repress the expression of plakoglobin, which is 
known to mediate adhesive functions and suppress tumorigenidty in a number of 
tumours such as breast and neuroblastoma (Zhurinsky et al, 2000; Amitay et al, 
2001). Bm-3b levels are inversely correlated to those of plakoglobin in breast 
tumours (Samady, personal communication). Whilst genes such as BRCA-1 and 
ER are more relevant to breast cancers, other factors such as CDK4 may be 
relevant in other cell types.
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As described in chapter 3 of this thesis, altering levels of Bm-3b alone was 
sufficient to significantly change growth properties of neuroblastoma cells, IMR-32. 
Hence, increasing Bm-3b levels resulted in increased proliferation while 
decreasing this factor caused retarded in vitro and in vivo growth of IMR-32 cells. 
These results paved the way to examine whether Bm-3b could directly affect 
genes associated with proliferation in these cells. In particular, the cell cycle 
protein, cyclin D1, which is required for G1 to S transition of the cell cycle, was an 
attractive target since it has been showed to be involved in aberrant proliferation of 
cells in a number of all human neoplasia (for review see, Weinberg 1995). Even 
though cyclin D1 mRNA and protein levels have been shown to be over-expressed 
in neuroblastoma primary tumours and cell lines (Molenaar et al, 2003), these are 
not associated with any mutations or amplifications of the gene in these tumours. 
This suggests possible dysregulation of pathways that control cyclin D1 
expression.
Furthermore, there are some striking similarities in the phenotypic features of Bm- 
3b homozygous null mutants (Gan et al, 1996) and cyclin D1 knock-out mice 
(Sicinski et al, 1995). Thus, both mutants are viable but have a marked reduction in 
the retinal cell numbers. Moreover, the effect of Bm-3b on increased proliferation in 
breast epithelial cells (Budhram-Mahadeo et al, 1999; Dennis et al, 2001) is 
mirrored by the effect of increased cyclin D1 in these cells (Zwijsen et al, 1997; 
1998; Lamb et al, 2000). Moreover, both Bm-3b (Budhram-Mahadeo et al, 1998) 
and cyclin D1 have been shown to be over-expressed in human breast cancers 
(Buckley et al, 1993), further highlighting cyclin D1 as an interesting potential 
candidate to study with respect to being a possible transcriptional target of Bm-3b.
In this study, we showed that neuroblastoma cells manipulated to express high 
levels of Bm-3b showed an increase in the levels of endogenous cyclin D1 
compared to the control cells. Reassuringly, the levels of endogenous cyclin D1 
protein was decreased in cells with reduced levels of Bm-3b(l) and Bm-3b(s) 
compared to the empty vector control cells, suggesting a correlation of expression 
of cyclin D1 and Bm-3b. Therefore, in order to elucidate whether this apparent 
coincidence in the levels of these two proteins is not simply reflecting changes in 
cellular proliferation caused by increasing Bm-3b(s) or conversely, decreased
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proliferation rate in Bm-3b anti-sense cell lines, we next tested the whether Bm- 
3b(l) and Bm-3b(s) could transactivate the cyclin D1 regulatory region. Results of 
co-transfection experiments showed that Bm-3b(l) could significantly activate the 
cyclin D1 promoter with a 4-5 fold increase in the promoter activity compared to the 
empty LTR vector control, whilst Bm-3b(s) increased this promoter activity by 2-3 
fold compared to the basal activity. Hence, this suggests both isoforms of Bm-3b 
regulate the cyclin D1 promoter and induce it
The ability of Bm-3b to transactivate cyclin D1 promoter was specific to this gene 
promoter as regulatory regions of other D-type cyclins, namely cyclin D2 and cyclin 
D3, were not affected by Bm-3b in similar co-transfection studies. It is interesting 
that during mouse development and in adult tissue, the three D-cyclins are 
expressed in a highly orchestrated manner in mutually exclusive cell types. The D- 
cyclins play similar roles in promoting cell cycle progression but exhibit high tissue 
specificity (Robkar and Richards, 1998; Wianny et al, 1998). Even though the three 
D-type cyclins share 50-60% identity in their coding region (Inaba et al, 1992; 
Xiong et al, 1992), analysis of the regulatory region that control the expression of 
each of the three D-type cyclins shows very limited homology (Blast search, 
NCBI). This suggests that different transcription factors may be involved in the 
regulation of expression of these genes. Hence, our findings (reported here) 
showing that Bm-3b only affects the transactivation of cyclin D1 further supports 
this notion.
In order to determine the region of the cyclin D1 promoter that is required for Bm- 
3b to mediate its transactivation effect, we tested deletion constructs in which 
specific regions of regulatory regions of cyclin D1 were lost. Loss of up to 377 base 
pairs of the promoter in the 5’ region (-848 and -567 deletion constructs) did not 
compromise activation of the promoter by Bm-3b as the effects were similar to 
wild-type. However, loss of 875 bases (-69) resulted in the loss of activation of the 
cyclin D1 promoter by both the isoforms of Bm-3b proteins. This lead us to 
conclude that the region between positions -567 and -69 was critical for Bm-3b to 
exert its effect. Analysis of this region for possible Bm-3b consensus binding 
sequences was undertaken using sequences described in other studies that were 
shown to bind Bm-3b. This led to the identification of a closely related sequence
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(5-CGA TTT GCA TTT CTA TGA AAA-3’) between -248 and -228 from the 
transcriptional start site in the cydin D1 promoter. Electrophoretic mobility shift 
assay was used to show that Bm-3b could bind strongly and spedfically to this 
oligonudeotide as shown by competition using both specific and non-specific 
competitors. Attempts to super-shift the Bm-3b/cydin D1 oligonudeotide with 
commerdally available Bm-3b antibody failed to affect the mobility of the complex. 
This may possibly be due to the masking of the epitope on the protein required for 
the antibody recognition during the complex formation. However, to ensure that 
these complexes were specific to Bm-3b, similar studies using cellular extracts 
from SAOS2 which do not express any endogenous Bm-3b did not give rise to 
these complexes. This confirmed that specific complexes were unique to and only 
present when Bm-3b is in the reaction.
We also identified the specific site required for recognition of this DNA sequence 
by Bm-3b by mutational analysis. These results showed that mutations of bases at 
positions -239 and -237 resulted in loss of Bm-3b binding whereas changing bases 
at positions -244 and -243 did not affect the binding specifidty. This suggests that 
the core sequence of 5’-A TTT CTA TGA-3’ is critical for Bm-3b to bind this region. 
The requirement of this sequence for Bm-3b to stimulate the expression of this 
promoter will need to be confirmed using site directed mutagenesis with the intact 
promoter. Furthermore, chromatin immunopredpitation (ChIP) assay can also be 
used to confirm the assodation of Bm-3b protein on the cydin D1 promoter in vivo. 
However, with the results presented in this chapter, we can suggest that the 
correlation of cydin D1 expression with Bm-3b in human neuroblastoma cells may 
result from the ability of this transcription factor to activate transcription from this 
gene promoter and hence, increase expression of the cydin D1 gene.
The ability of Bm-3b to regulate the expression of cyclin D1 promoter may give a 
possible mechanistic explanation for the altered growth rate observed in these 
neuroblastoma cells (chapter 4). Cydin D1 regulates cell cyde, being involved in 
the processes such as phosphorylation and inactivation of the retinoblastoma (Rb) 
protein, which in turn causes the release of E2F transcription factors required to 
drive the cell out of the G1 restriction point and initiation of S phase of the cell 
cyde. Given the significant alteration in growth and proliferation upon increased
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Bm-3b and decrease upon reducing endogenous expression, it is feasible to 
suggest that the effect on proliferation observed in manipulated Bm-3b cells may 
be partly due to its ability to transactivate the cyclin D1 promoter. An upregulation 
in cyclin D1 levels by Bm-3b may account for the increased proliferation rate in 
Bm-3b over-expressing cells. Furthermore, the positive regulatory effect of Bm-3b 
on CDK4 expression (Samady et al, 2004), a factor that associates with cyclin D1 
to allow cell cycle progression, suggests a combined effect that promotes cellular 
proliferation.
Hence, Bm-3b might act in a complex manner, regulating tissue specific genes, as 
exemplified by its regulation of breast specific BRCA-1 and its effects on ER 
targets in breast cancers, or SNAP-25 and a-intemexin in neuronal cells whilst also 
regulating more general targets such as those associated with the cell cycle, 
namely CDK4 and cyclin D1. Its activation of the CDK4 gene has been observed in 
breast adenocarcinoma cell lines while here we have shown its effects on cyclin 
D1 activation in neuroblastoma cells. It will be interesting to see if CDK4 is also 
activated by Bm-3b in neuroblastoma cells and whether its effects on cyclinDI in 
neuroblastoma cells are paralleled in breast cells. It is also important to determine 
other neuronal specific targets for Bm-3b that are associated with proliferation in 
neuroblastoma cells by methods such as Affymetrix™, to further understand how 
this transcription factor exerts its potent proliferative effect in these cells.
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Discussion
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6.0 General Discussion
Regulation of gene expression is controlled primarily at the level of transcription 
and involves an intricate networking between several intra- and extracellular 
factors in a spatio-temporal manner. Transcription factors are potent proteins that 
regulate gene expression by either activating or inhibiting production of messenger 
RNA There are two types of eukaryotic transcription factors. General transcription 
factors which are common to all RNA polymerase II transcribed genes, while gene 
specific transcription factors act on a more restricted number of genes depending 
on the cell type and precise timing of external stimuli.
The POU domain proteins are a family of gene regulators that have evolved to 
contain a structurally conserved component shown to be present in organisms as 
divergent as C.elegans, Drosophila, Xenopus, zebrafish and humans (for review 
see Andersen and Rosenfeld, 2001). POU proteins exhibit diverse functions such 
as cellular homeostasis (for example, Oct-1 regulation of the housekeeping histone 
H2B promoter [Pierani et al, 1990]) as well as specific spatio-temporal 
developmental processes (for example, Pit-1 control of the prolactin and growth 
hormone genes in the anterior pituitary gland [Nelson et al, 1988]). This family of 
transcription factors has been sub-classified into six different classes, based on the 
degree of homology in the common structural domains. The two proteins, Bm-3a 
and Bm-3b, which we have studied in the context of neuroblastoma cells, belong 
to the class IV sub-group of POU family, and are critical for the survival and normal 
function of specific neuronal cell types (for review Latchman, 1999).
The initial isolation of Bm-3a from brain cDNA (He et al, 1989) and that of Bm-3b 
from mouse neuroblastoma cells, ND7, (Lillycrop et al, 1992) suggested a role for 
these factors in neuronal cells. Subsequently, other studies have highlighted the 
critical roles for these factors in the normal development of particular neuronal 
cells. For example, using mouse models in which the expression of these genes 
had been deleted, Bm-3a has been shown to have a distinct developmental role in 
the maintenance and terminal differentiation of specific neuronal cells of the CNS 
such as the red nucleus, as well as in the trigeminal ganglia of the PNS (McEvilly
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et al, 1996; Xiang et al, 1996; Eng et al, 2001). Similarly, in vivo deletion studies of 
Bm-3b have shown this factor to be critical in the terminal differentiation of a sub­
set of retinal ganglial cells (Erkmann et al, 1996; Gan et al, 1996; 1999).
In parallel with studies determining the expression and role of Bm-3a and Bm-3b in 
vivo, extensive work has been carried out using in vitro models to elucidate the 
precise mechanisms by which these transcription factors exert their functional 
effects. Studies in mouse neuroblastoma cell line, ND7, have shown that Bm-3a 
and Bm-3b expression is regulated in opposite directions by common signaling 
pathways activated by factors such as cAMP or growth factors. Hence, elevated 
levels of Bm-3a mRNA and protein have been detected upon differentiation of 
ND7 cells by serum withdrawal and/or addition of cAMP. Moreover, concomitant 
decrease in the levels of Bm-3b is observed under these differentiating conditions. 
Conversely, high levels of Bm-3b mRNA and protein are expressed when ND7 
cells are actively proliferating, in sharp contrast to the low levels of Bm-3a in these 
dividing cells (Lillycrop et al, 1992; Budhram-Mahadeo et al, 1995a). Similarly, Bm- 
3a and Bm-3b also exhibit reciprocal expression in human neuroblastoma cell 
lines, IMR-32. High levels of Bm-3a are present in differentiated cells while low 
levels of Bm-3b are expressed in these cells. This expression pattern is reversed 
in actively proliferating IMR-32 cells (Smith and Latchman, 1996).
Over-expression of Bm-3a in ND7 cells in full growth medium enhances neurite 
outgrowth even under conditions that would not normally promote process 
formation (Smith et al 1997c). This is further supported by studies in ND7 cells 
where anti-sense strategy has been employed to reduce the levels of Bm-3a. 
Under such conditions loss of Bm-3a results in the failure of extension of neurites 
even under differentiation promoting conditions such as serum withdrawal (Lakin et 
al, 1995). Furthermore, there is also a decrease in the levels of some neuronal 
proteins associated with differentiation, such as SNAP-25, synaptophysin, 
synaptotagmin I, synapsin I and neurofilament proteins, NFH, NFM and NFL in 
these cells with reduced levels of Bm-3a while Bm-3a over-expressing cells have a 
corresponding increase in the levels of these proteins (Smith et al, 1997a; 1997b). 
Similar studies in ND7 with increased levels of Bm-3b showed a failure of neurite 
outgrowth even when the cells are grown in differentiation medium (Smith et al
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1997a). This contrasts with the effects of Bm-3a in these cells which is associated 
with mature, differentiated neuronal phenotype.
The opposite expression patterns of Bm-3a and Bm-3b in differentiating versus 
proliferating ND7 cells is accompanied by antagonistic effects of these factors on 
the activities of various promoters. While Bm-3a is a strong activator of promoter of 
genes associated with differentiation such as SNAP-25, synaptotagmin I, synapsin 
I, NFH, NFM and NFL (Smith et al, 1997a; 1997b), Bm-3b appears to repress 
genes expressed in differentiated neurons such as SNAP-25, a-intemexin, and all 
three neurofilament proteins (Morris et al, 1996; Budhram-Mahadeo et al, 1995; 
Smith et al, 1997c). Bm-3b, like Bm-3a, activates the promoter of synapsin 1, 
suggestive of a certain degree of compensatory function between these two 
closely related transcription factors (Morris et al, 1996). However, the opposite 
expression pattern and antagonistic effects on most target promoters observed in 
ND7 cells might reflect the involvement of Bm-3a and Bm-3b in providing a fine 
balance between proliferation and differentiation in these cells.
The role of Bm-3b in cells of neuronal origin presents an interesting paradox. While 
in vivo knock out studies have shown Bm-3b to be critical for the survival and 
terminal differentiation of retinal ganglial cells, it has been shown to be associated 
with proliferation in neuroblastoma cell lines. The lack of abnormalities in other 
regions of the CNS and PNS in Bm-3b homozygous null mutants has made it 
difficult to elucidate the precise role for this factor in other neuronal cell types. It has 
been speculated that Bm-3a might actually compensate for this factor in regions 
where its expression precedes that of Bm-3b such as dorsal root ganglia and 
trigeminal ganglia of the developing PNS (Gerrero et al, 1993; Turner et al, 1994). 
This would suggest that Bm-3b acts in a similar manner to Bm-3a and is 
associated with differentiation and maturation of these neurons. While this 
hypothesis remains to be tested, caution is needed in generalizing the function of a 
protein as exemplified by other members of the POU family of transcription factors. 
For example, Pit-1 POU protein acts by stimulating genes associated with terminal 
differentiation and maturation of the anterior pituitary such as PRL, GH and TSHp 
genes (Nelson et al, 1988). Simultaneously, this protein also promotes cellular 
proliferation in other pituitary specific cells such as somatotrophs (Li et al, 1990).
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Similarly, the role of Bm-3b in preventing differentiation of neuroblastoma cells 
while promoting differentiation in highly specialized retinal ganglial cells suggests 
that Bm-3b might work in a complex manner, dependent on cell specific factors.
Since their initial identification in neuronal cells, Bm-3a and Bm-3b have also been 
detected in other cells such as breast, testis, prostate, heart and lungs (Turner et 
al, 1994; Budhram-Mahadeo et al, 2001). In fact, it was the role of these factors in 
breast and testis that first highlighted their potential role in tumourogenesis. Bm-3b 
has been shown to be elevated in several cases of sporadic breast cancers and in 
mammary tumours with reduced levels of the tumour suppressor gene, BRCA-1 
(Budhram-Mahadeo et al, 1998; 1999). Indeed, Bm-3b represses the expression 
of the BRCA-1 promoter in breast cancer cell lines, suggesting that it is associated 
with promoting proliferation of these cells. The role of Bm-3b in breast cancers has 
been extensively studied and other targets for this factor in these cells have been 
identified and analysed. These provide some of the functional mechanisms by 
which high levels of Bm-3b may affect the proliferation of cells in breast cancer 
cells. For example, in breast adenocarcinoma cell lines, MCF7, Bm-3b activates 
the positive cell cycle regulator, CDK4 (Samady et al, 2004) while repressing the 
adhesion associated protein, plakoglobin (personal communication, Dr. L. 
Samady, MMBU, ICH, UCL). Furthermore, Bm-3b has also been shown to 
functionally interact with the estrogen receptor and hence, potentiates transcription 
from genes containing the oestrogen-responsive elements which are associated 
with growth and proliferation in breast tissue (Budhram-Mahadeo et al, 1998). 
Over-expression of Bm-3b in MCF7 cells results in increased proliferation and 
enhanced ability to grow under anchorage independent conditions compared to 
control cells or cells with decreased levels of Bm-3b (Dennis et al, 2001). Hence, 
there is strong evidence to suggest that Bm-3b promotes proliferation and invasion 
of breast cancer cells.
In the experiments described in this thesis, we have attempted to analyse the 
effects of Bm-3a and Bm-3b in human neuroblastoma cell lines, IMR-32, with a 
view to examine whether altering levels of these potent developmental regulators 
may have a role in the initiation and/or progression of neuroblastomas. 
Neuroblastomas are highly malignant, undifferentiated tumours originating in
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neuroectodermal cells derived from the neural crest that are destined for the 
adrenal medulla and the sympathetic nervous system (for review see Schwab et 
al, 2003). It accounts for 8-10% of all paediatric malignancies, with an annual 
incidence of 1 in every 7,000 live births. The molecular mechanisms contributing to 
the onset of this disease are poorly understood and are compounded by the 
remarkable clinical heterogeneity. This cancer can range from life-threatening 
aggressive undifferentiated neuroblastoma, to less malignant tumours that 
differentiate to ganglioneuroblastomas or ganglioneuromas. It is interesting to note 
that spontaneous regression of tumours is also observed in very young infants at a 
high frequency.
Hence, we tested the effects of manipulating Bm-3a and Bm-3b levels by either 
constitutively over-expressing Bm-3a/Bm-3b or reducing their expression using 
anti-sense strategies in IMR-32 cells as discussed in the chapter 3 and 4. Firstly, 
IMR-32 cells were stably transfected with plasmids either containing the Bm-3b 
sense cDNA or anti-sense cDNA sequence. Having established cells with either 
increased or decreased levels of Bm-3b, we tested for effects on cellular growth in 
monolayers and under anchorage independent conditions, as well as their invasive 
properties and response to differentiation/apoptotic stimulus such as all-trans- 
retinoic acid (RA).
Altering Bm-3b protein levels affects the growth and proliferation of 
neuroblastoma cells
Most human neoplasias result from abnormalities in the expression of genes that 
participate in the control of cell proliferation and differentiation. We have shown 
(chapter 3 of this thesis) that alteration in the levels of Bm-3b has profound effects 
on the cellular growth characteristics of IMR-32 cells. Upregulation of Bm-3b(s) 
(and subsequent increase in Bm-3b(l) possibly via an auto-regulatory loop) results 
in cells which have greater proliferation rates as well as saturation densities when 
grown in monolayers. Conversely, cells with reduced levels of Bm-3b exhibit 
slower proliferation and saturation densities compared to controls. We also 
examined the ability of Bm-3b manipulated cells to grow tumours in vivo, the 
ultimate marker for experimental malignant cell transformation, by injecting them 
into athymic and immuno-compromised mice models. Mice injected with Bm-3b
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over-expressing cells grow larger tumours in a significantly shorter time than 
controls while Bm-3b anti-sense cells do not promote tumour growth in these 
xenograft mice models. Therefore, increasing the levels of Bm-3b in 
neuroblastoma cells increased their growth and proliferation both in vitro as well as 
in vivo.
Bm-3b may mediate its effects on cellular proliferation by 
transactivating the cyclin D1 gene expression
The potent proliferative effect of Bm-3b in IMR-32 cells led us to determine a
possible mechanism by which this transcription factor could cause changes in
cellular growth and proliferation. In this regard, we showed for the first time that
Bm-3b can transactivate cyclin D1 gene, an important regulator of the mammalian
cell cycle. Expression of cyclin D1, and subsequent association with its partner
CDK4, results in the phosphorylation of retinoblastoma protein. This event results
in cycle progression from G1 to S phase. Recently, high expression levels of cyclin
D1 mRNA and protein have been detected in two-thirds of neuroblastoma cell lines
as well as primary human tumours (Molenaar et al, 2003). Other studies have also
shown that regulation of cyclin D1 in neuroblastoma cells is critical for the
proliferation of these cells (Munoz et al, 2003; Wainwright et al, 2001).
Cyclin D1 knock-out mice have a striking similarity to Bm-3b homozygous null 
mutants, such that both develop to full term but exhibit a marked reduction in the 
retinal ganglial cell numbers due to inability of retinal cell precursors to develop 
during embryogenesis (Sicinski et al, 1995; Gan et al, 1996). Additionally, 
independent studies have demonstrated that cyclin D1, like Bm-3b, is also over­
expressed in human breast cancers (Buckley et al, 1993; Wang et al, 1994; 
Budhram-Mahadeo et al, 1998). Recent studies have shown Bm-3b also positively 
affects the CDK 4 promoter (Samady et al, 2004), which acts as a partner for 
cyclin D1, thereby facilitating G1-S transition.
Our studies (chapter 5) confirm high levels of cyclin D1 protein in IMR-32 cells 
over-expressing Bm-3b protein whereas concomitant decrease is observed in cells 
with reduced levels of Bm-3b (data shown in chapter 5 of this thesis). In order to 
determine whether these similarities result from a direct effect of Bm-3b on cyclin
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D1 gene expression, we tested the effect of Bm-3b on the cyclin D1 gene 
promoter. Indeed, transactivation studies on cyclin D1 promoter show that both 
isoforms of Bm-3b are able to significantly activate this promoter. In addition, we 
have also shown that Bm-3b protein is able to bind directly to an octamer 
sequence in the cyclin D1 promoter between positions -248 and -228 from the 
transcriptional start site in vitro. Moreover, this binding is specific as base 
mutations between -239 and -237 region in the promoter abolishes the 
transactivation potential of Bm-3b on this gene. The full physiological relevance of 
this binding will require additional assays such as site directed mutagenesis and 
chromatin immunoprecipitation (ChIP), which is a powerful tool for examining the 
spatial and temporal mapping of chromatin-bound factors in vivo. Unfortunately, 
these could not be carried out due to limitation of time.
Hence, from the studies described in this thesis, we have shown that increasing 
Bm-3b levels in neuroblastoma cells has a profound effect on the growth and 
proliferation of these cells both in vitro and in vivo. This might partly be due to the 
ability of this transcription factor in transactivating the cyclin D1 gene promoter. The 
subsequent increase in the levels of cyclin D1, a well-known cell cycle regulator, 
would allow transition of cells from G1 to S phase and hence promote continued 
cell division. This is an interesting finding in neuroblastoma cell lines, providing a 
potentially important mechanism for understanding the aberrant proliferation 
observed in the neural crest derived tumours in neuroblastoma patients.
Overexpression of Bm-3b causes anchorage independence 
and enhanced invasion of neuroblastoma cells
Metastasis of cancer cells to distant sites is a severe and generally fatal
consequence of tumour progression. In neuroblastomas metastatic disease occurs
in approximately 70% of patients. This is indicative of advanced stage of the
disease and poor prognosis. The metastatic process is a dynamic process that
begins with tumour cell migration by which tumour cells leave the primary site of
growth, often penetrating the basement membrane and moving towards the local
vasculature. This is followed by intravasation, which describes the process of
tumour cell entry into the vasculature, and distribution to distant sites.
Subsequently, tumour cells need to extravasate into the surrounding tissue,
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survive in the foreign microenvironment, proliferate, and induce angiogenesis, all 
the while evading apoptotic death or immunological response (for review see Liotta 
and Stetler-Stevenson, 1993).
In vitro assays for cellular transformation and invasiveness have used the ability of 
transformed cells to grow on ‘soft-agarose’ and migration through a reconstituted 
basement membrane as an indication that cells with these abilities have metastatic 
potential. Hence, we tested the ability of IMR-32 cells with altered levels of Bm-3b 
to grow anchorage independently by growing them on soft agar. Wild-type IMR-32 
cells require a solid surface on which to flatten out and divide, and therefore, 
exhibit modest growth on soft-agar, which affords only moderate opportunity to 
adhere and spread. However, IMR-32 cells with elevated levels of Bm-3b continue 
to proliferate and form colonies when grown in 0.3% soft agar. Conversely, IMR-32 
cells with reduced levels of Bm-3b protein resulted in smaller colonies with 
markedly reduced proliferative potential. Furthermore, analysis of migration of Bm- 
3b modified IMR-32 cells through an artificial Matrigel Basement Membrane (BD 
Biocoat Matrigel™) showed that over-expressing Bm-3b in these cells increased 
their invasive properties while cells with reduced levels of this factor exhibited 
reduced migration through a matrix compared to control cells.
These observations are important given the highly metastatic nature of 
neuroblastoma tumours, suggesting that if Bm-3b levels are aberrantly expressed 
in primary neuroblastoma tumours, it might affect the metastatic potential of the 
cancerous cells. Direct mechanisms that contribute to the various stages in 
metastasis in neuroblastoma are poorly understood at present. However, 
contributions of other studies aimed at understanding the molecular and cellular 
processes of cell matrix organization, cell-cell interactions, cell matrix adhesion, 
migration, cell proliferation, and angiogenesis have highlighted potential 
mechanisms that may contribute to the metastasis process in cancers. It will be 
interesting to determine the specific Bm-3b targets in any of these processes such 
as cell adhesion molecules in neuroblastoma cells, and given the recent finding of 
Bm-3b expression in trunck neural crest cells (personal communication, Hudson C, 
ICH, UCL) it is possible that Bm-3b might be involved in the epithelial- 
mesenchymal cell transition, a well-established event known to occur during
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developmentally regulated migration of neural crest cells, (for review see Tucker, 
2004), which might contribute to the enhanced migratory properties of 
neuroblastoma cells. Furthermore, some light is beginning to be shed on the 
signaling pathways involved in anchorage dependence and it seems that PKA, 
PAK and the MAP kinases play important roles (Howe and Juliano, 2000), and 
therefore, it will be interesting to determine the involvement of Bm-3b in these 
pathways in neuroblastoma cells.
Brn-3b overexpression overcomes differentiation signals 
induced by all-trans-retinoic acid
Furthermore, data presented in chapter 3 confirms a significant difference between 
cells with different levels of Bm-3b in their ability to respond to RA compared to 
controls. All-trans-retinoic acid (RA) is generally growth inhibitory and causes 
neuroblastoma cell lines to differentiate or undergo apoptosis (Chu et al, 2003; 
Nagai et al, 2004; Bemardini et al, 1999). While Bm-3b anti-sense cells ceased to 
proliferate after exposure to this differentiating agent, in a manner comparable to 
the control cells, Bm-3b over-expressing cells fail to respond to this stimulus and 
continue to proliferate even when grown in the presence of RA. These results 
suggest that high levels of Bm-3b can overcome differentiation signals induced by 
RA in human neuroblastoma cells.
The role of Bm-3a in proliferation, differentiation and 
apoptosis of IMR-32 cells
Experiments described in chapter 4 of this thesis focus on the effects of Bm-3a in 
IMR-32 cells. After generating constitutively over-expressing Bm-3a clonal cells, 
we tested for any change in their growth properties, as well as response to 
differentiation and apoptotic stimuli such as RA and cisplatin, respectively. 
Introduction of a plasmid containing Bm-3a cDNA in an anti-sense orientation into 
IMR-32 cells failed to generate clones that survived in culture. These could be 
explained by the role of Bm-3a in protecting neurons in culture ascertained in other 
studies. For instance, increasing levels of this factor in ND7 cells and primary 
cultures of trigeminal and dorsal root ganglia can protect these neuronal cells 
against apoptotic stimuli such as withdrawal of nerve growth factor from the 
medium and sciatic nerve lesions (Smith et al, 1998a; 2001; Ensor et al, 2001).
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Conversely, decreasing the levels of Bm-3a causes increased death against the 
same apoptotic stimuli. In fact, other studies have shown Bm-3a to directly 
transactivate the anti-apoptotic Bcl-2 promoter in neuronal cells (Smith et al, 
1998a; 1998b; Ensor et al, 2001) while it represses the p53-mediated activation of 
pro-apoptotic factors Bax and Noxa (Budhram-Mahadeo et al, 2003; Hudson et al, 
2004). Hence, the requirement of Bm-3a for survival of neuronal cells could help to 
understand the death of all IMR-32 cells transfected with Bm-3a anti-sense 
plasmid.
Whilst we managed to obtain and propagate four clonal cells over-expressing Bm- 
3a, over 75% of transfected cells failed to grow and therefore could not be 
adequately propagated. It is possible that in our studies neuroblast cells over- 
expressing Bm-3a failed to proliferate because of the known effect this 
transcription factor has in inducing differentiation. Hence, cells over-expressing this 
factor and hence undergoing differentiation must have ceased to proliferate and 
subsequently, died in culture (Lakin et al, 1995; Smith et al, 1997c; Smith and 
Latchman, 1996). Furthermore, we utilised a non-homologous recombination 
technique and, therefore, it is also possible that the clones over-expressing Bm-3a 
that were propagated, had a growth advantage due to the random site of 
integration of the plasmid. Random integration of Bm-3a plasmid into the cellular 
genome may have disrupted a critical gene(s) involved in differentiation and/or 
survival of IMR-32 cells. A general consensus to overcome this problem is to carry 
out analyses with more than two clonal cell lines that are selected randomly from a 
larger pool of positive clones. However, this choice was strictly limited with Bm-3a 
manipulated clonal cells as only a total of four Bm-3a over-expressing clones 
survived. Therefore, this reduced our chance of selecting cells that had no 
disruptions in any of the genes.
Based on the effects observed in other neuronal cells in previous studies, we 
expected to find that over-expressing Bm-3a in IMR-32 cells would enhance 
differentiation of these cells whilst increasing survival to apoptotic stimuli. Analysis 
of rate of growth and proliferation shows that Bm-3a does not alter the rate of 
growth in these cells. Similarly, we did not observe any significant morphological 
differences between Bm-3a over-expressing and control cells. Bm-3a over­
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expressing cells do not demonstrate altered response upon treatment with 
differentiation inducing agent, RA, or with apoptosis inducing cisplatin as no 
significant difference in survival is observed between Bm-3a over-expressing and 
control cells. In light of the role of Bm-3a in differentiation and survival described in 
other studies, it is important to repeat these analyses in an inducible stable system, 
such that Bm-3a expression can be switched on and off upon administration of 
specific substrate such as doxycyclin. This would overcome the problem of 
propagation due to the failure of transfected cells to proliferate when Bm-3a levels 
are either constitutively elevated or decreased.
Summary
In conclusion, the results in this thesis have highlighted the potent proliferative role 
of Bm-3b as well as enhancing invasive properties of human neuroblastoma cells. 
In addition, we have also shown that Bm-3b mediates this effect by activating the 
cyclin D1 gene promoter, causing increased cell cycle progression.
Given the strong proliferative effect of Bm-3b in IMR-32 neuroblastoma cell lines, it 
is reasonable to speculate that this transcription factor may play a critical role in 
determining the growth characteristics of neuroblastoma tumours when it is 
elevated. In addition, Bm-3b expression may serve as a marker to identify a poor 
prognostic factor for a sub-group of neuroblastomas. Its correlation with the 
induction of cyclin D1 expression in neuroblastoma cells suggests its possible role 
as:
a) a prognosticator of neuroblastomas, and
b) a direct or indirect target to develop therapeutic strategies against Bm-3b. A 
direct strategy would be to ablate its expression while specific targeting of the 
octamer sequences in the cyclin D1 promoter (required for the positive regulation 
of cyclinDI by Bm-3b) could also, indirectly, affect the function of Bm-3b in 
neuroblastoma cells.
Future Work
It will be interesting to establish if Bm-3b protein levels are altered in a cell cycle 
dependent manner that might precede the onset of cyclin D1 expression. To this
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end, current studies are ongoing in our laboratory aiming at arresting human 
neuroblastoma cell lines (IMR-32 and SHSY5Y) at specific phases of the cell cycle 
by using strategies such as treating the cells with inhibitors (e.g. hydroxyurea, 
fluorouracil and colchicine), or re-initiating the cell cycle after serum withdrawal. 
Harvesting RNA and proteins from these cells will allow determination of the levels 
of the Bm-3b at different phases of the cell cycle in relation to known cell cycle 
markers such as PCNA and cyclin E, and facilitate correlation with the expression 
of cyclin D1. Alternatively, it is possible that Bm-3b levels remain steady but this 
protein is subject to post-translational modifications, such as phosphorylation, that 
might be needed to transactivate targets such as cyclin D1 gene promoter. Results 
from such studies should help to identify the mechanism of regulation of cyclin D1 
by Bm-3b in a physiological context.
In order to determine the importance of this transcription factor in proliferation of 
neuroblastoma tumours, we need to analyse its expression and function in primary 
human samples in order to make our data clinically relevant. Preliminary studies 
carried out by Dr. Budhram-Mahadeo in our laboratory (MMBU, ICH, UCL) have 
shown a significant increase in the levels of Bm-3b mRNA compared to Bm-3a in 
18 primary neurobastoma tumour biopsies. These findings are encouraging but 
larger cohort studies are required to fully determine the role of these transcription 
factors in the neuroblastoma tumours.
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Special Footnote
Subsequent to the submission and acceptance of this thesis some conflicting 
evidence has emerged to suggest that the IMR-32 cells used in our research may 
not be of human origin. IMR-32 cells were obtained from American Type Culture 
Collection, who characterised these as human neuroblastoma cell lines derived 
from an abdominal mass removed from a 13-month-old-Caucasian male. Recent 
preliminary karyotyping carried out by Dr. Tracy W aifs group (Department of 
Molecular Neuroscience, Institute of Neurology, London) has shown these IMR-32 
cells to be tetraploid and led the group to suggest that they may, in fact, be of rat 
origin. However, in-depth analysis of these cells needs to be carried out using 
species-specific probes to unequivocally determine the true origin of these cells. At 
present, it is therefore premature to amend any of the conclusions made in this 
thesis.
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